EPICORE Embase Updates: EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 109

Results Generated From:
Embase <1980 to 2024 Week 24>
Embase Weekly Updates (updates since 2024-06-07)

<1>
Accession Number
2032688812
Title
Ultrasound-guided mid point-transverse process to pleura block versus
thoracic paravertebral block in pediatric open-heart surgery: A randomized
controlled non-inferiority study.
Source
Journal of Clinical Anesthesia. 97 (no pagination), 2024. Article Number:
111507. Date of Publication: October 2024.
Author
Abourezk A.R.; Abdelbaser I.; Badran A.; Abdelfattah M.
Institution
(Abourezk, Abdelbaser, Badran, Abdelfattah) Department of Anesthesia and
Surgical Intensive Care, Faculty of Medicine, Mansoura University,
Mansoura, Egypt
Publisher
Elsevier Inc.
Abstract
Study objective: The mid point-transverse process to pleura block (MTPB)
is a new variant of thoracic paravertebral block (TPVB). This study aimed
to compare TPVB and MTPB with respect to intraoperative attenuation of the
hemodynamic stress response to surgery and postoperative analgesia in
pediatric open heart surgery with midline sternotomy. Design(s): A
single-center, randomized, controlled, double-blind, non-inferiority
study. Setting(s): Tertiary care children's university hospital.
 Patient(s): We recruited 83 children aged 2-12 years of both sexes
with American Society of Anesthesiologists (ASA) physical status class II
who were scheduled for elective open cardiac surgeries with midline
sternotomy for the repair of simple noncyanotic congenital heart defects.
 Intervention(s): Eligible participants were randomized into either
the TPVB or MTPB groups at a ratio of 1:1. In the TPVB group, patients
were bilaterally injected with 0.4 ml/kg of 0.25% bupivacaine in the
paravertebral space at T4 and T5. In the MTPB group, patients were
bilaterally injected with 0.4 ml/kg of 0.25% bupivacaine mid-transverse
process and pleura just posterior to superior costotransverse ligament at
the level of T4 and T5. Measurements: The primary outcome was the
hemodynamic responses to sternotomy incision, including heart rate (HR)
and invasive mean arterial pressure (MAP), recorded before and after the
induction of anesthesia, after skin incision, after sternotomy, 15 min
after cardiopulmonary bypass (CPB), and after the closure of the sternum.
The secondary outcomes were time needed to perform the bilateral block,
intraoperative fentanyl consumption, postoperative fentanyl consumption,
modified objective pain score (MOPS) measured at 1, 2, 6, 12, 18, and 24 h
after extubation, extubation time, intensive care unit (ICU) discharge
time, and the incidence of non-surgical complications (postoperative
pruritus, postoperative vomiting, pneumothorax, hematoma or local
anesthetic toxicity). Main Result(s): There were no significant
differences in HR and MAP in the TPVB group compared with the MTPB group
at the following time points: baseline, after induction, after skin
incision, after sternotomy, 15 min after CPB, and after sternal closure.
Intergroup comparisons of HR and MAP did not reveal significant
differences between the groups. The median (IQR) time needed to perform
bilateral MTPB (7[6-8] min) was significantly (p < 0.001) shorter than
that of TPVB (12[10-13] min). Intraoperative fentanyl consumption and
fentanyl consumption in the first postoperative 24 h after extubation were
similar in the TPVB and MTPB groups (4[2-4] vs 4[2-4] and 4.66 +/- 0.649
vs 4.88 +/- 1.082 mug/kg), respectively. Extubation time and ICU discharge
time were comparable in the TPVB and MTPB groups (2[1-3] vs 2[1-3] h and
21.2 +/- 2.5 vs 20.8 +/- 2.6 h), respectively. Measurements of MOPS pain
scores at 1, 2, 6, 12, 18, and 24 h after extubation were similar in both
groups. The incidence of nonsurgical complications was similar in both
groups. Conclusion(s): MTPB is non-inferior to TPVB in attenuating
the intraoperative hemodynamic stress response to noxious surgical stimuli
and in reducing perioperative opioid consumption, extubation time, and ICU
discharge time. Moreover, MTPB is technically easier than TPVB and
requires less time to perform. Clinical trial registration number The
clinical trial registration was prospectively performed at the Pan African
Clinical Trials Registry (PACTR202204901612169, approval date 01/04/2022,
URL
https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=22602). Copyright
© 2024 Elsevier Inc.

<2>
Accession Number
2031818632
Title
Association between plasma maresin 1 and the risk of atherosclerotic
cardiovascular disease in Chinese adults: A community-based cohort study.
Source
Nutrition, Metabolism and Cardiovascular Diseases. 34(7) (pp 1631-1638),
2024. Date of Publication: July 2024.
Author
Li M.; Sun Y.; Liu B.; Xue Y.; Zhu M.; Zhang K.; Jing Y.; Ding H.; Liang
Y.; Zhou H.; Dong C.
Institution
(Li, Liu, Zhang, Ding, Liang, Dong) Department of Epidemiology and
Statistics, School of Public Health, Jiangsu Key Laboratory and
Translational Medicine for Chronic Non-communicable Disease, Medical
College of Soochow University, Soochow, China
(Sun, Xue, Zhu) Huai'an No 3 People's Hospital, Huai'an, China
(Jing, Zhou) Suzhou Industrial Park Centers for Disease Control and
Prevention, Soochow, China
Publisher
Elsevier B.V.
Abstract
Background and aims: It has been reported that maresin 1 (MaR1) is able to
protect against the development of atherogenesis in cellular and animal
models. This study was performed to investigate whether plasma MaR1 is
associated with the risk of atherosclerotic cardiovascular disease (ASCVD)
at the population level. Methods and Results: The study included 2822
non-ASCVD participants from a community-based cohort who were followed for
about 8 years. Hazard ratios (HRs) and 95% confidence intervals (95% CIs)
for ASCVD events according to baseline MaR1 quartiles were calculated
using the Cox proportional hazards model. During follow-up, a total of 290
new ASCVD cases were identified. The restricted cubic spline analysis
indicated a linear dose-response association between plasma MaR1 and
incident ASCVD. In addition, the adjusted-HR (95% CI) for ASCVD events
associated with one standard deviation increase in MaR1 was 0.79
(0.68-0.91). Moreover, the adjusted-HRs (95% CIs) for ASCVD events
associated with the second, third and fourth quartiles versus the first
quartile of plasma MaR1 were 1.00, 1.04 (0.76, 1.42), 0.88 (0.64, 1.22)
and 0.58 (0.41, 0.84), respectively. Mediation analyses showed that the
association between MaR1 and incident ASCVD was partially mediated by
small dense low-density lipoprotein cholesterol, with a mediation
proportion of 9.23%. Further, the net reclassification improvement and
integrated discrimination improvement of ASCVD risk were significantly
improved when MaR1 was added to basic model established by conventional
risk factors (all p < 0.01). Conclusion(s): Elevated plasma MaR1
concentrations are associated with a lower risk of ASCVD
development. Copyright © 2024 The Author(s)

<3>
Accession Number
2029656414
Title
Current Landscape of Gene Therapy for the Treatment of Cardiovascular
Disorders.
Source
Current Gene Therapy. 24(5) (pp 356-376), 2024. Date of Publication: 2024.
Author
Wal P.; Aziz N.; Singh C.P.; Rasheed A.; Tyagi L.K.; Agrawal A.; Wal A.
Institution
(Wal, Aziz, Rasheed, Wal) PSIT-Pranveer Singh Institute of Technology
(Pharmacy), NH-19, Uttar Pradesh, Kanpur 209305, India
(Singh) Department of Pharmacy, Servier India Private Limited, India
(Tyagi) Department of Pharmacy, Lloyd Institute of Management and
Technology, Plot No.-11, Knowledge Park-II, Uttar Pradesh, Greater Noida
201306, India
(Agrawal) School of Pharmacy, Jai Institute of Pharmaceutical Sciences and
Research, MP, Gwalior, India
Publisher
Bentham Science Publishers
Abstract
Cardiovascular disorders (CVD) are the primary cause of death worldwide.
Multiple factors have been accepted to cause cardiovascular diseases;
among them, smoking, physical inactivity, unhealthy eating habits, age,
and family history are flag-bearers. Individuals at risk of developing CVD
are suggested to make drastic habitual changes as the primary intervention
to prevent CVD; however, over time, the disease is bound to worsen. This
is when secondary interventions come into play, including
antihypertensive, anti-lipidemic, anti-anginal, and inotropic drugs. These
drugs usually undergo surgical intervention in patients with a much higher
risk of heart failure. These therapeutic agents increase the survival
rate, decrease the severity of symptoms and the discomfort that comes with
them, and increase the overall quality of life. However, most individuals
succumb to this disease. None of these treatments address the molecular
mechanism of the disease and hence are unable to halt the pathological
worsening of the disease. Gene therapy offers a more efficient, potent,
and important novel approach to counter the disease, as it has the
potential to permanently eradicate the disease from the patients and even
in the upcoming generations. However, this therapy is associated with
significant risks and ethical considerations that pose noteworthy
resistance. In this review, we discuss various methods of gene therapy for
cardiovascular disorders and address the ethical conundrum surrounding
it. Copyright © 2024 Bentham Science Publishers.

<4>
Accession Number
2027776069
Title
Risk factors, clinical implications, and management of peridevice leak
following left atrial appendage closure: A systematic review.
Source
Journal of Interventional Cardiac Electrophysiology. 67(4) (pp 865-885),
2024. Date of Publication: June 2024.
Author
Helal B.; Khan J.; AlJayar D.; Khan M.S.; Alabdaljabar M.S.; Asad Z.U.A.;
DeSimone C.V.; Deshmukh A.
Institution
(Helal, Khan, AlJayar, Khan) College of Medicine, Alfaisal University,
Riyadh, Saudi Arabia
(Alabdaljabar) Department of Internal Medicine, Mayo Clinic, Rochester,
MN, United States
(Asad) Department of Medicine, University of Oklahoma Health Sciences
Center, Oklahoma City, OK, United States
(DeSimone, Deshmukh) Department of Cardiovascular Medicine, 200 1St Street
SW, Rochester, MN 55905, United States
Publisher
Springer
Abstract
Background: Left atrial appendage closure (LAAC) is a treatment modality
for stroke prevention in patients with atrial fibrillation (AF). One of
the potential complications of LAAC is a peri-device leak (PDL), which
could potentially increase the risk of thromboembolism formation.
 Method(s): This systematic review was done according to PRISMA
guidelines. Using four databases, all primary studies through April 2022
that met selection criteria were included. Outcomes of interest were
studies reporting on PDL characteristics, risk factors and management.
 Result(s): A total of 116 studies met selection criteria (97 original
studies and 19 case reports/series). In the original studies (n = 30,133
patients), the weighted mean age was 72.0 +/- 7.4 years (57% females) with
a HAS-BLED and CHA2DS2-VASc weighted means of 2.8 +/- 1.1 and 3.8 +/- 1.3,
respectively. The most common definition of PDL was based on size; 5 mm:
major, 3-5 mm: moderate, < 1 mm minor, or trivial. Follow up time for PDL
detection was 7.15 +/- 9.0 months. 33% had PDL, irrespective of PDL
severity/size, and only 0.9% had PDL of greater than 5 mm. The main risk
factors for PDL development included lower degree of over-sizing, lower
left ventricular ejection fraction, device/LAA shape mismatch, previous
radiofrequency ablation, and male sex. The most common methods to screen
for PDL included transesophageal echocardiogram and cardiac CT. PDL
Management approaches include Amplatzer Patent Foramen Ovale occluder,
Hookless ACP, Amplatzer vascular plug II, embolic coils, and detachable
vascular coils; removal or replacement of the device; and left atriotomy.
 Conclusion(s): Following LAAC, the emergence of a PDL is a
significant complication to be aware of. Current evidence suggests
possible risk factors that are worth assessing in-depth. Additional
research is required to assess suitable candidates, timing, and strategies
to managing patients with PDL. Copyright © The Author(s), under
exclusive licence to Springer Science+Business Media, LLC, part of
Springer Nature 2024.

<5>
Accession Number
2026751032
Title
Serratus plane block versus standard of care for pain control after
totally endoscopic aortic valve replacement: A double-blind, randomized
controlled, superiority trial.
Source
Regional Anesthesia and Pain Medicine. 49(6) (pp 429-435), 2024. Date of
Publication: 01 Jun 2024.
Author
Vandenbrande J.; Jamaer B.; Stessel B.; Van Hilst E.; Callebaut I.; Yilmaz
A.; Packle L.; Sermeus L.; Blanco R.; Jalil H.
Institution
(Vandenbrande, Jamaer, Stessel, Van Hilst, Callebaut, Jalil) Department of
Anaesthesiology and Pain Medicine, Jessa Hospital Campus Virga Jesse,
Hasselt, Belgium
(Vandenbrande, Stessel, Van Hilst, Callebaut) Faculty of Medicine and Life
Sciences, UHasselt, Hasselt, Belgium
(Jamaer) Cardiovascular Sciences, KU Leuven, Leuven, Belgium
(Yilmaz, Packle) Department of Cardiothoracic Surgery, Jessa Hospital
Campus Virga Jesse, Hasselt, Belgium
(Sermeus) Anesthesiology, University Hospital Saint-Luc, Brussels, Belgium
(Blanco) Anaesthesia and Intensive Care, King's College Hospital Dubai,
Abu Dhabi, United Arab Emirates
Publisher
BMJ Publishing Group
Abstract
Introduction Serratus anterior plane block has been proposed to reduce
opioid requirements after minimally invasive cardiac surgery, but
high-quality evidence is lacking. Methods This prospective,
double-blinded, randomized controlled trial recruited patients undergoing
totally endoscopic aortic valve replacement. Patients in the intervention
arm received a single-injection serratus anterior plane block on arrival
to the intensive care unit added to standard of care. Patients in the
control group received routine standard of care, including
patient-controlled intravenous analgesia. Primary outcome was piritramide
consumption within the first 24 hours after serratus anterior plane block
placement. We hypothesized that compared with no block, patients in the
intervention arm would consume 25% less opioids. Results Seventy-five
patients were analyzed (n=38 in intervention arm, n=37 in control arm).
When comparing the serratus anterior plane group with the control group,
median 24-hour cumulative opioid use was 9 (IQR 6-19.5) vs 15 (IQR
11.3-23.3) morphine milligram equivalents, respectively (p<0.01). Also,
pain scores at 4, 8 and 24 hours were lower in the intervention arm at 4,
8 and 24 hours, respectively. Conclusion Combined deep and superficial
single-injection serratus anterior plane block is superior to standard of
care in reducing opioid requirements and postoperative pain intensity up
to 24 hours after totally endoscopic aortic valve
replacement. Copyright © American Society of Regional Anesthesia
& Pain Medicine 2024. Re-use permitted under CC BY-NC. No commercial
re-use. Published by BMJ.

<6>
Accession Number
2031489671
Title
Outcomes of Vasopressin-Receptor Agonists Versus Norepinephrine in Adults
With Perioperative Hypotension: A Systematic Review.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 38(7) (pp 1577-1586),
2024. Date of Publication: July 2024.
Author
Heybati K.; Xie G.; Ellythy L.; Poudel K.; Deng J.; Zhou F.; Chelf C.J.;
Ripoll J.G.; Ramakrishna H.
Institution
(Heybati, Xie, Ellythy, Poudel) Mayo Clinic Alix School of Medicine, Mayo
Clinic, Rochester, MN, United States
(Deng) Temerty Faculty of Medicine, University of Toronto, Toronto, ON,
Canada
(Zhou) Faculty of Health Sciences, McMaster University, Hamilton, ON,
Canada
(Chelf) Mayo Clinic Libraries, Rochester, MN, United States
(Ripoll, Ramakrishna) Department of Anesthesiology and Perioperative
Medicine, Mayo Clinic, Rochester, MN, United States
Publisher
W.B. Saunders
Abstract
Consensus statements recommend the use of norepinephrine and/or
vasopressin for hypotension in cardiac surgery. However, there is a
paucity of data among other surgical subgroups and vasopressin analogs.
Therefore, the authors conducted a systematic review of randomized
controlled trials (RCTs) to compare vasopressin-receptor agonists with
norepinephrine for hypotension among those undergoing surgery with general
anesthesia. This review was registered prospectively (CRD42022316328).
Literature searches were conducted by a medical librarian to November 28,
2023, across MEDLINE, EMBASE, CENTRAL, and Web of Science. The authors
included RCTs enrolling adults (>=18 years of age) undergoing any surgery
under general anesthesia who developed perioperative hypotension and
comparing vasopressin receptor agonists with norepinephrine. The risk of
bias was assessed by the Cochrane risk of bias tool for randomized trials
(RoB-2). Thirteen (N = 719) RCTs were included, of which 8 (n = 585)
enrolled patients undergoing cardiac surgery. Five trials compared
norepinephrine with vasopressin, 4 trials with terlipressin, 1 trial with
ornipressin, and the other 3 trials used vasopressin as adjuvant therapy.
There was no significant difference in all-cause mortality. Among patients
with vasoplegic shock after cardiac surgery, vasopressin was associated
with significantly lower intensive care unit (N = 385; 2 trials; mean
100.8 v 175.2 hours, p < 0.005; median 120 [IQR 96-168] v 144 [96-216]
hours, p = 0.007) and hospital lengths of stay, as well as fewer cases of
acute kidney injury and atrial fibrillation compared with norepinephrine.
One trial also found that terlipressin was associated with a significantly
lower incidence of acute kidney injury versus norepinephrine overall.
Vasopressin and norepinephrine restored mean arterial blood pressure with
no significant differences; however, the use of vasopressin with
norepinephrine was associated with significantly higher mean arterial
blood pressure versus norepinephrine alone. Further high-quality trials
are needed to determine pooled treatment effects, especially among
noncardiac surgical patients and those treated with vasopressin
analogs. Copyright © 2024 Elsevier Inc.

<7>
Accession Number
2032755837
Title
4-Year Follow-Up After Transcatheter Tricuspid Valve Replacement Using the
EVOQUE System.
Source
JACC: Case Reports. 29(14) (no pagination), 2024. Article Number: 102393.
Date of Publication: 17 Jul 2024.
Author
Stolz L.; Stocker T.J.; Weckbach L.T.; Schmid S.; Novotny J.; Doldi P.M.;
Massberg S.; Nabauer M.; Hausleiter J.
Institution
(Stolz, Stocker, Weckbach, Schmid, Novotny, Doldi, Massberg, Nabauer,
Hausleiter) Medizinische Klinik und Poliklinik I, Klinikum der Universitat
Munchen, Munich, Germany
(Stocker, Weckbach, Massberg, Nabauer, Hausleiter) German Center for
Cardiovascular Research, Partner Site Munich Heart Alliance, Munich,
Germany
Publisher
Elsevier Inc.
Abstract
Transcatheter tricuspid valve replacement (TTVR) is an increasingly used
treatment technique for patients with severe tricuspid regurgitation (TR).
Currently, available data from international registries and randomized
controlled trials provide outcome data until a maximum follow-up of 2
years after the procedure. This case report presents 4-year follow-up data
for an 84-year-old woman who underwent TTVR for torrential TR in 2019. The
patient experienced durable TR reduction, symptomatic improvement, right
ventricular reverse remodeling, and substantial improvement in liver and
kidney function. Copyright © 2024 The Authors

<8>
[Use Link to view the full text]
Accession Number
2032693421
Title
Outcomes of Prophylactic Peritoneal Dialysis Catheter Insertion in
Children Undergoing Cardiac Surgery: A Systematic Review and
Meta-Analysis.
Source
Pediatric Critical Care Medicine. 25(6) (pp e291-e302), 2024. Date of
Publication: 01 Jun 2024.
Author
Ulrich E.H.; Bedi P.K.; Alobaidi R.; Morgan C.J.; Paulden M.; Zappitelli
M.; Bagshaw S.M.
Institution
(Ulrich, Morgan) Division of Pediatric Nephrology, Department of
Pediatrics, University of Alberta, Edmonton, AB, Canada
(Bedi) Department of Pediatrics, University of Manitoba, Winnipeg, MB,
Canada
(Alobaidi) Division of Pediatric Critical Care, Department of Pediatrics,
University of Alberta, Edmonton, AB, Canada
(Paulden) Health Economics, School of Public Health, University of
Alberta, Edmonton, AB, Canada
(Zappitelli) Division of Pediatric Nephrology, Department of Pediatrics,
University of Toronto, Toronto, ON, Canada
(Bagshaw) Department of Critical Care Medicine, Faculty of Medicine and
Dentistry, University of Alberta and Alberta Health Services, Edmonton,
AB, Canada
Publisher
Lippincott Williams and Wilkins
Abstract
OBJECTIVES: The objective of this Prospective Register of Systematic
Reviews (CRD42022384192) registered systematic review and meta-analysis
was to determine whether prophylactic peritoneal dialysis (PD) catheter
insertion at the time of pediatric cardiac surgery is associated with
improved short-term outcomes. DATA SOURCES: Databases search of the
MEDLINE, EMBASE, CINAHL, and Cochrane Library completed in April 2021 and
updated October 2023. STUDY SELECTION: Two reviewers independently
completed study selection, data extraction, and bias assessment. Inclusion
criteria were randomized controlled trials (RCTs) and observational
studies of children (<= 18 yr) undergoing cardiac surgery with
cardiopulmonary bypass. We evaluated use of prophylactic PD catheter
versus not. DATA EXTRACTION: The primary outcome was in-hospital
mortality, as well as secondary short-term outcomes. Pooled random-effect
meta-analysis odds ratio with 95% CI are reported. DATA SYNTHESIS:
Seventeen studies met inclusion criteria, including four RCTs. The non-PD
catheter group received supportive care that included diuretics and late
placement of PD catheters in the ICU. Most study populations included
children younger than 1 year and weight less than 10 kg. Cardiac surgery
was most commonly used for arterial switch operation. In-hospital
mortality was reported in 13 studies; pooled analysis showed no
association between prophylactic PD catheter placement and in-hospital
mortality. There were mixed results for ICU length of stay and time to
negative fluid balance, with some studies showing shortened duration
associated with use of prophylactic PD catheter insertion and others
showing no difference. Overall, the studies had high risk for bias, mainly
due to small sample size and lack of generalizability. CONCLUSION(S):
In this meta-analysis, we have failed to demonstrate an association
between prophylactic PD catheter insertion in children and infants
undergoing cardiac surgery and reduced in-hospital mortality. Other
relevant short-term outcomes, including markers of fluid overload, require
further study. Copyright © 2024 Lippincott Williams and Wilkins.
All rights reserved.

<9>
Accession Number
2032739633
Title
Direct Oral Anticoagulant Therapy With A Fully Magnetically Levitated LVAD
and Bridging to Heart Transplantation: A DOT-HM3 Study Analysis.
Source
Journal of Cardiac Failure. (no pagination), 2024. Date of Publication:
2024.
Author
NETUKA I.V.A.N.; TUCANOVA Z.; MEHRA M.R.
Institution
(NETUKA, TUCANOVA) Institute for Clinical and Experimental Medicine,
Prague, Czechia
(MEHRA) Brigham and Women's Hospital and Harvard Medical School, Boston,
MA, United States
Publisher
Elsevier B.V.

<10>
Accession Number
2030114893
Title
Percutaneous repair of moderate-to-severe or severe functional mitral
regurgitation in patients with symptomatic heart failure: Baseline
characteristics of patients in the RESHAPE-HF2 trial and comparison to
COAPT and MITRA-FR trials.
Source
European Journal of Heart Failure. (no pagination), 2024. Date of
Publication: 2024.
Author
Anker S.D.; Friede T.; von Bardeleben R.S.; Butler J.; Khan M.S.; Diek M.;
Heinrich J.; Geyer M.; Placzek M.; Ferrari R.; Abraham W.T.; Alfieri O.;
Auricchio A.; Bayes-Genis A.; Cleland J.G.F.; Filippatos G.; Gustafsson
F.; Haverkamp W.; Kelm M.; Kuck K.-H.; Landmesser U.; Maggioni A.P.; Metra
M.; Ninios V.; Petrie M.C.; Rassaf T.; Ruschitzka F.; Schafer U.; Schulze
P.C.; Spargias K.; Vahanian A.; Zamorano J.L.; Zeiher A.; Karakas M.;
Koehler F.; Lainscak M.; Oner A.; Mezilis N.; Theofilogiannakos E.K.;
Ninios I.; Chrissoheris M.; Kourkoveli P.; Papadopoulos K.; Smolka G.;
Wojakowski W.; Reczuch K.; Pinto F.J.; Zmudka K.; Kalarus Z.; Adamo M.;
Santiago-Vacas E.; Ruf T.F.; Gross M.; Tongers J.; Hasenfuss G.;
Schillinger W.; Ponikowski P.
Institution
(Anker, Diek, Haverkamp) Department of Cardiology (CVK) of German Heart
Center Charite; Institute of Health Center for Regenerative Therapies
(BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site
Berlin, Charite Universitatsmedizin, Berlin, Germany
(Anker, Diek, Hasenfus, Schillinger) Department of Cardiology and
Pneumology, University Medical Centre Gottingen, Georg August University
of Gottingen, Gottingen, Germany
(Anker, Friede, Diek, Placzek, Hasenfus) German Centre for Cardiovascular
Research (DZHK), Partner Site Gottingen, Gottingen, Germany
(Friede, Placzek) Department of Medical Statistics, University Medical
Center Gottingen, Gottingen, Germany
(von Bardeleben, Geyer, Ruf) Department of Cardiology, University Medical
Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
(Butler) Department of Medicine, University of Mississippi Medical Center,
Jackson, MS, United States
(Butler) Baylor Scott and White Research Institute, Dallas, TX, United
States
(Khan) Division of Cardiology, Duke University School of Medicine, Durham,
NC, United States
(Heinrich) Clinical Trial Unit, University Medical Center Gottingen,
Gottingen, Germany
(Ferrari) Department of Translational Medicine, University of Ferrara,
Ferrara, Italy
(Abraham) Division of Cardiovascular Medicine, The Ohio State University,
Columbus, OH, United States
(Alfieri) Cardiac Surgery Unit, IRCCS San Raffaele Scientific Institute,
Milan, Italy
(Auricchio) Department of Cardiology, Cardiocentro Ticino Institute-EOC,
Lugano, Switzerland
(Bayes-Genis, Santiago-Vacas) Heart Institute, Hospital Universitari
Germans Trias i Pujol, Barcelona, Spain
(Cleland, Petrie) School of Cardiovascular and Metabolic Health,
University of Glasgow, British Heart Foundation Glasgow Cardiovascular
Research Centre, Glasgow, United Kingdom
(Filippatos) Department of Cardiology, Attikon University Hospital, School
of Medicine, National and Kapodistrian University of Athens, Athens,
Greece
(Gustafsson) Department of Cardiology, Copenhagen University Hospital -
Rigshospitalet, Copenhagen, Denmark
(Kelm) Department of Cardiology, Pulmonology and Vascular Medicine,
University Hospital Dusseldorf, Medical Faculty of the Heinrich Heine
University Dusseldorf, Dusseldorf, Germany
(Kelm) CARID, Cardiovascular Research Institute, Medical Faculty and
University Hospital Dusseldorf, Heinrich-Heine University, Dusseldorf,
Germany
(Kuck) Department of Rhythmology, University Heart Center Lubeck,
University Hospital Schleswig-Holstein, Lubeck, Germany
(Landmesser) Department of Cardiology, Angiology and Intensive Care
Medicine, Deutsches Herzzentrum der Charite, Campus Benjamin Franklin,
Berlin, Germany
(Landmesser) Berlin Institute of Health, Berlin, Germany
(Landmesser, Koehler) DZHK (German Centre for Cardiovascular Research),
Partner Site Berlin, Berlin, Germany
(Maggioni) ANMCO Research Center, Heart Care Foundation, Florence, Italy
(Metra, Adamo) Institute of Cardiology, ASST Spedali Civili and Department
of Medical and Surgical Specialties, Radiological Sciences and Public
Health, University of Brescia, Brescia, Italy
(Ninios, Ninios, Papadopoulos) European Interbalkan Medical Center,
Thessaloniki, Greece
(Rassaf) West German Heart and Vascular Center, Department of Cardiology
and Vascular Medicine, University Hospital Essen, University
Duisburg-Essen, Essen, Germany
(Ruschitzka) Department of Cardiology, University Heart Center, University
Hospital Zurich and University of Zurich, Zurich, Switzerland
(Ruschitzka) Center for Translational and Experimental Cardiology (CTEC),
Department of Cardiology, University Hospital Zurich, University of
Zurich, Zurich, Switzerland
(Schafer) Heart and Vascular Centre, Bad Bevensen, Germany
(Schulze) Department of Internal Medicine I, Cardiology, University
Hospital Jena, Jena, Germany
(Spargias, Chrissoheris, Kourkoveli, Papadopoulos) Department of
Transcatheter Heart Valves, HYGEIA Hospital, Athens, Greece
(Vahanian) UFR Medecine, Universite de Paris-Cite, site Bichat, GH Bichat,
Paris, France
(Zamorano) Department of Cardiology, Hospital Universitario Ramon y Cajal,
Madrid, Spain
(Zamorano) CIBERCV, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
(Zeiher) Institute for Cardiovascular Regeneration, Goethe University
Frankfurt, Frankfurt am Main, Germany
(Zeiher) German Center of Cardiovascular Research (DZHK), Partner Site
Rhein-Main, Frankfurt am Main, Germany
(Karakas) Department of Intensive Care Medicine, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany
(Karakas) German Centre for Cardiovascular Research (DZHK), Partner Site
Hamburg/Kiel/Lubeck, Hamburg, Germany
(Koehler) Deutsches Herzzentrum der Charite (DHZC), Department of
Cardiology, Angiology and Intensive Care Medicine, Campus Charite Mitte,
Berlin, Germany
(Koehler) Center for Cardiovascular Telemedicine, Charite -
Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin
and Humboldt-Universitat zu Berlin, Berlin, Germany
(Lainscak) Division of Cardiology, General Hospital Murska Sobota, Murska
Sobota, Slovenia
(Lainscak) Faculty of Medicine, University of Ljubljana, Ljubljana,
Slovenia
(Oner) Department of Cardiology, Rostock University Medical Centre,
Rostock, Germany
(Mezilis, Theofilogiannakos) Department of Cardiology, St Luke's Hospital,
Thessaloniki, Greece
(Smolka, Wojakowski) Division of Cardiology and Structural Heart Diseases,
Medical University of Silesia, Katowice, Poland
(Reczuch) Institute of Heart Diseases, Medical University and University
Hospital, Wroclaw, Poland
(Pinto, Ponikowski) Centro Academico de Medicina de Lisboa, CCUL@RISE,
Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
(Zmudka) Clinic of Interventional Cardiology, John Paul II Hospital,
Krakow, Poland
(Kalarus) Department of Cardiology, Congenital Heart Diseases and
Electrotherapy, Medical University of Silesia, Katowice, Poland
(Gross) Department of Medicine, Heart and Vascular Center, Division of
Cardiology and Vascular Medicine, Johanniter Hospital Stendal, Stendal,
Germany
(Tongers) Mid-German Heart Center, Department of Cardiology, Angiology and
Intensive Care Medicine, University Hospital Halle/Saale, Halle, Germany
(Schillinger) Heart Center, Department of Cardiology,
Georg-August-University Gottingen, Gottingen, Germany
Publisher
John Wiley and Sons Ltd
Abstract
Aim: The RESHAPE-HF2 trial is designed to assess the efficacy and safety
of the MitraClip device system for the treatment of clinically important
functional mitral regurgitation (FMR) in patients with heart failure (HF).
This report describes the baseline characteristics of patients enrolled in
the RESHAPE-HF2 trial compared to those enrolled in the COAPT and MITRA-FR
trials. Methods and Results: The RESHAPE-HF2 study is an
investigator-initiated, prospective, randomized, multicentre trial
including patients with symptomatic HF, a left ventricular ejection
fraction (LVEF) between 20% and 50% with moderate-to-severe or severe FMR,
for whom isolated mitral valve surgery was not recommended. Patients were
randomized 1:1 to a strategy of delivering or withholding MitraClip. Of
506 patients randomized, the mean age of the patients was 70 +/- 10 years,
and 99 of them (20%) were women. The median EuroSCORE II was 5.3 (2.8-9.0)
and median plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP)
was 2745 (1407-5385) pg/ml. Most patients were prescribed beta-blockers
(96%), diuretics (96%), angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin
inhibitors (82%) and mineralocorticoid receptor antagonists (82%). The use
of sodium-glucose cotransporter 2 inhibitors was rare (7%). Cardiac
resynchronization therapy (CRT) devices had been previously implanted in
29% of patients. Mean LVEF, left ventricular end-diastolic volume and
effective regurgitant orifice area (EROA) were 31 +/- 8%, 211 +/- 76 ml
and 0.25 +/- 0.08 cm2, respectively, whereas 44% of patients
had mitral regurgitation severity of grade 4+. Compared to patients
enrolled in COAPT and MITRA-FR, those enrolled in RESHAPE-HF2 were less
likely to have mitral regurgitation grade 4+ and, on average, HAD lower
EROA, and plasma NT-proBNP and higher estimated glomerular filtration
rate, but otherwise had similar age, comorbidities, CRT therapy and LVEF.
 Conclusion(s): Patients enrolled in RESHAPE-HF2 represent a third
distinct population where MitraClip was tested in, that is one mainly
comprising of patients with moderate-to-severe FMR instead of only severe
FMR, as enrolled in the COAPT and MITRA-FR trials. The results of
RESHAPE-HF2 will provide crucial insights regarding broader application of
the transcatheter edge-to-edge repair procedure in clinical
practice. Copyright © 2024 The Authors. European Journal of Heart
Failure published by John Wiley & Sons Ltd on behalf of European Society
of Cardiology.

<11>
Accession Number
644465503
Title
Efficacy and safety of TAVR versus SAVR in patients with small aortic
annuli: A systematic review and meta-analysis.
Source
International journal of cardiology. (pp 132243), 2024. Date of
Publication: 06 Jun 2024.
Author
Ayyad M.; Jabri A.; Khalefa B.B.; Al-Abdouh A.; Madanat L.; Albandak M.;
Alhuneafat L.; Sukhon F.; Shahrori Z.; Mourid M.R.; Mhanna M.; Giustino
G.; Wang D.D.; Hanson I.D.; Abbas A.E.; AlQarqaz M.; Villablanca P.
Institution
(Ayyad, Jabri, Giustino, Wang, AlQarqaz) Division of Cardiovascular
Medicine, Henry Ford Hospital, Detroit, MI, USA; Michigan State
University, College of Human Medicine, USA
(Khalefa, Al-Abdouh, Albandak) Division of hospital medicine, University
of Kentucky, Lexington, KY, United States
(Madanat, Hanson, Abbas) Department of Cardiovascular Medicine, William
Beaumont University Hospital, Royal Oak, MI, USA; Oakland University
William Beaumont School of Medicine, USA
(Alhuneafat) Cardiovascular Division, University of Minnesota,
Minneapolis, MN, United States
(Sukhon, Shahrori, Mourid) Heart and Vascular Center, Metrohealth Medical
Center, Cleveland, OH, United States
(Mhanna) Division of Cardiovascular Medicine, University of Iowa, IA,
United States
(Villablanca) Division of Cardiovascular Medicine, Henry Ford Hospital,
Detroit, MI, USA; Michigan State University, College of Human Medicine,
USA. Electronic address: pvillab1@hfhs.org
Abstract
INTRODUCTION: Patients with a small aortic annulus (SAA) undergoing aortic
valve replacement are at increased risk of patient-prosthesis mismatch
(PPM), which adversely affects outcomes. Transcatheter aortic valve
replacement (TAVR) has shown promise in mitigating PPM compared to
surgical aortic valve replacement (SAVR). METHOD(S): We conducted a
systematic review and meta-analysis following PRISMA guidelines to compare
clinical outcomes, mortality, and PPM between SAA patients undergoing TAVR
and SAVR. Eligible studies were identified through comprehensive
literature searches and assessed for quality and relevance.
 RESULT(S): Nine studies with a total of 2476 patients were included.
TAVR demonstrated similar 30-day and 2-year mortality, myocardial
infarction, and stroke rates compared to SAVR. However, TAVR showed
significant advantages in reducing moderate survival post SAVR, the
observed hemodynamic outcomes may potentially contribute to substantial
survival variations between TAVR and SAVR during extended follow-up
periods.22 Furthermore, previous studies found comparable 30-day and
2-year mortality rates between TAVR and SAVR, with no significant
differences across annulus sizes.22, 23 Stroke and myocardial infarction
incidences and severe PPM and lowering rates of major bleeding at both
30days and 2years. Conversely, SAVR had better outcomes in 30-day
permanent pacemaker implantation. Echocardiographic outcomes were
comparable between the two interventions. CONCLUSION(S): Our findings
suggest that both TAVR and SAVR are viable options for treating AS in
patients with a small aortic annulus. TAVR offers advantages in reducing
PPM and major bleeding, while SAVR performs better in terms of pacemaker
implantation. Future studies should focus on comparing newer generation
TAVR techniques and devices with SAVR. Consideration of patient
characteristics is crucial in selecting the optimal treatment approach for
AS. Copyright © 2024. Published by Elsevier B.V.

<12>
Accession Number
644465484
Title
Efficacy and safety of trans-catheter repair devices for mitral
regurgitation: A systematic review and meta-analysis.
Source
International journal of cardiology. (pp 132245), 2024. Date of
Publication: 06 Jun 2024.
Author
D'Amario D.; Laborante R.; Mennuni M.; Adamo M.; Metra M.; Patti G.
Institution
(D'Amario, Mennuni, Patti) Department of Translational Medicine,
Universita del Piemonte Orientale, Novara, Italy; Division of Cardiology,
AOU Maggiore della Carita, Novara, Italy
(Laborante) Department of Cardiovascular and Thoracic Sciences, Fondazione
Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
(Adamo, Metra) Cardiology, ASST Spedali Civili, Brescia; Department of
Medical and Surgical Specialties, Radiological Sciences and Public Health,
University of Brescia, Italy
Abstract
BACKGROUND: Several repair strategies emerged as possible treatment for
severe mitral regurgitation (MR). A systematic review and meta-analysis
was performed to compare the different percutaneous mitral valve repair
approaches. METHOD(S): PubMed and Scopus electronic databases were
scanned for eligible studies until December 11th, 2023. Clinical efficacy
endpoints were all-cause mortality, major adverse cardiovascular events,
and post-procedural NYHA functional class <3; the echocardiographic
efficacy endpoint was a post-intervention residual MR less than moderate.
Safety endpoints and procedural outcome measures were also assessed.
 RESULT(S): Eleven studies were included: 8 [N=1662 patients, mean
follow-up (FUP) 294days] compared MitraClip vs Pascal device, 2 (N=195
patients) MitraClip vs Carillon and 1 study (N=186 patients) evaluated
MitraClip against Cardioband. The Pascal-treated group had lower MR degree
compared to the MitraClip-treated group, without difference in
post-intervention mean trans-mitral gradient and in clinical and safety
endpoints. A longer procedure time was observed in the Pascal group,
albeit with a lower average number of implanted devices per procedure. The
two studies comparing MitraClip and Carillon were inconsistent in terms of
both efficacy and safety outcomes, while the study evaluating MitraClip vs
Cardioband showed that the latter might confer a significant clinical
benefit, with a similar reduction in MR. CONCLUSION(S): Pascal is as
safe and clinically effective as MitraClip in treating patients with MR,
with an apparent greater reduction in the magnitude of residual valve
insufficiency over the long term. Data on Cardioband and Carillon are not
robust enough to draw conclusions from the use of such
devices. Copyright © 2024. Published by Elsevier B.V.

<13>
Accession Number
2032613062
Title
Superficial Serratus Anterior Plane Block for Minimal Invasive Cardiac
Surgery: a single-center randomized controlled trial.
Source
Acta Anaesthesiologica Belgica. 75(2) (pp 107-115), 2024. Date of
Publication: May 2024.
Author
Vaes B.; van Hoecke L.; Allaert S.; Maes J.-W.; Francois J.; Poelaert J.;
Lapage K.
Institution
(Vaes, Allaert, Maes, Poelaert, Lapage) Department of Anaesthesia,
Intensive Care Medicine and Pain Medicine, General Hospital Maria
Middelares, Ghent, Belgium
(van Hoecke) Department of Anaesthesia and Perioperative Medicine, Ghent
University Hospital, Ghent, Belgium
(Francois) Department of Cardiac Surgery, General Hospital Maria
Middelares, Ghent, Belgium
Publisher
BeSARPP
Abstract
Introduction: Multimodal pain management with serratus anterior plane
block (SAPB) in minimal invasive cardiac surgery (MICS) may potentially
reduce pain scores and opioid consumption. However, randomized controlled
trials investigating the efficacy of a superficial SAPB are missing.
 Design(s): Monocentric, prospective, outcome-assessor blinded
randomized-controlled trial performed at the General Hospital Maria
Middelares, Ghent, Belgium. Method(s): 80 patients scheduled for
mitral valve surgery (MVS) via port-access, aortic valve replacement via
right anterior thoracotomy (AVR-RAT) and minimal invasive direct coronary
artery bypass (MIDCAB) surgery were randomized to a superficial SAPB (42
patients) or to routine analgesia (38 patients). In the SAPB group, a
single-shot block was performed with 1.25 mg.kg-1 levobupivacaine 0.25%
between the latissimus dorsi and serratus anterior muscle. The primary
outcome was static pain intensity measured by Numeric Rating Scale (NRS)
12 hours after extubation. Secondary outcomes were static pain intensity
measured by NRS at 2, 4, 6 and 24 hours after extubation, cumulative
opioid consumption, incidence of postoperative nausea and vomiting (PONV),
time to extubation, ICU and hospital length of stay and the amount of
carbon dioxide measured by arterial partial pressure (PaCO2).
 Result(s): There was no treatment effect on static pain intensity at
12 hours after extubation (mean difference 0.238 [95% CI: -0.70 - 1.19; p
= 0.78]). There was no treatment effect on static pain intensity on the
other predefined timepoints nor on the cumulative opioid consumption
during the first 48 postoperative hours (mean difference 0.10 mg [95% CI:
-2.65 - 2.83; p = 0.911]) nor any of the other secondary outcomes. Looking
at each surgical intervention separately, the results show a decrement in
static pain intensity (mean difference -1.71 [95% CI: -2.94 - -0.40; p =
0.021]) for patients undergoing MIDCAB surgery at 6 hours post extubation.
 Conclusion(s): In our setup, the effect of a single-shot superficial
SAPB could not improve static pain intensity scores at 12 hours after
extubation compared to a control group receiving standard intravenous
opioid analgesia in a mixed group of minimal invasive cardiac surgical
patients. Subsequently, the single-shot superficial SAPB could not reduce
the cumulative opioid consumption in the first 48 postoperative hours.
However, patients undergoing MIDCAB surgery may potentially benefit from
this technique. Copyright © 2024 BeSARPP. All rights reserved.

<14>
Accession Number
2032595860
Title
Remnant cholesterol and intensive blood pressure control in older patients
with hypertension: a post hoc analysis of the STEP randomized
trial+.
Source
European Journal of Preventive Cardiology. 31(8) (pp 997-1004), 2024. Date
of Publication: 01 Jun 2024.
Author
Yang R.; Zhang J.; Yu X.; Yang G.; Cai J.
Institution
(Yang, Cai) Hypertension Center, National Center for Cardiovascular
Diseases, Peking Union Medical College, Chinese Academy of Medical
Sciences, Fuwai Hospital, Beilishi Road 167, Xicheng District, Beijing
100037, China
(Zhang) Department of Cardiology, First Hospital of Shanxi Medical
University, No. 85 Jiefang South Road, Yingze District, Shanxi Province,
Taiyuan 030001, China
(Yu) Department of Cardiology, Benxi Railway Hospital, No. 25 Yingchun
Street, Pingshan District, Liaoning Province, Benxi 117000, China
(Yang) Institute of Prevention and Treatment of Cardiovascular Diseases in
Alpine Environment of Plateau, Characteristic Medical Center of the
Chinese People's Armed Police Forces, No. 220 Chenglin Road, Tianjin
300162, China
Publisher
Oxford University Press
Abstract
Aims Emerging evidence shows a close relationship between remnant
cholesterol (RC) and hypertension. However, it is unknown whether RC is
associated with the effects of intensive systolic blood pressure (SBP)
lowering on cardiovascular outcomes. Methods We performed a post hoc
analysis of the Strategy of Blood Pressure Intervention in the Elderly
Hypertensive Patients (STEP) and results trial. Participants were randomly
allocated to intensive (110 to <130 mmHg) or standard (130 to <150 mmHg)
treatment groups. The effects of intensive SBP lowering on the primary
composite outcome (stroke, acute coronary syndrome, acute decompensated
heart failure, coronary revascularization, atrial fibrillation, or
cardiovascular death), the components thereof, and all-cause mortality
were analysed by the tertile of baseline RC (lowest, middle, and highest).
We followed 8206 patients for 3.33 years (median). The adjusted hazard
ratios (HRs) [95% confidence interval (CI)] for the primary outcome were
1.06 (0.73-1.56), 0.58 (0.38-0.87), and 0.67 (0.46-0.96) in the lowest,
middle, and highest RC tertiles, respectively (P for interaction = 0.11).
However, significant heterogeneity in the treatment effects was observed
when comparing the upper two tertiles with the lowest tertile (P for
interaction = 0.033). For all-cause mortality, the adjusted HRs (95% CI)
were 2.48 (1.30-4.73), 1.37 (0.71-2.65), and 0.42 (0.22-0.80) in the
lowest, middle, and highest RC tertiles, respectively (P for interaction
<0.0001). Conclusion Baseline RC concentrations were associated with the
effects of intensive SBP lowering on the primary composite cardiovascular
outcome and all-cause mortality in hypertensive patients. These results
are hypothesis-generating and merit further study. Copyright ©
The Author(s) 2024. Published by Oxford University Press on behalf of the
European Society of Cardiology. All rights reserved.

<15>
Accession Number
2032559139
Title
Within and post-trial effects of an intensive lifestyle intervention on
kidney disease in adults with overweight or obesity and type 2 diabetes
mellitus: A secondary analysis of the Look AHEAD clinical trial.
Source
BMJ Open Diabetes Research and Care. 12(3) (no pagination), 2024. Article
Number: e004079. Date of Publication: 30 May 2024.
Author
Knowler W.C.; Chen H.; Bahnson J.L.; Kahn S.E.; Lewis C.E.; Nathan D.M.;
Nelson R.G.; Pilla S.J.; Bantle J.P.
Institution
(Knowler, Nelson) National Institute of Diabetes and Digestive and Kidney
Diseases, Phoenix, AZ, United States
(Chen, Bahnson) Department of Biostatistics and Data Science, Wake Forest
University School of Medicine, Winston Salem, NC, United States
(Kahn) VA Puget Sound Health Care System, University of Washington,
Seattle, WA, United States
(Lewis) Department of Epidemiology, University of Alabama at Birmingham,
Birmingham, AL, United States
(Nathan) Massachusetts General Hospital, Harvard Medical School, Boston,
MA, United States
(Nelson) Current: Research Division, Joslin Diabetes Center, Boston, MA,
United States
(Pilla) Department of Medicine, Johns Hopkins University, Baltimore, MD,
United States
(Bantle) Department of Medicine, University of Minnesota, Minneapolis, MN,
United States
Publisher
BMJ Publishing Group
Abstract
Introduction The Look AHEAD randomized clinical trial reported that an
8-year intensive lifestyle intervention (ILI) compared with diabetes
support and education (DSE) in adults aged 45-76 years with type 2
diabetes and overweight/obesity delayed kidney disease progression. Here,
we report long-term post-intervention follow-up for the trial's secondary
outcome of kidney disease. Research design and methods We examined effects
of ILI (n=2570) versus DSE (n=2575) on decline in estimated glomerular
filtration rate (eGFR) to <45 mL/min/1.73 m 2 or need for kidney
replacement therapy (KRT: dialysis or kidney transplant) during
intervention and post-intervention follow-up (median 15.6 years overall).
Results Incidence of eGFR <45 mL/min/1.73 m 2 was lower in ILI during the
intervention (HR=0.80, 95% CI=0.66 to 0.98) but not post-intervention
(HR=1.03, 0.86 to 1.23) or overall (HR=0.92, 0.80 to 1.04). There were no
significant treatment group differences in KRT. In prespecified subgroup
analyses, agextreatment interactions were significant over total
follow-up: p=0.001 for eGFR <45 mL/min/1.73 m 2 and p=0.01 for KRT. The
2205 participants aged >60 years at baseline had benefit in both kidney
outcomes during intervention and overall (HR=0.75, 0.62 to 0.90 for eGFR
<45 mL/min/1.73 m 2; HR=0.62, 0.43 to 0.91 for KRT). The absolute
treatment effects were greater post-intervention: ILI reduced the rate of
eGFR <45 mL/min/1.73 m 2 by 0.46 and 0.76 cases/100 person-years during
and post-intervention, respectively; and reduced KRT by 0.15 and 0.21
cases/100 person-years. The younger participants experienced no such
post-intervention benefits. Conclusions ILI reduced kidney disease
progression during and following the active intervention in persons aged
>=60 years. ILI should be considered for reducing kidney disease incidence
in older persons with type 2 diabetes. Copyright © 2024 BMJ
Publishing Group. All rights reserved.

<16>
Accession Number
2031968298
Title
Untangling the Complex Multidimensionality of the Social Determinants of
Cardiovascular Health: A Systematic Review.
Source
Canadian Journal of Cardiology. 40(6) (pp 1000-1006), 2024. Date of
Publication: June 2024.
Author
Vyas N.; Zaheer A.; Wijeysundera H.C.
Institution
(Vyas, Zaheer, Wijeysundera) Schulich Heart Program, Sunnybrook Health
Sciences Centre, University of Toronto, Toronto, ON, Canada
(Wijeysundera) Temerty Faculty of Medicine, University of Toronto,
Toronto, ON, Canada
(Wijeysundera) ICES, Toronto, ON, Canada
(Wijeysundera) Institute of Health Policy, Management, and Evaluation,
University of Toronto, Toronto, ON, Canada
Publisher
Elsevier Inc.
Abstract
Background: The cardiovascular literature is limited by the lack of
consensus on what are the best metrics for reporting social determinants
of health (SDH) or social deprivation, and if they should be reported as a
single metric or separately by their domains. Method(s): A systematic
review of the literature on cardiovascular surgeries and procedures was
conducted, identifying articles from January 1, 2010, to December 31,
2023, that studied the relationship between health outcomes after
cardiovascular procedures or surgeries and SDH/social deprivation. The
cardiovascular procedures/surgeries of interest were coronary and valve
surgeries and procedures including coronary artery bypass grafting (CABG),
percutaneous coronary intervention (PCI), valve replacement or repair, and
transcatheter aortic valve intervention. Result(s): After screening
638 articles, we identified 47 papers that met our inclusion and exclusion
criteria. The most common procedure evaluated was CABG and PCI; 46 of the
studies focused on these 2 procedures. Almost all of the articles reported
a different metric for SDH/social deprivation (41 different metrics);
despite this, all of the metrics showed a consistent relationship with
worse outcomes associated with greater degrees of SDH/deprivation. Only 9
reported on the individual domains of SDH/social deprivation; 3 studies
showed a discordant relationship. Conclusion(s): Although our
systematic review identified numerous articles evaluating the relationship
between SDH/social deprivation in cardiovascular disease, there was
substantial heterogeneity in which metric was used and how it was
reported. This reinforces the need for standards as to the best metrics
for SDH/social deprivation as well as best practices for
reporting. Copyright © 2024 The Authors

<17>
Accession Number
2029629675
Title
Comparison of Postoperative Anxiety, Depression, Somatization, and
Somatosensory Perception Levels of Patients After Off-Pump and On-Pump
Coronary Artery Bypass Graft Surgery.
Source
Istanbul Medical Journal. 25(2) (pp 151-157), 2024. Date of Publication:
01 May 2024.
Author
Emir I.; Simsek M.H.; Isik N.A.; Onk O.A.
Institution
(Emir, Onk) Erzincan Binali Yildirim University, Faculty of Medicine,
Department of Cardiovascular Surgery, Erzincan, Turkey
(Simsek) Private Giresun Ada Hospital, Clinic of Psychiatry, Giresun,
Turkey
(Isik) Istanbul Medeniyet University, Faculty of Health Sciences,
Department of Mental Health and Psychiatric Nursing, Istanbul, Turkey
Publisher
Galenos Publishing House
Abstract
Introduction: This study investigated the effect of coronary artery bypass
grafting surgery performed using either the on-pump or off-pump technique
on the levels of postoperative anxiety, depression, somatization, and
somatosensory amplification in patients. Method(s): There were 100
participants in this cross-sectional study who completed the
"Sociodemographic Data Form", the "Hospital Anxiety and Depression Scale",
the "Somatization Scale (SS)", and the "Somatosensory Amplification
Scale". Result(s): Compared with the off-pump group, the on-pump
group had a higher mean SS score. Conclusion(s): Because the mean SS
score was lower in patients after off-pump surgery, it may be more
advantageous to perform off-pump surgeries in the future. Before the
superiority of the off-pump over the on-pump can be definitively
established, however, data from large, randomized trials are
required. Copyright © 2024 by the University of Health Sciences
Turkey, Istanbul Training and Research Hospital/Istanbul Medical Journal
published by Galenos Publishing House.

<18>
Accession Number
2032248075
Title
Influence of intravenous fentanyl or dexmedetomidine infusions, combined
with lidocaine and ketamine, on cardiovascular response, sevoflurane
requirement and postoperative pain in dogs anesthetized for unilateral
mastectomy.
Source
Veterinary Anaesthesia and Analgesia. 51(4) (pp 381-390), 2024. Date of
Publication: 01 Jul 2024.
Author
Cardozo H.G.; Monteiro E.R.; Correia B.S.; Victor B Ferronatto J.;
Almeida-Filho F.T.; Alievi M.M.; Valle S.F.
Institution
(Cardozo, Monteiro, Correia, Victor B Ferronatto, Almeida-Filho, Alievi,
Valle) Faculty of Veterinary Medicine, Federal University of Rio Grande do
Sul, RS, Porto Alegre, Brazil
Publisher
Association of Veterinary Anaesthetists and American College of Veterinary
Anesthesia and Analgesia
Abstract
Objective: To compare the effects of constant rate infusions (CRI) of
fentanyl or dexmedetomidine, combined with lidocaine and ketamine, on
cardiovascular response during surgery, sevoflurane requirement and
postoperative pain in dogs undergoing mastectomy. Study design:
Prospective, randomized, blinded, clinical trial. Animals: A total of 29
female dogs with mammary tumors. Method(s): Premedication consisted
of intramuscular acepromazine and morphine. General anesthesia was induced
with intravenous propofol and maintained with sevoflurane. Dogs were
randomized to be administered intravenous DLK [dexmedetomidine 1 mug
kg-1 loading dose (LD) and 1 mug kg-1
hour-1; lidocaine 2 mg kg-1 LD and 3 mg
kg-1 hour-1; ketamine 1 mg kg-1 LD and
0.6 mg kg-1 hour-1; n = 14] or FLK (fentanyl 5 mug
kg-1 LD and 9 mug kg-1 hour-1; same doses
of lidocaine and ketamine; n = 15) during anesthesia. Cardiorespiratory
variables and end-tidal sevoflurane (FE'Sevo) were recorded during
surgery. The number of dogs administered ephedrine to treat arterial
hypotension [mean arterial pressure (MAP) < 60 mmHg] was recorded.
Meloxicam was administered to both groups. Postoperative pain and rescue
analgesia requirement were assessed for 24 hours using the short form of
the Glasgow Composite Measure Pain Scale. Data were compared using a mixed
effects model or a Mann-Whitney test. Result(s): More dogs required
ephedrine in FLK than in DLK (67% versus 7%). Heart rate was not
significantly different between groups, whereas lower values of MAP (p <=
0.01) and FE'Sevo (p = 0.018) were observed in FLK than in DLK. Rescue
analgesia was administered to 2/15 dogs in FLK and 0/14 dogs in DLK.
Conclusions and clinical relevance: Based on the cardiovascular response
during surgery, intraoperative infusions of FLK and DLK provided adequate
antinociception. Infusion of DLK provided greater stability of blood
pressure. Both protocols resulted in minimal need for additional analgesia
within 24 hours postoperatively. Copyright © 2024 Association of
Veterinary Anaesthetists and American College of Veterinary Anesthesia and
Analgesia

<19>
Accession Number
2030122238
Title
Associations between intraoperative nociceptive response index and early
postoperative acute kidney injury in patients undergoing non-cardiac
surgery under general anesthesia: a single-center retrospective cohort
study.
Source
Journal of Clinical Monitoring and Computing. (no pagination), 2024. Date
of Publication: 2024.
Author
Kobata M.; Miyamoto K.; Ooba S.; Saeki A.; Okutani H.; Ueki R.; Kariya N.;
Hirose M.
Institution
(Kobata, Miyamoto, Ooba, Saeki, Okutani, Ueki, Kariya, Hirose) Department
of Anesthesiology, Hyogo Medical University, Faculty of Medicine, 1-1
Mukogawa-cho, Hyogo, Nishinomiya 663-8501, Japan
Publisher
Springer Science and Business Media B.V.
Abstract
Both tissue hypoperfusion and elevated surgical stress during surgery are
involved in the pathogenesis of postoperative acute kidney injury (AKI).
Although intraoperative hypotension, which evokes renal hypoperfusion, has
been reported to be associated with the development of postoperative AKI,
there is no consensus on the association between surgical stress responses
(e.g., hypertension and inflammation) and postoperative AKI. Given that
intraoperative values of nociceptive response (NR) index are reportedly
associated with surgical stress responses, the present study was performed
to assess associations between intraoperative NR index and postoperative
AKI in patients undergoing non-cardiac surgery. In this
single-institutional retrospective cohort study, data of the highest and
lowest values of NR index during surgery were obtained in consecutive
adult patients undergoing non-cardiac surgery under general anesthesia
from February 2022 to August 2023. Data on highest and lowest mean blood
pressure (MBP) during surgery were also obtained. In 5,765 patients
enrolled, multivariate regression analysis revealed that the development
of early postoperative AKI was significantly associated with highest NR
during surgery >= 0.920, lowest MBP during surgery < 54 mmHg, age >= 48
years, male sex, ASA-PS >= III, emergency, and duration of surgery >= 226
min. In addition to intraoperative hypotension, a higher level of
intraoperative NR index is likely associated with higher incidence of
early postoperative AKI in adult patients undergoing non-cardiac surgery
under general anesthesia. Copyright © The Author(s), under
exclusive licence to Springer Nature B.V. 2024.

<20>
Accession Number
2029700167
Title
Individual dipeptidyl peptidase-4 inhibitors and acute kidney injury in
patients with type 2 diabetes: A systematic review and network
meta-analysis.
Source
Basic and Clinical Pharmacology and Toxicology. 135(1) (pp 71-80), 2024.
Date of Publication: July 2024.
Author
Mitsuboshi S.; Morizumi M.; Kotake K.; Kaseda R.; Narita I.
Institution
(Mitsuboshi) Department of Pharmacy, Kaetsu Hospital, Niigata, Japan
(Morizumi) Department of Pharmacy, Ohno Memorial Hospital, Osaka, Japan
(Kotake) Department of Pharmacy, Okayama Saiseikai General Hospital,
Okayama, Japan
(Kaseda, Narita) Division of Clinical Nephrology and Rheumatology, Niigata
University Graduate School of Medical and Dental Sciences, Niigata, Japan
Publisher
John Wiley and Sons Inc
Abstract
This network meta-analysis of randomized controlled trials aimed to
determine whether any individual dipeptidyl peptidase-4 (DPP-4) inhibitors
increase the risk of acute kidney injury (AKI). The Medical Literature
Analysis and Retrieval System Online via PubMed, the Cochrane Central
Register of Controlled Trials and ClinicalTrials.gov were systematically
searched to identify relevant studies. The primary outcome was AKI. A
frequentist network meta-analysis was performed using a random-effects
model to account for heterogeneity. Twenty-nine studies involving 56 117
participants were included. There were 918 cases of AKI (1.63%). The risk
of bias was generally considered to be low. The only DPP-4 inhibitor that
significantly increased the frequency of AKI when compared with placebo
was sitagliptin (risk ratio 1.65, 95% confidence interval 1.22-2.23).
However, because one study showed significant outliers in the funnel plot,
in a highly heterogeneous population composed solely of patients
undergoing surgery for coronary artery bypass graft, we conducted a
post-hoc sensitivity analysis to exclude this study. The results showed no
statistically significant difference in the risk of AKI between
sitagliptin and placebo. Individual DPP-4 inhibitors do not appear to
increase the risk of AKI. However, sitagliptin may be associated with AKI
in patients with underlying severe cardiovascular disease. Copyright
© 2024 Nordic Association for the Publication of BCPT (former Nordic
Pharmacological Society). Published by John Wiley & Sons Ltd.

<21>
Accession Number
2028606532
Title
Ultrasound-guided versus conventional lung recruitment manoeuvres in
thoracic surgery: a randomised controlled study.
Source
Journal of Clinical Monitoring and Computing. 38(3) (pp 731-739), 2024.
Date of Publication: June 2024.
Author
Wu L.; Yang L.; Yang Y.; Wu X.; Zhang J.
Institution
(Wu, Yang, Yang, Wu, Zhang) Department of Anesthesiology, Fudan University
Shanghai Cancer Center, No. 270, Dong'An Road, Xuhui District, Shanghai
200032, China
(Zhang) Department of Oncology, Shanghai Medical College, Fudan
University, No. 270, Dong'An Road, Xuhui District, Shanghai 200032, China
Publisher
Springer Science and Business Media B.V.
Abstract
Lung recruitment manoeuvres (RMs) during mechanical ventilation may reduce
atelectasis, however, the optimal recruitment strategy for patients
undergoing thoracic surgery remains unknown. Our study was designed to
investigate whether ultrasound-guided lung RMs is superior to conventional
RMs in reducing perioperative atelectasis during thoracic surgery with
one-lung ventilation. We conducted a randomised controlled clinical trial
from August 2022 to September 2022. Sixty patients scheduled for
video-assisted thoracoscopic surgery (VATS) under general anaesthesia were
enrolled. Subjects were randomly divided into the ultrasound-guided RMs
group (manual inflation guided by lung ultrasound) or conventional RMs
group (manual inflation with 30 cmH<inf>2</inf>O pressure). Lung
ultrasound were performed at three predefined time points (1 min after
anaesthetic induction; after RMs at the end of surgery; before discharge
from postanesthesia care unit [PACU]). The primary outcome was lung
ultrasound score before discharge from the PACU after extubation. In the
early postoperative period, lung aeration deteriorated in both groups even
after lung RMs. However, ultrasound-guided lung RMs had significantly
lower lung ultrasound scores when compared with conventional RMs in
bilateral lungs (2.0 [0.8-4.0] vs. 8.0 [3.8-10.3], P < 0.01) at the end of
surgery, which remained before patients discharged from the PACU.
Accordingly, the lower incidence of atelectasis was found in
ultrasound-guided RMs group than in conventional RMs group (7% vs. 53%; P
< 0.01) at the end of surgery. Ultrasound-guided RMs is superior to
conventional RMs in improving lung aeration and reducing the incidence of
lung atelectasis at early postoperative period in patients undergoing
VATS. The study protocol was approved by the Institutional Review Board of
the Fudan University Shanghai Cancer Center (No. 220,825,810; date of
approval: August 5, 2022) and registered on Chinese Clinical Trial
Registry (registration number: ChiCTR2200062761). Copyright © The
Author(s), under exclusive licence to Springer Nature B.V. 2024.

<22>
Accession Number
2027275404
Title
Treatment of hypoplastic left heart syndrome: A systematic review and
meta-analysis of randomised controlled trials.
Source
Cardiology in the Young. 34(3) (pp 659-666), 2024. Date of Publication: 19
Mar 2024.
Author
Kim A.Y.; Woo W.; Saxena A.; Tanidir I.C.; Yao A.; Kurniawati Y.; Thakur
V.; Shin Y.R.; Shin J.I.; Jung J.W.; Barron D.J.
Institution
(Kim, Jung) Division of Pediatric Cardiology, Department of Pediatrics,
Severance Cardiovascular Hospital, Yonsei University, College of Medicine,
KOR, Seoul, South Korea
(Kim, Jung) Department of Pediatrics, Yonsei University, College of
Medicine, Seoul, South Korea
(Woo) Department of Thoracic and Cardiovascular Surgery, Gangnam Severance
Hospital, Yonsei University, College of Medicine, Seoul, South Korea
(Saxena) Department of Cardiology, All India Institute of Medical
Sciences, New Delhi, India
(Tanidir) Department of Pediatric Cardiology, Basaksehir Cam and Sakura
City Hospital, Istanbul, Turkey
(Yao) Department of Health Service Promotion, University of Tokyo, Japan
(Kurniawati) Department of Pediatric Cardiology, National Cardiovascular
Center Harapan Kita, Jakarta, Indonesia
(Thakur, Shin) Department of Pediatrics, Labatt Family Heart Center, The
Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
(Shin) Department of Cardiovascular Surgery, Yonsei University, College of
Medicine, Seoul, South Korea
(Shin) Severance Underwood Meta-research Center, Institute of Convergence
Science, Yonsei University, Seoul, South Korea
(Barron) Division of Cardiovascular Surgery, Department of Surgery, The
Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Publisher
Cambridge University Press
Abstract
Background: This meta-analysis aimed to consolidate existing data from
randomised controlled trials on hypoplastic left heart syndrome.
 Method(s): Hypoplastic left heart syndrome specific randomised
controlled trials published between January 2005 and September 2021 in
MEDLINE, EMBASE, and Cochrane databases were included. Regardless of
clinical outcomes, we included all randomised controlled trials about
hypoplastic left heart syndrome and categorised them according to their
results. Two reviewers independently assessed for eligibility, relevance,
and data extraction. The primary outcome was mortality after Norwood
surgery. Study quality and heterogeneity were assessed. A random-effects
model was used for analysis. Result(s): Of the 33 included randomised
controlled trials, 21 compared right ventricle-to-pulmonary artery shunt
and modified Blalock-Taussig-Thomas shunt during the Norwood procedure,
and 12 regarded medication, surgical strategy, cardiopulmonary bypass
tactics, and ICU management. Survival rates up to 1 year were superior in
the right ventricle-to-pulmonary artery shunt group; this difference began
to disappear at 3 years and remained unchanged until 6 years. The right
ventricle-to-pulmonary artery shunt group had a significantly higher
reintervention rate from the interstage to the 6-year follow-up period.
Right ventricular function was better in the modified
Blalock-Taussig-Thomas shunt group 1-3 years after the Norwood procedure,
but its superiority diminished in the 6-year follow-up. Randomised
controlled trials regarding medical treatment, surgical strategy during
cardiopulmonary bypass, and ICU management yielded insignificant results.
 Conclusion(s): Although right ventricle-to-pulmonary artery shunt
appeared to be superior in the early period, the two shunts applied during
the Norwood procedure demonstrated comparable long-term prognosis despite
high reintervention rates in right ventricle-to-pulmonary artery shunt due
to pulmonary artery stenosis. For medical/perioperative management of
hypoplastic left heart syndrome, further randomised controlled trials are
needed to deliver specific evidence-based recommendations. Copyright
© The Author(s), 2023. Published by Cambridge University Press.

<23>
Accession Number
643732746
Title
N-Acetylcysteine to Reduce Mortality for Patients Requiring Cardiac
Catheterization or Cardiac Surgery: A Systematic Review and Meta-analysis.
Source
Journal of cardiovascular pharmacology. 83(6) (pp 580-587), 2024. Date of
Publication: 01 Jun 2024.
Author
Gakuba C.; Dumitrascu A.-D.; Marsan P.-E.; Legallois D.; Hanouz J.-L.;
Vivien D.; Martinez de Lizarrondo S.; Gauberti M.; Cerasuolo D.
Institution
(Gakuba, Dumitrascu, Marsan, Hanouz) departement d'Anesthesie Reanimation,
CHU de Caen Normandie, Caen, France
(Gakuba, Hanouz, Vivien, Martinez de Lizarrondo, Gauberti) departement
PhIND << Physiopathology and imaging of Neurological Disorders >>,
Institut Blood and Brain @ Caen-Normandie, Normandie Univ, UNICAEN,
INSERM, Caen, France
(Legallois) departement de Cardiologie, CHU de Caen Normandie, EA4650
(SEILIRM), FHU REMOD-VHF,Caen, France
(Vivien) departement de Recherche Clinique, CHU de Caen Normandie, Caen,
France
(Gauberti) departement de Radiologie diagnostique et interventionnelle,
CHU de Caen Normandie, Caen, France
(Cerasuolo) departement de sante publique, Centre hospitalier
universitaire de Caen, Caen, France; and
(Cerasuolo) Normandie Univ, UNICAEN, INSERM U1086, Caen, France
Abstract
ABSTRACT: Multimers of von Willebrand factor play a critical role in
various processes inducing morbidity and mortality in cardiovascular-risk
patients. With the ability to reduce von Willebrand factor multimers,
N-acetylcysteine (NAC) could reduce mortality in patients undergoing
coronary catheterization or cardiac surgery. However, its impact in
perioperative period has never been studied so far in regard of its
potential cardiovascular benefits. Then, 4 databases were searched for
randomized controlled trials that compared in-hospital mortality between
an experimental group, with NAC, and a control group without NAC, in
patients undergoing coronary catheterization or cardiac surgery. The
primary efficacy outcome was in-hospital mortality. Secondary outcomes
were the occurrence of thrombotic events, major cardiovascular events,
myocardial infarction, and contrast-induced nephropathy. The safety
outcome was occurrence of hemorrhagic events. Nineteen studies totaling
3718 patients were included. Pooled analysis demonstrated a reduction of
in-hospital mortality associated with NAC: odds ratio, 0.60; 95%
confidence interval, 0.39-0.92; P = 0.02. The occurrence of secondary
outcomes was not significantly reduced with NAC except for
contrast-induced nephropathy. No difference was reported for hemorrhagic
events. Subgroup analyses revealed a life-saving effect of NAC in a
dose-dependent manner with reduction of in-hospital mortality for the NAC
high-dose group, but not for the NAC standard-dose (<3500-mg) group. In
conclusion, without being able to conclude on the nature of the mechanism
involved, our review suggests a benefit of NAC in cardiovascular-risk
patients in perioperative period in terms of mortality and supports
prospective confirmatory studies. Copyright © 2024 Wolters Kluwer
Health, Inc. All rights reserved.

<24>
Accession Number
2032488731
Title
Prognostic Value of Left Ventricular Global Longitudinal Strain for Major
Adverse Cardiovascular Events in Patients with Aortic Valve Disease: A
Meta-Analysis.
Source
Cardiology (Switzerland). 149(3) (pp 277-285), 2024. Date of Publication:
01 Feb 2024.
Author
Liao H.; Yang S.; Yu S.; Hu X.; Meng X.; Wu K.
Institution
(Liao) Graduate School, Guizhou Medical University, Guiyang, China
(Yang, Hu, Meng, Wu) Department of Cardiovascular Surgery, Affiliated
Hospital of Guizhou Medical University, Guiyang, China
(Yu) Ultrasound Center, Affiliated Hospital of Guizhou Medical University,
Guiyang, China
Publisher
S. Karger AG
Abstract
Introduction: Valvular heart disease is one of the most common heart
diseases. It is characterized by abnormal function or structure of the
heart valves. There may be no clinical symptoms in the early stages.
Clinical symptoms of arrhythmia, heart failure, or thromboembolic events
may occur in the late stages of the disease, such as palpitation after
activities, breathing difficulties, fatigue, and so on. Aortic valve
disease is a major part of valvular heart disease. The main treatment for
aortic valve disease is valve replacement or repair surgery, but it is
extremely risky. Therefore, a rigorous prognostic assessment is extremely
important for patients with aortic valve disease. The global longitudinal
strain is an index that describes the deformation capacity of myocardium.
There is evidence that it provides a test for systolic dysfunction other
than LVEF (left ventricular ejection fraction) and provides additional
prognostic information. Method(s): Search literature published
between 2010 and 2023 on relevant platforms and contain the following
keywords: "Aortic valve disease,""Aortic stenosis,""Aortic
regurgitation,"and "longitudinal strain"or "strain."The data is then
extracted and collated for analysis. Result(s): A total of 15
articles were included. The total population involved in this study was
3,678 individuals. The absolute value of LVGLS was higher in the no-MACE
group than in the MACE group in patients with aortic stenosis (Z = 8.10, p
< 0.00001), and impaired LVGLS was a risk factor for MACE in patients with
aortic stenosis (HR = 1.14, p < 0.00001, 95% CI: 1.08-1.20). There was
also a correlation between impaired LVGLS and aortic valve surgery in
patients with aortic valve disease (HR = 1.16, p < 0.0001, 95% CI:
1.08-1.25) or patients with aortic valve regurgitation (HR = 1.21, p =
0.0004, 95% CI: 1.09-1.34). We also found that impaired LVGLS had no
significant association between LVGLS and mortality during the period of
follow-up in patients with aortic valve stenosis (HR = 1.08, 95% CI:
0.94-1.25, p = 0.28), but it was associated with mortality in studies of
prospective analyses (HR = 1.34, 95% CI: 1.02-1.75, p = 0.04).
 Conclusion(s): Impaired LVGLS correlates with major adverse
cardiovascular events in patients with aortic valve disease, and it has
predictive value for the prognosis of patients with aortic valve disease.
 Copyright © 2024 S. Karger AG, Basel.

<25>
Accession Number
2032720243
Title
Correction: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and
Management of Atrial Fibrillation: A Report of the American College of
Cardiology/American Heart Association Joint Committee on Clinical Practice
Guidelines (Journal of the American College of Cardiology (2024) 83(1)
(109-279), (S0735109723064653), (10.1016/j.jacc.2023.08.017)).
Source
Journal of the American College of Cardiology. 83(25) (pp 2714), 2024.
Date of Publication: 25 Jun 2024.
Author
Anonymous
Publisher
Elsevier Inc.
Abstract
Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM,
Deswal A, Eckhardt L, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL,
Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta
KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP,
Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente
AM, Van Wagoner DR 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and
Management of Atrial Fibrillation: A Report of the American College of
Cardiology/American Heart Association Joint Committee on Clinical Practice
Guidelines J Am Coll Cardiol. 2024;83:109-279. In the article by Joglar et
al, "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of
Atrial Fibrillation: A Report of the American College of
Cardiology/American Heart Association Joint Committee on Clinical Practice
Guidelines," which published ahead of print on November 30, 2023, and
appeared in the January 2, 2024, issue of the journal (J Am Coll Cardiol.
2024;83:109-279), a correction was needed. 1. On page 143, in Table 8, in
the row for the "Risk Factor," "Hypertension," the entry for the "ATRIA"
column was inadvertently omitted. It has been updated to read, "1."2. On
page 177, in Figure 17, the last row, in the third box from the left, the
asterisk has been moved from the top portion of the box after "IV
Amiodarone" to the bottom portion of the box after "Verapamil,
diltiazem." Copyright © 2024 American College of Cardiology
Foundation and the American Heart Association, Inc. Published by Elsevier.

<26>
Accession Number
2032637486
Title
Opioid-free anaesthesia with dexmedetomidine and lidocaine versus
remifentanil-based anaesthesia in cardiac surgery: study protocol of a
French randomised, multicentre and single-blinded OFACS trial.
Source
BMJ Open. 14(6) (no pagination), 2024. Article Number: e079984. Date of
Publication: 03 Jun 2024.
Author
Besnier E.; Moussa M.D.; Thill C.; Vallin F.; Donnadieu N.; Ruault S.;
Lorne E.; Scherrer V.; Lanoiselee J.; Lefebvre T.; Sentenac P.; Abou-Arab
O.
Institution
(Besnier, Scherrer) Department of Anesthesia and Critical Care, Rouen
University Hospital, Rouen, France
(Besnier) U1096, Inserm, Rouen, France
(Moussa, Lanoiselee) Department of Anesthesiology and Critical Care, Lille
University Hospital, Lille, France
(Moussa) Ulr 2694-METRICS: Evaluation des Technologies de Sante et des
Pratiques Medicales, Univ.Lille, Lille, France
(Thill) Department of Biostatistics, Rouen University Hospital, Rouen,
France
(Vallin, Ruault) Research Department, Rouen University Hospital, Rouen,
France
(Donnadieu) Department of Pharmacy, Rouen University Hospital, Rouen,
France
(Lorne, Sentenac) Anesthesia and Critical Care Medicine, Clinique du
Millenaire, Montpellier, France
(Lefebvre, Abou-Arab) Department of Anesthesiology and Critical Care,
University Hospital Centre Amiens-Picardie, Amiens, France
Publisher
BMJ Publishing Group
Abstract
Introduction Intraoperative opioids have been used for decades to reduce
negative responses to nociception. However, opioids may have several, and
sometimes serious, adverse effects. Cardiac surgery exposes patients to a
high risk of postoperative complications, some of which are common to
those caused by opioids: acute respiratory failure, postoperative
cognitive dysfunction, postoperative ileus (POI) or death. An opioid-free
anaesthesia (OFA) strategy, based on the use of dexmedetomidine and
lidocaine, may limit these adverse effects, but no randomised trials on
this issue have been published in cardiac surgery. We hypothesised that
OFA versus opioid-based anaesthesia (OBA) may reduce the incidence of
major opioid-related complications after cardiac surgery. Methods and
analysis Multicentre, randomised, parallel and single-blinded clinical
trial in four cardiac surgical centres in France, including 268 patients
scheduled for coronary artery bypass grafting under cardiac bypass, with
or without aortic valve replacement. Patients will be randomised to either
a control OBA protocol using remifentanil or an OFA protocol using
dexmedetomidine/lidocaine. The primary composite endpoint is the
occurrence of at least one of the following: (1) postoperative cognitive
disorder evaluated by the Confusion Assessment Method for the Intensive
Care Unit test, (2) POI, (3) acute respiratory distress or (4) death
within the first 48 postoperative hours. Secondary endpoints are
postoperative pain, morphine consumption, nausea-vomiting, shock, acute
kidney injury, atrioventricular block, pneumonia and length of hospital
stay. Ethics and dissemination This trial has been approved by an
independent ethics committee (Comite de Protection des Personnes Ouest
III-Angers on 23 February 2021). Results will be submitted in
international journals for peer reviewing. Trial registration number
NCT04940689, EudraCT 2020-002126-90. Copyright © 2007 BMJ
Publishing Group Ltd.

<27>
Accession Number
2029690203
Title
Evaluation of the Combined Effect of the Local Effect of Epidural
Anesthesia with General Anesthesia in Thoracic Surgery.
Source
International Journal of Pharmacology. 20(5) (pp 742-747), 2024. Date of
Publication: 2024.
Author
Lai J.; Zhang Z.; Xie L.; Liang X.; Zhou H.; Pan Q.
Institution
(Lai, Zhang, Xie, Liang, Liang, Zhou, Pan) Department of Anaesthesia,
Central People's Hospital of Zhanjiang, Guangdong, Zhanjiang 524045, China
Publisher
Asian Network for Scientific Information
Abstract
Background and Objective: General anesthesia (GN) may cause thoracic
surgery patients to lose consciousness and block the Central Nervous
System (CNS). The present investigation was carried out to assess the
combined effects of the local impact of epidural anaesthesia (EA) with GN
in thoracic surgery. Material(s) and Method(s): The investigation
included 100 chest surgery participants. The 50 patients were randomly
assigned untreated or investigational based on admission time. The
investigating group got epidural and GN, whereas the untreated group
received general. Both groups' routine indicators, anaesthesia conditions
and surgical side effects were assessed. Result(s): Both groups had
similar preoperative oxygen saturation, systolic and diastolic blood
pressure, mean arterial pressure and heart rate (p>0.05). The experimental
group showed significant reductions in intraoperative and postoperative
blood oxygen saturation, systolic and diastolic blood pressure, mean
arterial pressure and heart rate compared to the untreated group (p<0.05).
A 32.6+/-3.4 mL inhaled anaesthetic dose, 9.46+/-3.61 min intraoperative
eye-opening time and 18.13+/-6.29 min speech function recovery time were
seen in the untreated group. Significantly higher than the investigational
group (14.2+/-2.5 mL, 6.1 3+/-2.78 min) and 9.26+/-4.07 min, p<0.05. The
experimental group had significantly less postoperative side effects than
the untreated group (p<0.05). Conclusion(s): Epidural and GN increase
thoracic surgery safety and effectiveness. Copyright © 2024
JingSheng Lai et al.

<28>
Accession Number
2030153074
Title
Clinical characteristics and outcomes in pseudomonas endocarditis: a
systematic review of individual cases: Systematic review of pseudomonas
endocarditis.
Source
Infection. (no pagination), 2024. Date of Publication: 2024.
Author
Meena D.S.; Kumar D.; Kumar B.; Bohra G.K.; Midha N.; Garg M.K.
Institution
(Meena, Kumar, Kumar, Bohra, Midha, Garg) Division of Infectious Diseases,
Department of Internal Medicine, All India Institute of Medical Sciences,
Jodhpur 342005, India
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: The landscape of Pseudomonas infective endocarditis (IE) is
evolving with the widespread use of cardiac implantable devices and
hospital-acquired infections. This systematic review aimed to evaluate the
emerging risk factors and outcomes in Pseudomonas IE. Method(s): A
literature search was performed in major electronic databases (PubMed,
Scopus, and Google Scholar) with appropriate keywords and combinations
till November 2023. We recorded data for risk factors, diagnostic and
treatment modalities. This study is registered with PROSPERO,
CRD42023442807. Result(s): A total of 218 cases (131 articles) were
included. Intravenous drug use (IDUs) and prosthetic valve endocarditis
(PVE) were major risk factors for IE (37.6% and 22%). However, the
prosthetic valve was the predominant risk factor in the last two decades
(23.5%). Paravalvular complications (paravalvular leak, abscess, or
pseudoaneurysm) were described in 40 cases (18%), and the vast majority
belonged to the aortic valve (70%). The mean time from symptom onset to
presentation was 14 days. The incidence of difficult-to-treat resistant
(DTR) pseudomonas was 7.4%. Valve replacement was performed in 57.3% of
cases. Combination antibiotics were used in most cases (77%), with the
aminoglycosides-based combination being the most frequently used (66%).
The overall mortality rate was 26.1%. The recurrence rate was 11.2%.
Almost half of these patients were IDUs (47%), and most had aortic valve
endocarditis (76%). Conclusion(s): This review highlights the
changing epidemiology of Pseudomonas endocarditis with the emergence of
prosthetic valve infections. Acute presentation and associated high
mortality are characteristic of Pseudomonas IE and require aggressive
diagnostic and therapeutic approach. Copyright © Springer-Verlag
GmbH Germany, part of Springer Nature 2024.

<29>
Accession Number
2030110122
Title
Conventional versus minimally invasive extra-corporeal circulation in
patients undergoing cardiac surgery: A randomized controlled trial
(COMICS).
Source
Perfusion (United Kingdom). (no pagination), 2024. Date of Publication:
2024.
Author
Angelini G.D.; Reeves B.C.; Culliford L.A.; Maishman R.; Rogers C.A.;
Anastasiadis K.; Antonitsis P.; Argiriadou H.; Carrel T.; Keller D.;
Liebold A.; Ashkaniani F.; El-Essawi A.; Breitenbach I.; Lloyd C.; Bennett
M.; Cale A.; Gunaydin S.; Gunertem E.; Oueida F.; Yassin I.M.; Serrick C.;
Murkin J.M.; Rao V.; Moscarelli M.; Condello I.; Punjabi P.; Rajakaruna
C.; Deliopoulos A.; Bone D.; Lansdown W.; Moorjani N.; Dennis S.
Institution
(Angelini, Reeves, Culliford, Maishman, Rogers) Bristol Medical School,
University of Bristol, Bristol, United Kingdom
(Anastasiadis, Antonitsis, Argiriadou) Aristotle University of
Thessaloniki School of Medicine, Thessaloniki, Greece
(Carrel, Keller) University Hospital Bern, Bern, Switzerland
(Liebold, Ashkaniani) Universitatsklinikum Ulm, Ulm, Germany
(El-Essawi) Universitatsmedizin Gottingen, Gottingen, Germany
(Breitenbach) Klinikum Braunschweig, Braunschweig, Germany
(Lloyd, Bennett) University Hospitals Plymouth NHS Trust, Plymouth, United
Kingdom
(Cale) Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom
(Gunaydin, Gunertem) Numune Training and Research Hospital in Ankara,
Ankara, Turkey
(Oueida, Yassin) Saud Al-Babtain Cardiac Centre, Dammam, Saudi Arabia
(Serrick, Rao) University Health Network, Toronto, ON, Canada
(Murkin) University of Western Ontario, London, ON, Canada
(Moscarelli, Condello) Anthea Hospital Bari, Italy
(Punjabi) Imperial College Healthcare, London, United Kingdom
(Rajakaruna, Bone, Lansdown) University Hospitals Bristol NHS Foundation
Trust, Bristol, United Kingdom
(Deliopoulos) AHEPA University Hospital, Thessaloniki, Greece
(Moorjani, Dennis) Royal Papworth Hospital, Cambridge, United Kingdom
Publisher
SAGE Publications Ltd
Abstract
Introduction: The trial hypothesized that minimally invasive
extra-corporeal circulation (MiECC) reduces the risk of serious adverse
events (SAEs) after cardiac surgery operations requiring extra-corporeal
circulation without circulatory arrest. Method(s): This is a
multicentre, international randomized controlled trial across fourteen
cardiac surgery centres including patients aged >=18 and <85 years
undergoing elective or urgent isolated coronary artery bypass grafting
(CABG), isolated aortic valve replacement (AVR) surgery, or CABG + AVR
surgery. Participants were randomized to MiECC or conventional
extra-corporeal circulation (CECC), stratified by centre and operation.
The primary outcome was a composite of 12 post-operative SAEs up to 30
days after surgery, the risk of which MiECC was hypothesized to reduce.
Secondary outcomes comprised: other SAEs; all-cause mortality; transfusion
of blood products; time to discharge from intensive care and hospital;
health-related quality-of-life. Analyses were performed on a modified
intention-to-treat basis. Result(s): The trial terminated early due
to the COVID-19 pandemic; 1071 participants (896 isolated CABG, 97
isolated AVR, 69 CABG + AVR) with median age 66 years and median EuroSCORE
II 1.24 were randomized (535 to MiECC, 536 to CECC). Twenty-six
participants withdrew after randomization, 22 before and four after
intervention. Fifty of 517 (9.7%) randomized to MiECC and 69/522 (13.2%)
randomized to CECC group experienced the primary outcome (risk ratio =
0.732, 95% confidence interval (95% CI) = 0.556 to 0.962, p = 0.025). The
risk of any SAE not contributing to the primary outcome was similarly
reduced (risk ratio = 0.791, 95% CI 0.530 to 1.179, p = 0.250).
 Conclusion(s): MiECC reduces the relative risk of primary outcome
events by about 25%. The risk of other SAEs was similarly reduced. Because
the trial terminated early without achieving the target sample size, these
potential benefits of MiECC are uncertain. Copyright © The
Author(s) 2024.

<30>
Accession Number
2030100028
Title
Promising therapies for adults with symptomatic obstructive hypertrophic
cardiomyopathy: 2023 and beyond.
Source
Expert Opinion on Pharmacotherapy. (no pagination), 2024. Date of
Publication: 2024.
Author
Gaballa A.; Jadam S.; Desai M.Y.
Institution
(Gaballa, Jadam, Desai) Hypertrophic Cardiomyopathy Center, Cleveland
Clinic, Cleveland, OH, United States
Publisher
Taylor and Francis Ltd.
Abstract
Introduction: Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic
heart disease with an estimated prevalence in the general population of
0.2% to 0.6%. Clinically, HCM can range from no symptoms to severe
symptoms such as heart failure or sudden cardiac death. Currently, the
management of HCM involves lifestyle modifications, familial screening,
genetic counseling, pharmacotherapy to manage symptoms, sudden cardiac
death risk assessment, septal reduction therapy, and heart transplantation
for specific patients. Multicenter randomized controlled trials have only
recently explored the potential of cardiac myosin inhibitors (CMIs) such
as mavacamten as a directed pharmacological approach for managing HCM.
Areas covered: We will assess the existing medical treatments for HCM:
beta-blockers, calcium channel blockers, disopyramide, and different CMIs.
We will also discuss future HCM pharmacotherapy guidelines and underline
this patient population's unfulfilled needs. Expert opinion: Mavacamten is
the first-in-class CMI approved by the FDA to target HCM pathophysiology
specifically. Mavacamten should be incorporated into the standard therapy
for oHCM in case of symptom persistence despite using maximally tolerated
beta blockers and/or calcium channel blockers. Potential drug-drug
interactions should be assessed before initiating this drug. More studies
are needed on the use of CMIs in patients with kidney and/or liver failure
and pregnant/breastfeeding patients. Copyright © 2024 Informa UK
Limited, trading as Taylor & Francis Group.

<31>
Accession Number
644458128
Title
Re-exploration for bleeding and long-term survival after adult cardiac
surgery: a meta-analysis of reconstructed time-to-event data.
Source
International journal of surgery (London, England). (no pagination),
2024. Date of Publication: 07 Jun 2024.
Author
Soletti G.; Cancelli G.; Dell'Aquila M.; Caldonazo T.; Harik L.; Rossi C.;
Tasoudis P.; Leith J.; An K.R.; Dimagli A.; Demetres M.; Gaudino M.
Institution
(Soletti, Cancelli, Dell'Aquila, Caldonazo, Harik, Rossi, Leith, An,
Dimagli, Gaudino) Department of Cardiothoracic Surgery at New York
Presbyterian, Weill Cornell Medicine, NY, United States
(Caldonazo) Department of Cardiothoracic Surgery,
Friedrich-Schiller-University Jena, Germany
(Tasoudis) Division of Cardiothoracic Surgery, University of North
Carolina, Chapel Hill, United States
(Demetres)
Abstract
BACKGROUND: Postoperative bleeding requiring re-exploration is a serious
complication that occurs in 2.8% to 4.6% of patients undergoing cardiac
surgery. Re-exploration has previously been associated with a higher risk
of short-term mortality. However, a comprehensive analysis of long-term
outcomes after re-exploration for bleeding has not been published.
MATERIALS AND METHODS: We performed a systematic, three databases search
to identify studies reporting long-term outcomes in patients who required
re-exploration for bleeding after cardiac surgery compared to patients who
did not, with at least 1 year of follow-up. Long-term survival was the
primary outcome. Secondary outcomes were operative mortality, myocardial
infarction, stroke, renal and respiratory complications, and hospital
length of stay. Random-effects models was used. Individual patient
survival data was extracted from available survival curves and
reconstructed using restricted mean survival time. RESULT(S): Six
studies totaling 135,456 patients were included. The average follow-up was
5.5 years. In the individual patient data, patients who required
re-exploration had a significantly higher risk of death compared with
patients who did not (hazard ratio [HR]: 1.21; 95% confidence interval
[CI]: 1.14-1.27; P<0.001), which was confirmed by the study-level survival
analysis (HR: 1.32; 95% CI: 1.12-1.56; P<0.01). Re-exploration was also
associated with a higher risk of operative mortality (odds ratio [OR]:
5.25, 95% CI, 4.74-5.82, P<0.0001), stroke (OR: 2.05, 95% CI, 1.72-2.43,
P<0.0001), renal (OR: 4.13, 95% CI, 3.43-4.39 P<0.0001) respiratory
complications (OR: 3.91, 95% CI, 2.96-5.17, P<0.0001), longer hospital
length of stay (mean difference [MD]: 2.69, 95% CI, 1.68 to 3.69,
P<0.0001), and myocardial infarction (OR: 1.85, 95% CI, 1.30-2.65,
P=0.0007). CONCLUSION(S): Postoperative bleeding requiring
re-exploration is associated with lower long-term survival and increased
risk of short-term adverse events including operative mortality, stroke,
renal and respiratory complications, and longer hospital length of stay.
To improve both short- and long-term outcomes, strategies to prevent the
need for re-exploration are necessary. Copyright © 2024 The
Author(s). Published by Wolters Kluwer Health, Inc.

<32>
Accession Number
644454474
Title
Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic
Coronary Syndrome.
Source
JACC. Cardiovascular interventions. (no pagination), 2024. Date of
Publication: 17 May 2024.
Author
Manzo-Silberman S.; Guedeney P.; Cayla G.; Beygui F.; Range G.; Motovska
Z.; Procopi N.; Kerneis M.; Zeitouni M.; El Kasty M.; Teiger E.; Filippi
E.; Coste P.; Huchet F.; Cottin Y.; Karasek J.; Arnould M.-A.; Braik N.;
Barthelemy O.; Portal J.-J.; Vicaut E.; Montalescot G.; Silvain J.
Institution
(Manzo-Silberman, Guedeney, Procopi, Kerneis, Zeitouni, Braik, Barthelemy,
Montalescot, Silvain) Sorbonne Universite, Allies in Cardiovascular Trials
Initiatives and Organized Networks (ACTION) Study Group, INSERM UMRS1166,
Hopital Pitie-Salpetriere (AP-HP), Paris, France
(Cayla) Cardiology Department, Nimes University Hospital, Montpellier
University, ACTION Study Group, Nimes, France
(Beygui) Cardiology Department, Caen University Hospital, Normandie
University, ACTION Study Group, Caen, France
(Range) Cardiology Department, Chartres Hospital, Chartres, France
(Motovska) 3rd Faculty of Medicine, Charles University and Cardiocentre
University Hospital Kralovske Vinohrady, Prague, Czechia
(El Kasty) Cardiology Department, Grand Hopital de l'Est Francilien,
Jossigny, France
(Teiger) Cardiology Department, Henri-Mondor Hospital (AP-HP), Creteil,
France
(Filippi) Cardiology Department, Bretagne-Atlantique Hospital, Vannes,
France
(Coste) Cardiology Department, Bordeaux University Hospital, Pessac,
France
(Huchet) Cardiology Department, Saint-Nazaire Hospital, France
(Cottin) Cardiology Department, CHU Dijon Bourgogne, Dijon, France
(Karasek) Cardiology Department, Liberec Hospital, Liberec, Czech
Republic; 2nd Faculty of Medicine, Charles University, Prague, Czech
Republic
(Arnould) Service de Cardiologie, Clinique Saint-Gatien, France
(Portal, Vicaut) ACTION Study Group, Unite de Recherche Clinique,
Lariboisiere Hospital, AP-HP, Paris, France
Abstract
BACKGROUND: Whether ticagrelor may reduce periprocedural myocardial
necrosis after elective percutaneous coronary intervention (PCI) in
patients with and without chronic clopidogrel therapy is unclear.
 OBJECTIVE(S): This study sought to compare ticagrelor vs clopidogrel
in patients with and without chronic clopidogrel therapy before undergoing
elective PCI. METHOD(S): In this prespecified analysis of the ALPHEUS
(Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel
to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting)
trial, patients were defined as clopidogrel(+) and clopidogrel(-)
according to the presence and absence of clopidogrel treatment for >=7
days before PCI, respectively. The primary endpoint was the composite of
PCI-related myocardial infarction and major injury as defined by the third
and fourth universal definition 48 hours after PCI. RESULT(S): A
total of 1,882 patients were included, 805 (42.7%) of whom were
clopidogrel(+). These patients were older, had more comorbidities, and had
more frequent features of complex PCI. The primary endpoint was less
frequently present in clopidogrel(-) compared to clopidogrel(+) patients
(32.8% vs 40.0%; OR: 0.73; 95% CI: 0.60-0.88), but no significant
differences were reported for the risk of death, myocardial infarction,
stroke, or transient ischemic attack at 48 hours or 30 days. Ticagrelor
did not reduce periprocedural myocardial necrosis or the risk of adverse
outcomes, and there was no significant interaction regarding the presence
of chronic clopidogrel treatment. CONCLUSION(S): Clopidogrel-naive
patients presented less periprocedural complications compared to
clopidogrel(+) patients, a difference related to a lower risk profile and
less complex PCI. The absence of clopidogrel at baseline did not affect
the absence of a difference between ticagrelor and clopidogrel in terms of
PCI-related complications supporting the use of clopidogrel as the
standard of care in elective PCI in patients with or without chronic
clopidogrel treatment. Copyright © 2024 American College of
Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

<33>
Accession Number
2028652340
Title
Preoperative Considerations for Ambulatory Surgery: What Is New, What Is
Controversial.
Source
Current Anesthesiology Reports. 14(2) (pp 263-273), 2024. Date of
Publication: June 2024.
Author
Pai S.-L.; Gloff M.; Blitz J.
Institution
(Pai) Department of Anesthesiology and Perioperative Medicine, Mayo
Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, United States
(Gloff) Department of Anesthesiology and Perioperative Medicine,
University of Rochester, Rochester, NY, United States
(Blitz) Department of Anesthesiology, Duke University, Durham, NC, United
States
Publisher
Springer
Abstract
Purpose of Review: Ambulatory anesthesia has experienced a rapid expansion
in procedural breadth and patient complexity. Proper patient selection via
preoperative evaluation and testing is imperative to ensure the safety of
patients with major comorbidities and advanced age who undergo procedures
in ambulatory surgical settings. Recent Findings: New developments and
controversies have arisen in the preoperative considerations for
ambulatory surgical patients with class III obesity, obstructive sleep
apnea, pulmonary hypertension, cardiomyopathy, heart failure, and other
severe diseases. The value of preoperative laboratory testing is also
debated. Summary: There are controversies and new developments with
important implications for current and future practice in ambulatory
anesthesia. With careful preoperative evaluation, testing, and patient
selection process, patients with severe diseases may safely undergo
ambulatory surgery. Individualized evaluations should dictate which
patients are appropriate for ambulatory surgery. Copyright © The
Author(s), under exclusive licence to Springer Science+Business Media,
LLC, part of Springer Nature 2024.

<34>
Accession Number
2029304421
Title
Prediction of new-onset heart failure in patients with type 2 diabetes
derived from ALTITUDE and CANVAS.
Source
Diabetes, Obesity and Metabolism. 26(7) (pp 2741-2751), 2024. Date of
Publication: July 2024.
Author
Said F.; Arnott C.; Voors A.A.; Heerspink H.J.L.; ter Maaten J.M.
Institution
(Said, Voors, ter Maaten) Department of Cardiology, University Medical
Center Groningen, University of Groningen, Groningen, Netherlands
(Arnott, Heerspink) The George Institute for Global Health, Sydney,
Australia
(Arnott) Department of Cardiology, Royal Prince Alfred Hospital, Sydney,
Australia
(Heerspink) Department of Clinical Pharmacy and Pharmacology, University
Medical Center Groningen, University of Groningen, Groningen, Netherlands
Publisher
John Wiley and Sons Inc
Abstract
Aim: To create and validate a prediction model to identify patients with
type 2 diabetes (T2D) at high risk of new-onset heart failure (HF),
including those treated with a sodium-glucose cotransporter-2 (SGLT2)
inhibitor. Method(s): A prediction model was developed from the
Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE),
a trial in T2D patients with albuminuria or cardiovascular disease. We
included 5081 patients with baseline N-terminal pro B-type natriuretic
peptide (NT-proBNP) measurement and no history of HF. The model was
developed using Cox regression and validated externally in the placebo arm
of the Canagliflozin Cardiovascular Assessment Study (CANVAS), which
included 996 participants with T2D and established cardiovascular disease
or high cardiovascular risk, and in patients treated with canagliflozin.
 Result(s): ALTITUDE participants (mean age 64 +/- 9.8 years) had a
median serum NT-proBNP level of 157 (25th-75th percentile 70-359) pg/mL.
Higher NT-proBNP level, troponin T (TnT) level and body mass index (BMI)
emerged as significant and independent predictors of new-onset HF in both
cohorts. The model further contained urinary albumin-to-creatinine ratio,
glycated haemoglobin, age, haematocrit, and use of calcium channel
blockers. A prediction model including these variables had a C-statistic
of 0.828 (95% confidence interval [CI] 0.801-0.855) in ALTITUDE and 0.800
(95% CI 0.720-0.880) in CANVAS. The C-statistic of this model increased to
0.847 (95% CI 0.792-0.902) in patients after 1 year of canagliflozin
treatment. Conclusion(s): In patients with T2D, higher NT-proBNP
level, TnT level and BMI are independent and externally validated
predictors of new-onset HF, including patients using an SGLT2 inhibitor.
This newly developed model may identify patients at high risk of new-onset
HF, contributing to early recognition and possibly
prevention. Copyright © 2024 The Authors. Diabetes, Obesity and
Metabolism published by John Wiley & Sons Ltd.

<35>
Accession Number
2029258042
Title
Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy
intake in type 2 diabetes with obesity.
Source
Diabetes, Obesity and Metabolism. 26(7) (pp 2634-2644), 2024. Date of
Publication: July 2024.
Author
Golubic R.; Kennet J.; Parker V.; Robertson D.; Luo D.; Hansen L.;
Jermutus L.; Ambery P.; Ryaboshapkina M.; Surakala M.; Laker R.C.;
Venables M.; Koulman A.; Park A.; Evans M.
Institution
(Golubic, Kennet, Park, Evans) Wellcome-MRC Institute of Metabolic
Science, University of Cambridge, Cambridge, United Kingdom
(Golubic) Oxford Centre for Diabetes Endocrinology and Metabolism,
University of Oxford, Oxford, United Kingdom
(Parker, Robertson, Jermutus) Research and Early Development,
Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca,
Cambridge, United Kingdom
(Luo) Statistics, Biometrics Oncology, Oncology R&D, AstraZeneca,
Gaithersburg, MD, United States
(Hansen) Research and Early Development, Cardiovascular, Renal and
Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United
States
(Ambery) Late Clinical Development, Cardiovascular, Renal and Metabolism,
BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
(Ryaboshapkina) Translational Science and Experimental Medicine, Research
and Early Development, Cardiovascular, Renal and Metabolism,
BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
(Surakala) R&D IT, AstraZeneca, Cambridge, United Kingdom
(Laker) Bioscience Metabolism, Research and Early Development,
Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca,
Gaithersburg, MD, United States
(Venables, Koulman) MRC Epidemiology Unit, University of Cambridge,
Cambridge, United Kingdom
Publisher
John Wiley and Sons Inc
Abstract
Aims: To establish which components of energy balance mediate the
clinically significant weight loss demonstrated with use of cotadutide, a
glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, in
early-phase studies. Material(s) and Method(s): We conducted a phase
2a, single-centre, randomized, placebo-controlled trial in overweight and
obese adults with type 2 diabetes. Following a 16-day single-blind placebo
run-in, participants were randomized 2:1 to double-blind 42-day
subcutaneous treatment with cotadutide (100-300 mug daily) or placebo. The
primary outcome was percentage weight change. Secondary outcomes included
change in energy intake (EI) and energy expenditure (EE). Result(s):
A total of 12 participants (63%) in the cotadutide group and seven (78%)
in the placebo group completed the study. The mean (90% confidence
interval [CI]) weight change was -4.0% (-4.9%, -3.1%) and -1.4% (-2.7%,
-0.1%) for the cotadutide and placebo groups, respectively (p = 0.011). EI
was lower with cotadutide versus placebo (-41.3% [-66.7, -15.9]; p =
0.011). Difference in EE (per kJ/kg lean body mass) for cotadutide versus
placebo was 1.0% (90% CI -8.4, 10.4; p = 0.784), assessed by doubly
labelled water, and -6.5% (90% CI -9.3, -3.7; p < 0.001), assessed by
indirect calorimetry. Conclusion(s): Weight loss with cotadutide is
primarily driven by reduced EI, with relatively small compensatory changes
in EE. Copyright © 2024 The Authors. Diabetes, Obesity and
Metabolism published by John Wiley & Sons Ltd.

<36>
Accession Number
2030038612
Title
3D transesophageal echocardiographic visualization of the pulmonary artery
catheter through the tricuspid valve and their position relative to the
tricuspid valve leaflets.
Source
JA Clinical Reports. 10(1) (no pagination), 2024. Article Number: 35. Date
of Publication: December 2024.
Author
Takada S.; Fujimoto T.; Tomita-Kobayashi A.; Hayashi Y.
Institution
(Takada, Fujimoto, Tomita-Kobayashi, Hayashi) Anesthesiology Service,
Sakurabashi-Watanabe Hospital, 2-4-32 Umeda, Kita-ku, Osaka 530-0001,
Japan
(Hayashi) Present Address: Anesthesiology Service, Yoka Municipal
Hospital, 1878-1, Yoka, Yoka-cho, Hyogo, Yabu 667-8555, Japan
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: The tricuspid valve is an atrioventricular valve consisting of
three lobes. We used the 3D transesophageal echocardiography to visualize
position of the pulmonary artery catheter at the tricuspid valve annulus
and examined where the catheter passed through at the level of the
tricuspid annulus. Method(s): In this prospective and observational
study, we monitored the pressure wave on patients undergoing cardiac
surgery with the catheter placement by monitoring the pressure waveform
for 8 months. We measured the time required for the catheter to pass
through the tricuspid and pulmonary valves, respectively. We acquired the
3D image of the tricuspid valve by transesophageal echocardiography and
determined the position of the pulmonary artery catheter at the level of
the tricuspid annulus. The data were analyzed by Kruskal-Wallis test
followed by Mann-Whitney test with Holm multiple comparisons. P < 0.05 was
considered significant. Result(s): Of the 116 cases, the pulmonary
artery catheter passed through the tricuspid valve between
antero-posterior leaflets in 78 cases (67.2 %), between septal-posterior
leaflets in 25 cases (21.6 %), and between antero-septal leaflets in 2
cases (1.7 %) and the center in 11 cases (9.5 %), respectively. The time
required for the catheter to pass through the pulmonary valves was
significantly different among the catheter positions at the level of the
tricuspid annulus. Conclusion(s): The pulmonary artery catheter
location at the level of the tricuspid annulus can be identified using 3D
transesophageal echocardiography. The location of the catheter
significantly affects the pulmonary artery catheter placement
time. Copyright © The Author(s) 2024.

<37>
Accession Number
2032607913
Title
Estimating the risk of obstructive sleep apnea during wakefulness using
facial images: A review.
Source
Biomedical Signal Processing and Control. Part A. 96 (no pagination),
2024. Article Number: 106503. Date of Publication: October 2024.
Author
TaghiBeyglou B.; Ng B.; Bagheri F.; Yadollahi A.
Institution
(TaghiBeyglou, Ng, Yadollahi) Institute of Biomedical Engineering,
University of Toronto, Toronto, ON, Canada
(TaghiBeyglou, Yadollahi) KITE Research Institute, Toronto Rehabilitation
Institute- University Health Network, Toronto, ON, Canada
(Bagheri) Department of Electrical and Computer Engineering, University of
Toronto, Toronto, ON, Canada
(Bagheri) North York General Hospital, Toronto, ON, Canada
Publisher
Elsevier Ltd
Abstract
Obstructive sleep apnea (OSA) is a chronic sleep-related breathing
disorder associated with cardiovascular diseases, cognitive impairments,
and an increased risk of accidents. Although polysomnography (PSG) stands
as the gold standard for diagnosing OSA, its limitations - such as being
cumbersome, expensive, and having long waitlists - have motivated
researchers to develop alternative screening methods. Facial photography,
serving as an accessible modality, offers insights into anatomical
structures linked to OSA. This study aims to comprehensively review
existing research on leveraging facial images to estimate OSA severity. We
first investigate the physiological intersections between OSA and
craniofacial structures. Furthermore, we discuss extracted facial image
features, employed feature selection techniques, and details of developed
models aimed at detecting OSA severity. Through a comprehensive discussion
of current findings and limitations within the field, we aim to shed light
on critical gaps necessitating attention in future research
directions. Copyright © 2024 The Authors

<38>
[Use Link to view the full text]
Accession Number
2032589817
Title
Contemporary Left Ventricular Assist Device Therapy as a Bridge or
Alternative to Transplantation.
Source
Transplantation. 108(6) (pp 1333-1341), 2024. Date of Publication: 01 Jun
2024.
Author
Boulet J.; Wanderley M.R.B.; Mehra M.R.
Institution
(Boulet, Wanderley, Mehra) Center for Advanced Heart Disease, Brigham and
Women's Hospital, Harvard Medical School, Boston, MA, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Left ventricular assist devices (LVADs), which were introduced as a bridge
to heart transplantation, are now an established alternative to heart
transplantation (HT) for patients with advanced heart failure. These
devices have undergone significant technological advancements over the
years, and contemporary LVADs prolong life substantially in patients
dependent on inotropic therapy or in those with severe ambulatory advanced
heart failure with a median survival that exceeds 5 y, and most patients
benefit from a doubling in functional capacity, even among those intended
as destination therapy because of ineligibility for transplantation. Other
intended goals for LVAD implantation consist of (1) bridge to remission or
recovery and (2) bridge to transplant or candidacy for transplant. In the
former situation, few selected patients underwent LVAD implantation,
facilitating myocardial remission to recovery that allowed explantation.
Among those bridged to transplantation, survival in the intended goal was
excellent, with 80% success at 5 y (with a 50% rate of transplantation).
In this review, we provide a brief historical background on the evolution
of LVADs and discuss outcomes with contemporary pumps, immunological and
infection-related impact of such devices, impact of bridging in HT, and
use of devices for facilitating myocardial recovery and remission.
Furthermore, we discuss implications of HT allocation policies, with a
specific focus within the United States, and outline future perspectives
and novel device in development. Copyright © 2024 Lippincott
Williams and Wilkins. All rights reserved.

<39>
Accession Number
2032574595
Title
Impact of atherosclerosis imaging-quantitative computed tomography on
diagnostic certainty, downstream testing, coronary revascularization, and
medical therapy: the CERTAIN study.
Source
European Heart Journal Cardiovascular Imaging. 25(6) (pp 857-866), 2024.
Date of Publication: 01 Jun 2024.
Author
Nurmohamed N.S.; Cole J.H.; Budoff M.J.; Karlsberg R.P.; Gupta H.;
Sullenberger L.E.; Quesada C.G.; Rahban H.; Woods K.M.; Uzzilia J.R.;
Purga S.L.; Aquino M.; Hoffmann U.; Min J.K.; Earls J.P.; Choi A.D.
Institution
(Nurmohamed) Department of Cardiology, Amsterdam UMC, Vrije Universiteit
Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, Netherlands
(Nurmohamed) Department of Vascular Medicine, Amsterdam UMC, University of
Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, Netherlands
(Nurmohamed, Earls, Choi) Division of Cardiology, Department of Radiology,
The George Washington University School of Medicine, Washington, DC,
United States
(Cole) Cardiology Associates of Mobile, Mobile, AL, United States
(Budoff) Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA,
United States
(Karlsberg, Quesada, Rahban) Cardiovascular Research Foundation of
Southern California, Cedars-Sinai Heart Institute, Beverly Hills, CA,
United States
(Gupta) Division of Cardiac Imaging, Valley Heart and Vascular Institute,
Valley Health System, Ridgewood, NJ, United States
(Sullenberger, Woods, Uzzilia, Purga) Capital Cardiology Associates,
Albany, NY, United States
(Aquino, Hoffmann, Min, Earls) Cleerly Inc., Denver, CO, United States
Publisher
Oxford University Press
Abstract
Aims The incremental impact of atherosclerosis imaging-quantitative
computed tomography (AI-QCT) on diagnostic certainty and downstream
patient management is not yet known. The aim of this study was to compare
the clinical utility of the routine implementation of AI-QCT versus
conventional visual coronary CT angiography (CCTA) interpretation. Methods
In this multi-centre cross-over study in 5 expert CCTA sites, 750
consecutive adult patients referred for CCTA were pro- and results
spectively recruited. Blinded to the AI-QCT analysis, site physicians
established patient diagnoses and plans for downstream non-invasive
testing, coronary intervention, and medication management based on the
conventional site assessment. Next, physicians were asked to repeat their
assessments based upon AI-QCT results. The included patients had an age of
63.8 +/- 12.2 years; 433 (57.7%) were male. Compared with the conventional
site CCTA evaluation, AI-QCT analysis improved physician's confidence two-
to five-fold at every step of the care pathway and was associated with
change in diagnosis or management in the majority of patients (428; 57.1%;
P < 0.001), including for measures such as Coronary Artery
Disease-Reporting and Data System (CAD-RADS) (295; 39.3%; P < 0.001) and
plaque burden (197; 26.3%; P < 0.001). After AI-QCT including ischaemia
assessment, the need for downstream non-invasive and invasive testing was
reduced by 37.1% (P < 0.001), compared with the conventional site CCTA
evaluation. Incremental to the site CCTA evaluation alone, AI-QCT resulted
in statin initiation/increase an aspirin initiation in an additional 28.1%
(P < 0.001) and 23.0% (P < 0.001) of patients, respectively. Conclusion
The use of AI-QCT improves diagnostic certainty and may result in reduced
downstream need for non-invasive testing and increased rates of preventive
medical therapy. Copyright © The Author(s) 2024.

<40>
Accession Number
2032635762
Title
The Clinical Impact of Paravalvular Leaks With Transcutaneous Aortic Valve
Implantation (TAVI) Versus Surgical Aortic Valve Replacement (SAVR): A
Systematic Review and Meta-Analysis.
Source
Heart Lung and Circulation. (no pagination), 2024. Date of Publication:
2024.
Author
Moawad K.R.; Mohamed S.; Hammad A.; Barker T.
Institution
(Moawad, Mohamed, Hammad, Barker) Department of Cardio-Thoracic Surgery
University Hospital Coventry and Warwickshire NHS Trust, Coventry, United
Kingdom
(Moawad) Division of Surgical Sciences, University of Edinburgh,
Edinburgh, Scotland, United Kingdom
Publisher
Elsevier Ltd
Abstract
Background: Aortic valve stenosis is a common cardiac condition that
requires intervention for symptomatic and/or prognostic reasons. The two
most common interventions are surgical aortic valve replacement (SAVR) and
transcatheter aortic valve implantation (TAVI). The ratio of TAVI:SAVR has
increased twofold over the past few years and is now being considered in
intermediate-risk patients as well. One of the significant benefits of
TAVI is that it is less invasive; however, one of the drawbacks is a high
paravalvular leaks (PVLs) rate compared to SAVR. To assess the impact of
PVLs on survival, progression of heart failure, and the need for
re-intervention. Method(s): We conducted a comprehensive systematic
literature search from the conception of TAVI 2002 until December 2022
through Embase (Ovid), MEDLINE (Ovid), Science Direct, and CENTRAL
(Wiley). We followed PRISMA guidelines and checklists. Review protocol
registration ID in PROSPERO: CRD42023393742. Result(s): We identified
28 studies that met our eligibility criteria, and only 24 studies were
suitable for pooling in a meta-analysis (including their hazard ratio with
a confidence interval of 95%) assessing our primary outcome (all-cause
mortality). The remaining four studies were narratively synthesised.
RevMan V5.4 (Version 5.4. Cochrane Collaboration, 2020) was utilised to
pool meta-analysis data to assess effect estimates of PVLs in both
intervention arms, using a random effect model for calculation (hazard
ratio 1.14 confidence interval 95% 1.08-1.21 [p<0.0001]), with a follow-up
duration between 30 days to 5 years. Conclusion(s): Patients with
mild or higher degrees of PVLs in both intervention arms incurred
unfavourable outcomes. The incidence of PVLs was significantly higher with
TAVI; even a mild degree led to poor quality of life and increased
all-cause mortality on long-term follow-up. Copyright © 2024
Australian and New Zealand Society of Cardiac and Thoracic Surgeons
(ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ)

<41>
Accession Number
2032635632
Title
Effect of volatile versus propofol anaesthesia on major complications and
mortality after cardiac surgery: a multicentre randomised trial.
Source
British Journal of Anaesthesia. (no pagination), 2024. Date of
Publication: 2024.
Author
Deng X.-Q.; Wang W.-J.; Wu Q.-L.; Wei H.; Deng J.-S.; Li Z.-J.; Wu J.-Z.;
Yang J.-J.; Zheng X.-M.; Wei J.-J.; Fan S.-S.; Zou X.-H.; Shi J.; Zhang
F.-X.; Wu D.-Q.; Kou D.-P.; Wang T.; Wang E.; Ye Z.; Zheng X.; Chen G.;
Chen Y.; Wei X.; Chai X.-Q.; Huang W.-Q.; Wang L.; Li K.; Li L.; Zhang Y.;
Li R.; Jiao J.-L.; Yu H.; Liu J.
Institution
(Deng, Yu, Yu, Liu) Department of Anaesthesiology, West China Hospital,
Sichuan University, Chengdu, China
(Wang, Wu) Department of Anaesthesiology, The First Affiliated Hospital of
Wenzhou Medical University, Wenzhou, China
(Wei, Deng) Department of Anaesthesiology, Gaozhou People's Hospital,
Guangdong, China
(Li, Wu) Department of Anaesthesiology, Second Xiangya Hospital, Central
South University, Changsha, China
(Yang, Zheng) Department of Anaesthesiology, Pain and Perioperative
Medicine, The First Affiliated Hospital of Zhengzhou University,
Zhengzhou, China
(Wei, Fan) Department of Anaesthesiology, Cardiovascular Hospital (The 7th
People's Hospital of Zhengzhou), Zhengzhou, China
(Zou, Shi) Department of Anaesthesiology, Affiliated Hospital of Guizhou
Medical University, Guiyang, China
(Zhang, Wu) Department of Anaesthesiology, Guizhou Provincial People's
Hospital, Guiyang, China
(Kou, Wang) Department of Anaesthesiology, Tianjin Chest Hospital, Tian
Jin, China
(Wang, Ye) Department of Anaesthesiology, Xiangya Hospital of Central
South University, National Clinical Research Centre for Geriatric
Disorders, Central South University, Changsha, China
(Zheng, Chen) Department of Anaesthesiology, Sir Run Run Shaw Hospital,
Zhejiang University, Hangzhou, China
(Huang, Chen) Department of Anaesthesiology, The First Affiliated
Hospital, Sun Yat-sen University, Guangzhou, China
(Wei, Chai) Department of Anaesthesiology, Anhui Provincial Hospital,
Hefei, China
(Huang, Wang) Department of Anaesthesiology, Wuhan Asia Heart Hospital,
Wuhan, China
(Li, Li) Department of Anaesthesiology, China Japan Union Hospital, Jilin
University, Changchun, China
(Zhang, Li) Department of Anaesthesiology and Perioperative Medicine, The
Second Affiliated Hospital of Anhui Medical University, Hefei, China
(Jiao) Institute of Translational Medicine, Shanghai Jiao Tong University,
Shanghai, China
Publisher
Elsevier Ltd
Abstract
Background: The comparative effectiveness of volatile anaesthesia and
total intravenous anaesthesia (TIVA) in terms of patient outcomes after
cardiac surgery remains a topic of debate. Method(s): Multicentre
randomised trial in 16 tertiary hospitals in China. Adult patients
undergoing elective cardiac surgery were randomised in a 1:1 ratio to
receive volatile anaesthesia (sevoflurane or desflurane) or propofol-based
TIVA. The primary outcome was a composite of predefined major
complications during hospitalisation and mortality 30 days after surgery.
 Result(s): Of the 3123 randomised patients, 3083 (98.7%; mean age 55
yr; 1419 [46.0%] women) were included in the modified intention-to-treat
analysis. The composite primary outcome was met by a similar number of
patients in both groups (volatile group: 517 of 1531 (33.8%) patients vs
TIVA group: 515 of 1552 (33.2%) patients; relative risk 1.02 [0.92-1.12];
P=0.76; adjusted odds ratio 1.05 [0.90-1.22]; P=0.57). Secondary outcomes
including 6-month and 1-yr mortality, duration of mechanical ventilation,
length of ICU and hospital stay, and healthcare costs, were also similar
for the two groups. Conclusion(s): Among adults undergoing cardiac
surgery, we found no difference in the clinical effectiveness of volatile
anaesthesia and propofol-based TIVA. Clinical trial registration: Chinese
Clinical Trial Registry (ChiCTR-IOR-17013578). Copyright © 2024
British Journal of Anaesthesia

<42>
[Use Link to view the full text]
Accession Number
631834644
Title
Volatile Anesthetics versus Propofol for Cardiac Surgery with
Cardiopulmonary Bypass: Meta-analysis of Randomized Trials.
Source
Anesthesiology. 132(6) (pp 1429-1446), 2020. Date of Publication: 01 Jun
2020.
Author
Bonanni A.; Signori A.; Alicino C.; Mannucci I.; Grasso M.A.; Martinelli
L.; Deferrari G.
Institution
(Bonanni, Mannucci, Deferrari) The Department of Cardionephrology,
Clinical Ligurian Institute of High Specialty, Villa Maria Group (GVM)
Care and Research, Rapallo, Italy
(Grasso) The Department of Intensive Care Unit, Clinical Ligurian
Institute of High Specialty, Villa Maria Group (GVM) Care and Research,
Rapallo, Italy
(Martinelli) The Department of Cardiac Surgery, Clinical Ligurian
Institute of High Specialty, Villa Maria Group (GVM) Care and Research,
Rapallo, Italy
(Bonanni) The Division of Internal Medicine, International Evangelical
Hospital, Genoa, Italy
(Signori) The Department of Health Science, University of Genoa, Italy
(Deferrari) The Department of Internal Medicine, University of Genoa,
Italy
(Alicino) The ASL-2-Regional Health System of Liguria, Italy
Publisher
Lippincott Williams and Wilkins
Abstract
Background: The aim of this systematic review and meta-analysis was to
assess the effect of anesthesia maintenance with volatile agents compared
with propofol on both short- and long-term mortality (primary outcomes)
and major clinical events in adults undergoing cardiac surgery with
cardiopulmonary bypass. Method(s): Randomized clinical trials on the
effects of current volatile anesthetics versus propofol in adults
undergoing cardiac surgery with cardiopulmonary bypass were searched (1965
to September 30, 2019) in PubMed, the Cochrane Library, and article
reference lists. A random effect model on standardized mean difference for
continuous outcomes and odds ratio for dichotomous outcomes were used to
meta-analyze data. Result(s): In total, 37 full-text articles (42
studies, 8,197 participants) were included. The class of volatile
anesthetics compared with propofol was associated with lower 1-yr
mortality (5.5 vs. 6.8%; odds ratio, 0.76 [95% CI, 0.60 to 0.96]; P =
0.023), myocardial infarction (odds ratio, 0.60 [95% CI, 0.39 to 0.92]; P
= 0.023), cardiac troponin release (standardized mean difference, -0.39
[95% CI, -0.59 to -0.18], P = 0.0002), need for inotropic medications
(odds ratio, 0.40 [95% CI, 0.24 to 0.67]; P = 0.0004), extubation time
(standardized mean difference, -0.35 [95% CI, -0.68 to -0.02]; P = 0.038),
and with higher cardiac index/output (standardized mean difference, 0.70
[95% CI, 0.37 to 1.04]; P < 0.0001). The class of volatile anesthetics was
not associated with changes in short-term mortality (1.63 vs. 1.65%; odds
ratio, 1.04 [95% CI, 0.73 to 1.49]; P = 0.820) and acute kidney injury
(odds ratio, 1.25 [95% CI, 0.77 to 2.03]; P = 0.358). Conclusion(s):
In adults undergoing cardiac surgery with cardiopulmonary bypass, the
class of volatile anesthetics was superior to propofol with regard to
long-term mortality, as well as to many secondary outcomes indicating
myocardial protection. Copyright © 2020, the American Society of
Anesthesiologists, Inc. All Rights Reserved.

<43>
Accession Number
2032720297
Title
Spontaneous Coronary Artery Dissection in Pregnancy (pSCAD): Patient
Characteristics, Outcomes and Management.
Source
Heart Lung and Circulation. Conference: CSANZ New Zealand Annual
Scientific Meeting 2024. Christchurch New Zealand. 33(Supplement 2) (pp
S72-S73), 2024. Date of Publication: June 2024.
Author
Bhana V.; Alsamarra'I A.; Jo J.
Institution
(Bhana, Alsamarra'I) Te Whatu Ora Counties Manukau, Auckland, New Zealand
(Jo) Te Whatu Ora Auckland, Auckland, New Zealand
Publisher
Elsevier Ltd
Abstract
Background: We present an up-to-date summary of the current data regarding
pSCAD including patient characteristics, risk factors, management
strategies and outcomes. Further, we compare this patient group to those
with non-pregnancy related SCAD (non-pSCAD). Method(s): PubMed and
Google Scholar databases were searched to identify case series,
observational studies and meta-analyses until December 2022. A total of
nine papers were identified and included in this review. Pertinent data
points were recorded. Result(s): STEMI: Found to be more common in
pSCAD vs non pSCAD populations. Recurrence: Although some studies
suggested that pSCAD patients often had recurrence there wasn't strong
evidence this was the case in comparison to non pSCAD. Cardiogenic Shock:
Only a small proportion of pSCAD patients had this presentation with mild
correlation specifically to pSCAD. Cardiac Arrest: Only affected a small
proportion of pSCAD patients comparatively. CAD Risk Factors: Often
patients bearing these had pSCAD more commonly. There was a moderate
association with requirement of CABG. We also found women with pSCAD more
often underwent PCI or CABG compared to those with non pSCAD.
 Conclusion(s): pSCAD is associated with significant adverse cardiac
outcomes and appears to be a higher risk presentation compared to non
pSCAD, but the overall survival is similar. There is limited guidance on
specific management strategies in pSCAD, but the general treatment
principles of non-pSCAD apply, taking into account additional
considerations related to the presence of a fetus. Copyright ©
2024

<44>
Accession Number
644442089
Title
Nitric Oxide Administration in Cardiac Surgical Patients With Endothelial
Dysfunction to Prevent Acute Kidney Injury.
Source
American Journal of Respiratory and Critical Care Medicine. Conference:
American Thoracic Society 2024 International Conference. San Diego, CA
United States. 209 (no pagination), 2024. Date of Publication: May 2024.
Author
Berra L.; Giammatteo V.; Shetty N.S.; Ichinose F.; Arora P.
Institution
(Berra, Giammatteo) Anesthesia, Critical Care and Pain Medicine,
Massachusetts General Hospital, Harvard Medical School, Massachusetts
General Hospital, Boston, MA, United States
(Shetty) Division of Cardiovascular Disease, University of Alabama at
Birmingham, Birmingham, AL, United States
(Ichinose) Anesthesia, Massachusetts General Hospital, Boston, MA, United
States
(Arora) Division of Cardiovascular Disease, University of Alabama at
Birmingham, Boston, MA, United States
Publisher
American Thoracic Society
Abstract
RATIONALE: Post-cardiac surgery AKI is a common complication linked to
prolonged cardiopulmonary bypass (CPB) (>90min). AKI in post-cardiac
surgery patients may be attributed to CPB-associated hemolysis, which
releases oxyhemoglobin, depleting nitric oxide (NO) and causing
vasoconstriction, inflammation, and impaired tissue perfusion. Concurrent
medical conditions like hypertension, diabetes, and atherosclerosis, all
of which are associated with endothelial dysfunction, further compromise
endothelial NO synthesis and peripheral blood circulation. A prior
clinical trial in young cardiac patients with rheumatic heart disease,
without signs of endothelial dysfunction, demonstrated a decrease in
postoperative AKI with the administration of 80 ppm inhaled NO (iNO) for
24 hours starting at the onset of CBP. This current trial explores whether
the administration of iNO for 24 hours reduces the occurrence of AKI in
patients with established endothelial dysfunction. METHOD(S): This
single-center, double-blind, randomized (1:1) controlled, parallel-arm
superiority trial enrolled patients requiring cardiac surgery with an
estimated CBP time of >=90 minutes, with signs of endothelial dysfunction
(hypertension, diabetes, active smoking, hypercholesterolemia, or history
of a transient ischemic attack/stroke, peripheral vascular disease,)and
stable renal function for 3 months before surgery. Patients were
randomized to either receive 80 ppm of iNO or nitrogen (N2) for 24 hours
from the initiation of CPB, stratified by the pre-operative mPAP (<30 mm
Hg or >=30 mm Hg). The primary outcome was AKI defined by KDIGO criteria.
The secondary outcomes included AKI severity, requirement of RRT, and MAKE
at 6 weeks. RESULT(S): Among 250 patients[median age: 66; 22%
females; 96% White] included, 53(42.4%) patients in the NO group and
57(45.6%) patients in the control group developed AKI. The odds of AKI did
not vary in the study arms [OR: 0.88(95%CI:0.53-1.45)]. Stage 2 or 3 AKI
occurred in 13(10.4%) in the NO group and 16(12.8%) in the control group.
The likelihood of developing Stage 2 or 3 AKI was similar in both study
arms [OR: 0.77(95%CI:00.34-1.71)]. Similarly, the requirement of RRT
during hospitalization [2(1.6%) in the NO group and 5(4.0%) in the control
group;] and MAKE at 6 weeks [6(4.8%) in the NO group and 7(5.6%) in
control group; OR:0.85(95%CI:0.28-2.60)] didn'tt vary in the study groups.
 CONCLUSION(S): In patients with endothelial dysfunction undergoing
cardiac surgery with prolonged CBP, the administration of 80 ppm of nitric
oxide for 24 hours did not reduce the incidence of AKI and other major
renal outcomes.

<45>
Accession Number
644442086
Title
Differences in Blood Methemoglobin Formation With Different Methods of
Nitric Oxide Delivery.
Source
American Journal of Respiratory and Critical Care Medicine. Conference:
American Thoracic Society 2024 International Conference. San Diego, CA
United States. 209 (no pagination), 2024. Date of Publication: May 2024.
Author
Berra L.; Bruno G.M.; Cenci S.; Medeiros K.J.; Villalobos R.A.
Institution
(Berra) Anesthesia, Critical Care and Pain Medicine, Respiratory Care
Services, Boston, MA, United States
(Bruno, Cenci, Medeiros, Villalobos) Anesthesia, Critical Care and Pain
Medicine, Boston, MA, United States
Publisher
American Thoracic Society
Abstract
RATIONALE The benefits of delivering nitric oxide (NO) during
cardiopulmonary bypass (CPB) in cardiac surgery are unknown. It is
possible that factors related to the NO administration process in
extracorporeal circuits influence the amount of NO molecules transferred
to the blood and thus play a role in the clinical response to this
therapy. Methemoglobin concentration increases in plasma during NO
administration and could be an indirect marker of NO delivery to the
blood. METHODSThis is a subanalysis of a single-center, randomized,
controlled, trial conducted at the Massachusetts General Hospital (Boston,
MA). Patients scheduled for prolonged CPB for cardiac surgery were
randomized to receive NO 80 ppm or placebo (pure nitrogen). Gas
administration started at the initiation of CPB via CPB oxygenator.
Afterwards gas administration continued for the next 24 hours through
invasive mechanical ventilation (both operating room and ICU) and through
nasal cannulas after extubation. We retrospectively analyzed methemoglobin
data from the group randomized NO treatment. RESULTSMethemoglobin data of
105 patients were analyzed (Fig.1). Methemoglobin significantly varied
over-time (ANOVA p-value < 0.005). Changes are graphically related to
different methods of NO delivery. Mean methemoglobin values are: baseline
= 0.2%, 210 minutes after CPB = 0.97%, 210 minutes of ICU mechanical
ventilation = 2.89 %. The corresponding mean NO delivery rate were 10
mumoles/min and 26.4 mumoles/min. CONCLUSIONSDifferent methods of NO
delivery are associated with different increase in blood methemoglobin
concentrations and different NO delivery rate. Methemoglobin increase in
blood could be a selective target to guide NO treatment and achieve
clinical benefits. Figure 1. Time course of methemoglobin concentrations
(%) from baseline values in the OR to the end of NO administration in ICU.
Time is expressed in minutes relatively to the time of the first ABG
collected after CPB initiation. Colors represents different methods of NO
administration. Data from the same patient are connected by lines. The
black curve represents median values over time and the error bars
represent IQR. OR = operating room, NO = nitric oxide, ICU = intensive
care unit, ABG = arterial blood gas analysis, IQR = interquartile range.

<46>
Accession Number
644441136
Title
A Baby Isn't the Only Surprise Here: Recurring Spontaneous Pneumothorax in
Pregnancy.
Source
American Journal of Respiratory and Critical Care Medicine. Conference:
American Thoracic Society 2024 International Conference. San Diego, CA
United States. 209 (no pagination), 2024. Date of Publication: May 2024.
Author
Chopra-Tandon N.; Nguyen S.; Fouad J.
Institution
(Chopra-Tandon) Internal Medicine, UMass Memorial Medical Center,
Worcester, MA, United States
(Nguyen, Fouad) Division of Pulmonary, Allergy, Critical Care Medicine,
UMass Memorial Medical Center, Worcester, MA, United States
Publisher
American Thoracic Society
Abstract
Primary spontaneous pneumothorax, while relatively uncommon, is known to
have a recurrence rate between 20% and 60%3. Risk factors include male
gender, tall stature, connective tissue disorders, subpleural blebs, and
smoking history. However, recurrent spontaneous pneumothorax in pregnancy
is an extremely rare occurrence. Here we present a case of a healthy young
female with an initial spontaneous pneumothorax postpartum with multiple
recurrences during her second pregnancy, ultimately requiring surgical
intervention. A 31 year-old G2P1001 female at 22 weeks gestation, with
former remote marijuana use, presented with right chest pain and dyspnea.
CXR revealed a right apical pneumothorax measuring 2 cm from the apex. Two
years prior, she had a right spontaneous pneumothorax requiring chest
tube, and over the last 45 days leading to this admission, she had two
similar presentations, both with symptomatic pneumothoraces requiring
percutaneous chest tube placement. As this was her fourth spontaneous
pneumothorax in two years, a multidisciplinary discussion between thoracic
surgery, interventional pulmonology, and maternal fetal medicine concluded
the need for VATS with pleurodesis. Intraoperative findings included
multiple blebs of the right upper lobe. She underwent wedge resection
followed by mechanical pleurodesis, with an uncomplicated postoperative
course. Outpatient follow-up radiography was stable with only expected
operative changes noted. Recurrent pneumothorax during pregnancy is a rare
condition, sparingly noted in medical literature. Similar to those cases
in non-pregnancy, the underpinning etiology is thought to be the rupture
of existing bullae or blebs4. In a systematic review of 87 cases of
pneumothorax in pregnancy, most cases occurred in the second trimester,
the majority (67.4%) of which were treated conservatively with chest
tubes, followed by antepartum or postpartum VATS1. Evaluation of chest
pain and dyspnea during pregnancy should include consideration of
pneumothorax. During labor and delivery, there is increased
intra-abdominal pressure, with associated increased tidal volume and
minute ventilation, which may precipitate worsening pneumothorax with
potentially lifethreatening consequence. Therefore, clinically-appropriate
treatment should be pursued with the guidance of a multidisciplinary team
involving obstetrics, thoracic surgery, pulmonology, and anesthesia. If
surgery is deemed necessary, the second trimester is preferred and VATS is
emerging as a successful treatment approach2. It is worth re-emphasizing
that CXR and CT chest should be used without delay or fear of fetal harm,
given the marginal, safe cumulative dose of ionizing radiation5. Although
case reports for this condition remain uncommon, we hope that our addition
will further help guide a uniform approach in management.

<47>
Accession Number
644440828
Title
Impact of Delaying Access to Sotatercept on Patients Living With Pulmonary
Arterial Hypertension.
Source
American Journal of Respiratory and Critical Care Medicine. Conference:
American Thoracic Society 2024 International Conference. San Diego, CA
United States. 209 (no pagination), 2024. Date of Publication: May 2024.
Author
Mclaughlin V.V.; Alsumali A.; Lui R.; Martinez E.C.; Nourhussein I.; Klok
R.; David B.; Chevure J.; De Oliveira Pena J.; Lautsch D.; Hoeper M.
Institution
(Mclaughlin) Univ of Michigan Hosp, Ann Arbor, MI, United States
(Alsumali, Klok) Center for Observational and Real-World
Evidence,Merck&Co,Inc., Rahway, NJ, United States
(Lui, Nourhussein, David) OPEN Health Evidence and Access, Bethesda, MD,
United States
(Martinez) Merck&Co,Inc., Rahway, NJ, United States
(Chevure) Merck Sharp and Dohme (UK) Ltd, London, United Kingdom
(De Oliveira Pena) Merck Research Labs,Merck&Co,Inc., Boston, MA, United
States
(Lautsch) Merck and Co.,Inc., Rahway, NJ, United States
(Hoeper) Respiratory Medicine, Hannover Medical School, Hannover, Germany
Publisher
American Thoracic Society
Abstract
Rationale: Pulmonary arterial hypertension (PAH) is a progressive disease
with high morbidity and mortality. A simulation population health model
was published previously, which modeled long term survival in patients
treated with sotatercept + background therapy vs. placebo + background
therapy. However, the impact of delayed access to an innovation such as
sotatercept on PAH patients is unknown. The aim of this study is to
quantify the potential impact of delaying the access to sotatercept by 2
years. Method(s): For this analysis we compared 2 scenarios: 1)
immediate access to sotatercept in the eligible population based on the
STELLAR trial; 2) access to sotatercept with a delay of 2 years in the
same eligible population. For both scenarios a published Markov type
cohort model was used to estimate survival and PAH hospitalization over a
30-year horizon. Probability of PAH hospitalization and all-cause
mortality were based on STELLAR and the European COMPERA registry.
Heart/lung transplantation probabilities and post-transplantation
mortality were obtained from COMPERA and the literature, respectively.
Model outcomes were discounted at 3% annually. Result(s): According
to this model, delaying initiation of sotatercept therapy by 2 years is
estimated to result in 4.1 life years (LYs) lost per patient (16.5 versus
12.4) over a 30-year time horizon. Furthermore, delaying the introduction
of sotatercept by 2 years would also lead to 210 additional PAH
hospitalizations (121 versus 330) per 1000 patients over this 30- year
time horizon. Conclusion(s): According to this projection of the
population health model, delaying access to sotatercept by 2 years could
potentially limit the gains in life expectancy and reduction in
hospitalizations that might have otherwise been realized by immediate
access to sotatercept.

<48>
Accession Number
644439778
Title
Efficacy of Specific Drug Class Therapy in Pulmonary Arterial Hypertension
Associated With HIV, Portal Hypertension or Both: A Single Center
Experience.
Source
American Journal of Respiratory and Critical Care Medicine. Conference:
American Thoracic Society 2024 International Conference. San Diego, CA
United States. 209 (no pagination), 2024. Date of Publication: May 2024.
Author
Guarino D.; Ballerini A.; Bertozzi R.; Donato F.; Salvi M.; Cennerazzo F.;
Dardi F.; Manes A.; Palazzini M.; Galie N.
Institution
(Guarino, Bertozzi, Donato, Salvi, Cennerazzo, Galie) DIMES, Ospedale
S.Orsola, Bologna, Italy
(Ballerini) BolognaItaly
(Dardi, Palazzini) IRCCS Sant'Orsola, Bologna, Italy
(Manes) Cardiology Department, University of Bologna, Bologna, Italy
Publisher
American Thoracic Society
Abstract
Rationale: Pulmonary arterial hypertension (PAH) is a rare complication of
both HIV infection (HIVPAH) and portal hypertension (Po-PAH); it can occur
in patients with both diseases (HIV/Po-PAH). The use of the PAH-specific
drug classes (prostanoids, endothelin-1 receptor antagonists [ERA] and
phosphodiesterase-5 inhibitors [PDE5-i]) is largely justified by
retrospective and observational case reports since, to date, there are no
randomized clinical trials except for the PORTICO trial which demonstrated
the efficacy of macitentan in Po-PAH. The aim of the study was to evaluate
the efficacy of PAH-specific drugs, both monotherapy and dual oral upfront
therapy (ERA + PDE5i started within 1 month apart), in patients with
Po-PAH, HIV/Po-PAH and HIV-PAH. Method(s): Between 1998 and 2023 we
enrolled patients with Po-PAH, HIV-PAH and HIV/Po-PAH referred to our
Center and undergoing monotherapy with prostanoid, ERA and PDE5-I or dual
upfront oral therapy. The efficacy of the drugs was assessed by comparing
clinical parameters (NYHA functional class), exercise capacity (six-minute
walking test) and hemodynamic parameters at baseline and after a treatment
period of 3-6 months. The data are expressed as mean and standard
deviation and were compared with Student's t-test for paired data.
 Result(s): 128 patients were enrolled (83 Po-PAH, 23 HIV/Po-PAH and
22 HIV-PAH). 20 were treated with ERA monotherapy, 90 with PDE5-I, 13 with
prostanoids and 5 treated with dual oral upfront therapy.
 Conclusion(s): Prostanoids, ERAs and PDE5-Is, both in monotherapy and
as dual upfront oral therapy, are associated with a significant
improvement in functional class, exercise capacity and hemodynamic
parameters. The effect of such drugs is similar to patients suffering from
other forms of PAH. (Figure Presented).

<49>
Accession Number
644437830
Title
Lung Cancer Screening for Individuals With Peutz Jeghers Syndrome.
Source
American Journal of Respiratory and Critical Care Medicine. Conference:
American Thoracic Society 2024 International Conference. San Diego, CA
United States. 209 (no pagination), 2024. Date of Publication: May 2024.
Author
Shareef F.; Konjeti M.; Weiss J.; Gupta S.
Institution
(Shareef) Internal Medicine,UCSD Medical Center, San Diego, CA, United
States
(Konjeti) Internal Medicine, University of Wisconsin Hospitals and
Clinics, Madison, WI, United States
(Weiss) Division of Gastroenterology and Hepatology, University of
Wisconsin, School of Medicine and Public Health, Madison, WI, United
States
(Gupta) Division of Gastroenterology, Moores Cancer Center, San Diego, CA,
United States
Publisher
American Thoracic Society
Abstract
RATIONALE: Peutz-Jeghers Syndrome (PJS) is an autosomal dominant syndrome
caused by pathogenic variants in the STK11 gene that predisposes to
gastrointestinal hamartomatous polyposis, as well as risk for intestinal
and extraintestinal cancers, including lung cancer. While it is
recommended that patients with PJS undergo breast, stomach, colon,
pancreas, gynecologic, and testicular cancer screening, no formal
recommendations exist for lung cancer screening through the National
Comprehensive Cancer Network (NCCN). Our aim was to assess whether
available data on lung cancer risk in PJS reach a level comparable to
clinical scenarios for which lung cancer screening with low dose computed
tomography scan (LDCT) is already recommended. Method(s): We
initiated a systematic review of observational studies outlining lung
cancer risk in PJS, registered at PROSPERO. Lung cancer risk estimates for
PJS were compared to a synthesis of lifetime, as well as 5 and 10-year
risks for lung cancer for populations for which current guidelines
recommend lung cancer screening based on pack-years of smoking and age. We
estimated whether PJS risk is similar, lower, or higher than current
populations for which lung cancer screening is recommended.
 Result(s): Across n=20 studies reviewed to date, lifetime risk of
lung cancer in patients with PJS has been estimated between 7% and 17%,
with the cumulative risk of lung cancer in PJS surpassing 5% by age 55
years, with adenocarcinomas being the most common type. Lung cancer
screening guidelines from the United States Preventive Taskforce (USPSTF)
recommend that individuals between 50 and 80 years old with a 20 pack-year
smoking history and currently smoke or have quit within the past 15 years
should receive a LDCT annually. The American Association for Thoracic
Surgery and NCCN recommend that those aged >=50 years, with >=20 pack-year
smoking history and an additional 5-year cumulative risk >5% should also
undergo annual LDCT. For USPSTF eligible smokers the 5-year risk of
developing lung cancer is 3.9%, and thus lower than the observed lung
cancer risk among individuals with PJS. Conclusion(s): Initial
results from our in progress systematic review suggest that individuals
with PJS may have lung cancer risk that exceeds current thresholds for
recommending lung cancer screening based on age and smoking status in the
general population. If our observations of lung cancer risk among
individuals with PJS are consistent across available literature, guideline
recommendations for lung cancer screening for individuals with PJS may be
warranted.

<50>
Accession Number
644437768
Title
You Heard Me Right! A Rare Case of Proteus Mirabilis Endocarditis.
Source
American Journal of Respiratory and Critical Care Medicine. Conference:
American Thoracic Society 2024 International Conference. San Diego, CA
United States. 209 (no pagination), 2024. Date of Publication: May 2024.
Author
Santone D.; Sigua N.L.
Institution
(Santone) Pulmonology and Critical Care Medicine, Indiana University,
School of Medicine, Indianapolis, IN, United States
(Sigua) Indiana University, College of Medicine, Indianapolis, IN, United
States
Publisher
American Thoracic Society
Abstract
RD is an 87 year old gentleman with multiple comorbidities notable for
heart failure with preserved ejection fraction, mild aortic valve
regurgitation and stenosis, mild cognitive impairment, history of Miller
Fisher Syndrome, and a recent admission for Proteus mirabilis urinary
tract infection and bacteremia along with Clostridium difficil colitis and
discharged after completing appropriate antibiotics for Proteus and on PO
vancomycin. (Repeat blood cultures at the end of his hospitalization
showed clearance of the blood infection.) He presented 8 days after
discharge with hypotension refractory to fluid boluses, worsening
encephalopathy, and new left arm weakness. The patient required intubation
and dual pressor support to maintain perfusion. Initial CT head imaging
was negative for hemorrhagic stroke or large ischemic infarct, and MRI was
postponed due to clinical instability. Infectious disease was consulted,
and the patient was started on empiric broad spectrum antibiotics for
clostridial colitis and undifferentiated with vancomycin, cefepime,
metronidazole, and a one time dose of tobramycin. Blood cultures grew
Proteus mirabalis on hospital day 2 and patient was narrowed to
ampicillin-sulbactam and PO vancomycin. Initial concern was for a
nephrogenic or gastrointestinal, but CT scan of the abdomen only showed
mild colitis. On hospital day 3, a transthoracic echocardiogram showed
normal ejection fraction, mild diastolic dysfunction and no vegetations.
Hospital day 4, a brain MRI showed multifocal acute infarcts throughout
all portions of the brain likely from a cardioembolic etiology. Given the
patient's comorbid aortic valve calcification and positive blood culture,
there was concern for endocarditis, even though it is exceedingly rare in
Proteus species. On hospital day 7 (delay due to limited echocardiography
staff on weekend), a transesophageal echocardiogram noted a 1.9 x 1.5 cm
vegetation on the posterior flap of the mitral valve. Cardiothoracic
surgery was consulted but declined surgery given the estimated risk of
serious morbidity and mortality for surgical repair approached 80%. The
patient slowly improved with antibiotics, was weaned off pressors, and
able to be extubated. Given the poor prognosis, the family made the
patient comfort care, and the patient passed on hospital day 16. While
exceedingly rare (a 2020 systematic review identified 16 case reports),
Proteus species are able to form biofilms and are an uncommon and often
lethal form of endocarditis.

<51>
Accession Number
644437268
Title
Combined Endobronchial Valve Placement and Inter-lobar Fissure Completion
for Lung Volume Reduction in Emphysema: A Pilot Randomized Controlled
Trial (COMPLETE-1).
Source
American Journal of Respiratory and Critical Care Medicine. Conference:
American Thoracic Society 2024 International Conference. San Diego, CA
United States. 209 (no pagination), 2024. Date of Publication: May 2024.
Author
Burbano A.V.; Ospina-Delgado D.; Rosenberg B.J.; Parikh M.S.; Beattie J.;
Swenson K.E.; Wilson J.L.; Kent M.; Gangadharan S.P.; Majid A.
Institution
(Burbano, Rosenberg, Parikh, Beattie, Swenson, Wilson, Kent, Gangadharan,
Majid) Department of Surgery, Division of Thoracic Surgery and
Interventional Pulmonology, Beth Israel Deaconess Medical Center, Boston,
MA, United States
(Ospina-Delgado) Bloomberg School of Public Health and Carey Business
School, Johns Hopkins University, Baltimore, MD, United States
Publisher
American Thoracic Society
Abstract
Introduction: Bronchoscopic Lung Volume Reduction (BLVR) with
endobronchial valves (EBVs) has been shown to be clinically effective in
highly selected patients with severe emphysema. However, the presence of
collateral ventilation (CV) can result in treatment failure. The aim of
this study was to evaluate the feasibility, safety, and effectiveness of
thoracoscopic inter-lobar fissure completion followed by BLVR for lobar
atelectasis. Method(s): In this pilot randomized controlled trial,
patients age 40-80 with severe emphysema, hyperinflation, and positive CV
were randomized to either fissure completion or medical management. Those
in the medical management arm underwent maximum medical therapy for 3
months after which they were offered to crossover to the fissure
completion arm. Those randomized to the fissure completion arm underwent
combined surgical inter-lobar fissure completion via robotic assisted
thoracoscopic surgery (RATS) or video assisted thoracic surgery (VATS)
immediately followed by BLVR with placement of Zephyr EBVs. Patients were
followed at 3 and 12 months. Outcomes included FEV1, TLC, RV, 6MWT, TLVR,
SGRQ, CAT score, and mMRC. Descriptive statistics were reported as median
(inter quartile range) and mean +/- standard deviation. Result(s): A
total of 12 patients were randomized, 7 to medical management and 5 to
fissure completion. Before randomization median FEV1 was 28 (24-31), TLC
129.5 (119- 137), RV 215 (178-232), 6MWT 305 (225-313), SGRQ 58.8
(49.2-69.9), CAT 21 (16-23) and mMRC of 3.2+/-0.42. At 3 months patients
in the medical management arm had a median FEV1 of 29 (26-32.5), TLC 125
(111-142), RV 212 (163-270), 6MWT 286 (212-330), SGRQ 60.03 (49.2- 67.4),
CAT 21.5 (17-23) and mMRC of 2.83+/-0.4. At 3 months postop patients in
the fissure completion arm had a median FEV1 of 33 (23-35), TLC 118
(98-157), RV 169 (132-190), 6MWT 317.5 (260.5-360), SGRQ 49.97
(26.1-68.5), CAT 17 (10-29) and mMRC 2.42+/-1.13. At 12 months postop
median FEV1 was 33 (23-42), TLC 113 (98-130), RV 148 (120-212), 6MWT 375
(268- 411), SGRQ 51.33 (36.11-53.1), CAT 13 (10-16) and mMRC of 2+/-0.57.
All patients were CV negative after the combined procedure and median TLVR
was 1996 (1467-2409). Post operatively, mean air leak duration was
9.8+/-5.1, two patients had small pleural effusions, one developed
respiratory failure, and one had a COPD exacerbation. Conclusion(s):
The combination of thoracoscopic inter-lobar fissure completion and BLVR
to induce lobar atelectasis is feasible and safe, resulting in significant
lung volume reduction.

<52>
Accession Number
2030137917
Title
Moderate aortic stenosis: Navigating the uncharted.
Source
Echocardiography. 41(6) (no pagination), 2024. Article Number: e15859.
Date of Publication: June 2024.
Author
Caprio M.V.; De Donno F.; Bisaccia G.; Mantini C.; Di Baldassarre A.;
Gallina S.; Khanji M.Y.; Ricci F.
Institution
(Caprio, De Donno, Bisaccia, Mantini, Gallina, Ricci) Department of
Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of
Chieti-Pescara, Chieti, Italy
(Caprio, De Donno, Gallina, Ricci) SS Annunziata Polyclinic University
Hospital, University Cardiology Division, Chieti, Italy
(Di Baldassarre) Department of Medicine and Aging Sciences, and
Reprogramming and Cell Differentiation Lab, Center for Advanced Studies
and Technology (CAST), G. D'Annunzio University of Chieti-Pescara, Chieti,
Italy
(Khanji) Newham University Hospital, Barts Health NHS Trust, London,
Plaistow, United Kingdom
(Khanji) Barts Heart Centre, Barts Health NHS Trust, London, West
Smithfield, United Kingdom
(Khanji) NIHR Barts Biomedical Research Centre, William Harvey Research
Institute, Queen Mary University, London, United Kingdom
(Ricci) Department of Clinical Sciences, Lund University, Malmo, Sweden
Publisher
John Wiley and Sons Inc
Abstract
Aortic stenosis (AS) stands as the most common valvular heart disease in
developed countries and is characterized by progressive narrowing of the
aortic valve orifice resulting in elevated transvalvular flow resistance,
left ventricular hypertrophy, and progressive increased risk of heart
failure and sudden death. This narrative review explores clinical
challenges and evolving perspectives in moderate AS, where discrepancies
between aortic valve area and pressure gradient measurements may pose
diagnostic and therapeutic quandaries. Transthoracic echocardiography is
the first-line imaging modality for AS evaluation, yet cases of
discordance may require the application of ancillary noninvasive
diagnostic modalities. This review underscores the importance of accurate
grading of AS severity, especially in low-gradient phenotypes, emphasizing
the need for vigilant follow-up. Current clinical guidelines primarily
recommend aortic valve replacement for severe AS, potentially overlooking
latent risks in moderate disease stages. The noninvasive multimodality
imaging approach-including echocardiography, cardiac magnetic resonance,
computed tomography, and nuclear techniques-provides unique insights into
adaptive and maladaptive cardiac remodeling in AS and offers a promising
avenue to deliver precise indications and exact timing for intervention in
moderate AS phenotypes and asymptomatic patients, potentially improving
long-term outcomes. Nevertheless, what we may have gleaned from a large
amount of observational data is still insufficient to build a robust
framework for clinical decision-making in moderate AS. Future research
will prioritize randomized clinical trials designed to weigh the benefits
and risks of preemptive aortic valve replacement in the management of
moderate AS, as directed by specific imaging and nonimaging
biomarkers. Copyright © 2024 Wiley Periodicals LLC.

<53>
Accession Number
2032706462
Title
LANDMARK comparison of early outcomes of newer-generation Myval
transcatheter heart valve series with contemporary valves (Sapien and
Evolut) in real-world individuals with severe symptomatic native aortic
stenosis: a randomised non-inferiority trial.
Source
The Lancet. (no pagination), 2024. Date of Publication: 2024.
Author
Baumbach A.; van Royen N.; Amat-Santos I.J.; Hudec M.; Bunc M.;
Ijsselmuiden A.; Laanmets P.; Unic D.; Merkely B.; Hermanides R.S.; Ninios
V.; Protasiewicz M.; Rensing B.J.W.M.; Martin P.L.; Feres F.; De Sousa
Almeida M.; van Belle E.; Linke A.; Ielasi A.; Montorfano M.; Webster M.;
Toutouzas K.; Teiger E.; Bedogni F.; Voskuil M.; Pan M.; Angeras O.; Kim
W.-K.; Rothe J.; Kristic I.; Peral V.; Garg S.; Elzomor H.; Tobe A.;
Morice M.-C.; Onuma Y.; Soliman O.; Serruys P.W.; Siqueira D.; Pinto I.;
Cervone A.; Assef J.; Vilela A.; Paladino A.; Ramos A.; Rezende M.;
Ghorayeb S.; Braga Silva T.R.; Gjorgjievska S.; Hadzibegovic I.; Jurin I.;
Sipic T.; Pavlovic N.; Rudez I.; Manola S.; GALLET DE SAINT-AURIN R.;
BOUKANTAR M.; NICOLAS E.; ENNEZAT P.V.; URIEN J.M.; Vincent F.; Delhaye
C.; Denimal T.; Cosenza A.; Pamart T.; Porouchani S.; Pontana F.;
Montaigne D.; Balmette V.; Bechiri M.; Chen E.; Janah D.; Matthias R.;
Westermann D.; Valina C.; Ferenc M.; Loffelhardt N.; Rahimi F.; Breitbart
P.; Franke K.; Czerny M.; Diab N.; Sick P.; Adeishvili M.; Mangner N.;
Haussig S.; Sveric K.; Crusius L.; Roehlig M.; Koliastasis L.; Drakopoulou
M.; Katsaros O.; Ktenopoulos N.; Ioanniadis A.; Evangelou S.; Ninios I.;
Molnar L.; Papp R.; Arnold-Bela F.; Demeterne Kiss O.; Nagy A.; Czimbalmos
C.; Pellegrinni D.; Montonati C.; Pellicano M.; Guagliumi G.; Tespili M.;
Barbara B.; Filippo R.; Marco A.; Ciro V.; Luca F.; Eustachio A.; Giacomo
I.; Cannone G.; Brambilla N.; Testa L.; Avondo S.; Valvo R.; Clarke R.;
Fish M.; Kosowski M.; Krawczyk M.; Kubler P.; Kotwica T.; Teles R.;
Goncalves P.; Raposo L.; Brito J.; Leal S.; Freitas P.; Ribeiras R.;
Poliacikova P.; Mihaolovic P.M.; Terseglav S.; Steblovnik K.; Cercek M.;
Vitez L.; Sustersic M.; Kovac A.; Kogoj P.; Dimitrovska L.; Arana J.R.D.;
Martinez S.S.; Dieguez A.R.; Barrero A.; Gonzalez-Bartol E.; Aristizabal
C.; Frutos A.S.; Luna J.P.S.; Gomez M.G.; Gabella T.R.; Nelson V.Q.;
Medina J.N.; Ojeda S.; de Lezo J.S.; Romero M.; Gonzalez-Manzanares R.;
Alvarado M.; Mesa D.; Perea J.; Petursson P.; Alchay M.; Andreen S.; Van
Gameren M.; den Heijer P.; Meuwissen M.; CHENG J.M.; Vos J.; Scholzel
B.E.; Simsek C.; Hubbers S.; Stens N.A.; Versteeg G.A.A.; Rooijakkers
M.J.P.; Gehlmann H.R.; Verkroost M.W.A.; Geuzebroek G.S.C.; Van Wely M.H.;
Van Geuns R.J.; van Nunen L.X.; van Garsse L.A.F.M.; Timmers L.; ten Berg
J.; Kraaijeveld A.O.; Dickinson M.G.; Dessing T.C.; Mokhles M.M.
Institution
(Baumbach) Centre for Cardiovascular Medicine and Devices, William Harvey
Research Institute, Queen Mary University of London and Barts Heart
Centre, London, United Kingdom
(van Royen) Department of Cardiology, Radboud University Hospital,
Nijmegen, Netherlands
(Amat-Santos) Department of Cardiology, University Clinical Hospital of
Valladolid, Valladolid, Spain
(Hudec) Department of Acute Cardiology, Middle-Slovak Institute Of
Cardiovascular Diseases, Banska Bystrica, Slovakia
(Bunc) Department of Cardiology, University Medical Centre Ljubljana,
Ljubljana, Slovenia
(Ijsselmuiden) Department of Cardiology, Amphia Hospital, Breda,
Netherlands
(Laanmets) Department of Invasive Cardiology, North Estonia Medical
Centre, Tallinn, Estonia
(Unic) Department of Cardiac and Transplant Surgery, University Hospital
Dubrava, Zagreb, Croatia
(Merkely) Heart and Vascular Centre, Semmelweis University Heart and
Vascular Centre, Budapest, Hungary
(Hermanides) Department of Cardiology, Isala Hospital, Zwolle, Netherlands
(Ninios) Department of Cardiology, European Interbalkan Medical Center,
Thessaloniki, Greece
(Protasiewicz) Department of Cardiology, Institute of Heart Diseases,
Wroclaw Medical University, Wroclaw, Poland
(Rensing) Department of Cardiology, St Antonius Hospital, Nieuwegein,
Netherlands
(Martin) Department of Interventional Cardiology, University Hospital of
Gran Canaria Dr Negrin, Las Palmas, Spain
(Feres) Department of Invasive Cardiology, Instituto Dante Pazzanese, Sao
Paulo, Brazil
(De Sousa Almeida) CHRC, NOVA Medical School, NOVA University Lisbon,
Lisbon, Portugal
(van Belle) Department of Interventional Cardiology, Lille University,
Lille, France
(Linke) Department of Internal Medicine and Cardiology, University Clinic,
Heart Center Dresden, University of Technology Dresden, Dresden, Germany
(Ielasi) Department of Interventional Cardiology, IRCCS Galeazzi
Sant'Ambrogio Hospital, Milan, Italy
(Montorfano) School of Medicine, Vita-Salute San Raffaele University,
Milan, Italy
(Montorfano) Interventional Cardiology Unit IRCCS San Raffaele Scientific
Institute, Milan, Italy
(Webster) Department of Cardiology, Auckland City Hospital, Auckland, New
Zealand
(Toutouzas) Department of Cardiology, Hippokration Hospital, Athens,
Greece
(Teiger) Department of Medico-surgical Cardiovascular and Anaesthesiology,
Henri-Mondor University Hospital, Creteil, France
(Bedogni) Department of Clinical Cardiology, San Donato Hospital, Milan,
Italy
(Voskuil) Department of Interventional Cardiology, University Medical
Center Utrecht, Utrecht, Netherlands
(Pan) Department of Cardiology, University Hospital Reina Sofia,
University of Cordoba, Cordoba, Spain
(Angeras) Department of Cardiology, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Angeras) Department of Clinical and Molecular Medicine, Gothenburg
University, Gothenburg, Sweden
(Kim) Department of Cardiology and Angiology, University of Giessen and
Marburg, Giessen, Germany
(Kim) Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim,
Germany
(Rothe) Department of Cardiology and Angiology, University Heart Center
Freiburg Bad Krozingen, University Medical Center Freiburg, Freiburg,
Germany
(Rothe) Department of Cardiology and Angiology, Faculty of Medicine,
University of Freiburg, Freiburg, Germany
(Kristic) Department of Cardiology, University Hospital of Split, Split,
Croatia
(Peral) Department of Cardiology, Son Espases University Hospital, Palma,
Spain
(Garg) Department of Cardiology, Royal Blackburn Hospital, Blackburn,
United Kingdom
(Elzomor, Tobe, Onuma, Soliman, Serruys) Department of Cardiology, School
of Medicine, University of Galway, Galway, Ireland
(Morice) Cardiovascular European Research Center, Paris, France
Publisher
Elsevier B.V.
Abstract
Background: Transcatheter aortic valve implantation is an established,
guideline-endorsed treatment for severe aortic stenosis. Precise sizing of
the balloon-expandable Myval transcatheter heart valve (THV) series with
the aortic annulus is facilitated by increasing its diameter in 1.5 mm
increments, compared with the usual 3 mm increments in valve size. The
LANDMARK trial aimed to show non-inferiority of the Myval THV series
compared with the contemporary THVs Sapien Series (Edwards Lifesciences,
Irvine, CA, USA) or Evolut Series (Medtronic, Minneapolis, MN, USA).
 Method(s): In this prospective, multinational, randomised,
open-label, non-inferiority trial across 31 hospitals in 16 countries
(Germany, France, Sweden, the Netherlands, Italy, Spain, New Zealand,
Portugal, Greece, Hungary, Poland, Slovakia, Slovenia, Croatia, Estonia,
and Brazil), 768 participants with severe symptomatic native aortic
stenosis were randomly assigned (1:1) to the Myval THV or a contemporary
THV. Eligibility was primarily decided by the heart team in accordance
with 2021 European Society of Cardiology guidelines. As per the criteria
of the third Valve Academic Research Consortium, the primary endpoint at
30 days was a composite of all-cause mortality, all stroke, bleeding
(types 3 and 4), acute kidney injury (stages 2-4), major vascular
complications, moderate or severe prosthetic valve regurgitation, and
conduction system disturbances resulting in a permanent pacemaker
implantation. Non-inferiority of the study device was tested in the
intention-to-treat population using a non-inferiority margin of 10.44% and
assuming an event rate of 26.10%. This trial is registered with
ClinicalTrials.gov, NCT04275726, and EudraCT, 2020-000137-40, and is
closed to new participants. Finding(s): Between Jan 6, 2021, and Dec
5, 2023, 768 participants with severe symptomatic native aortic stenosis
were randomly assigned, 384 to the Myval THV and 384 to a contemporary
THV. 369 (48%) participants had their sex recorded as female, and 399
(52%) as male. The mean age of participants was 80.0 years (SD 5.7) for
those treated with the Myval THV and 80.4 years (5.4) for those treated
with a contemporary THV. Median Society of Thoracic Surgeons scores were
the same in both groups (Myval 2.6% [IQR 1.7-4.0] vs contemporary 2.6%
[1.7-4.0]). The primary endpoint showed non-inferiority of the Myval (25%)
compared with contemporary THV (27%), with a risk difference of -2.3%
(one-sided upper 95% CI 3.8, p<inf>non-inferiority</inf><0.0001). No
significant difference was seen in individual components of the primary
composite endpoint. Interpretation(s): In individuals with severe
symptomatic native aortic stenosis, the Myval THV met its primary endpoint
at 30 days. Funding(s): Meril Life Sciences. Copyright ©
2024 Elsevier Ltd

<54>
Accession Number
644447461
Title
Association between lipoprotein levels and outcomes after coronary artery
bypass grafting surgery: a systematic review and meta-analysis.
Source
Minerva cardiology and angiology. (no pagination), 2024. Date of
Publication: 05 Jun 2024.
Author
Cancelli G.; Harik L.; Ibrahim M.; Hameed I.; Rossi C.; Caldonazo T.;
Dell'aquila M.; Soletti G.J.; An K.R.; Leith J.; Demetres M.; Dimagli A.;
Gaudino M.F.
Institution
(Cancelli, Harik, Rossi, Caldonazo, Dell'aquila, Soletti, An, Leith,
Dimagli) Department of Cardiothoracic Surgery, Weill Cornell Medicine, New
York, NY, USA
(Ibrahim) Department of General Surgery, Maimonides Medical Center,
Brooklyn, NY, United States
(Hameed) Department of Cardiothoracic Surgery, Yale University School of
Medicine, New Haven, CT, United States
(Demetres) Samuel J. Wood Library and C.V. Starr Biomedical Information
Center, Weill Cornell Medicine, New York, NY, USA
(Gaudino) Department of Cardiothoracic Surgery, Weill Cornell Medicine,
New York, NY, USA - mfg9004@med.cornell.edu
Abstract
INTRODUCTION: Lipoprotein(a) (Lp[a]) is a variant of low-density
lipoprotein (LDL) and has been associated with increased risk of vascular
inflammation and thrombosis. Coronary artery bypass grafting (CABG) has
been associated with local inflammation of the myocardium. It is
plausible, therefore, that patients with elevated baseline Lp(a) may be
prone to unfavorable clinical outcomes following CABG. We evaluate
differences in outcomes between CABG patients with high and low serum
Lp(a) in this meta-analysis. EVIDENCE ACQUISITION: A comprehensive
literature search was performed to identify studies reporting outcomes in
CABG patients stratified by preoperative Lp(a) level. When possible, the
outcomes were pooled in a meta-analysis. We assessed post-operative
mortality, major cardiovascular events, stroke occurrence and saphenous
graft occlusion. EVIDENCE SYNTHESIS: Eight studies involving 8681 patients
were included. Articles used varying cut-offs for high versus low Lp(a),
and outcomes varied. In the three studies evaluating mortality, two showed
no statistically significant difference between groups while one reported
increased mortality associated with high Lp(a) level. Both studies
investigating major adverse cardiovascular events reported higher risk in
patients with high Lp(a). A study-level meta-analysis of four studies
reporting saphenous vein graft occlusion incidence after CABG was
performed. High (>=30 mg/dL) preoperative Lp(a) was not associated with an
increased risk of graft occlusion compared with low (<30 mg/dL)
preoperative Lp(a) (OR=1.88, 95% CI: 0.66-5.36; P=0.15).
 CONCLUSION(S): Studies evaluating the impact of Lp(a) on outcomes in
CABG patients are few, with heterogenous cut-offs and outcomes. In the
limited published studies, Lp(a) level was not associated with graft
occlusion.

<55>
Accession Number
644447371
Title
Efficacy of N-acetylcysteine in reducing the risk of postoperative atrial
fibrillation in cardiothoracic surgery: a systematic review and
meta-analysis of randomized controlled trials.
Source
Minerva cardiology and angiology. (no pagination), 2024. Date of
Publication: 05 Jun 2024.
Author
Hassan A.A.; Ismail N.R.; Rezk A.E.; Elfeky H.M.; Mady A.M.; Allam A.G.;
Abbas K.S.
Institution
(Hassan) Medical Research Group of Egypt (MRGE), Arlington, MA, United
States
(Hassan) Faculty of Medicine, Al-Azhar University, Cairo, Egypt
(Ismail, Rezk, Elfeky, Mady, Allam, Abbas) Medical Research Group of Egypt
(MRGE), Arlington, MA, United States
(Ismail) Faculty of Medicine, University of Zagazig, Zagazig, Egypt
(Rezk) Faculty of Medicine
(Elfeky) th of October University, Cairo, Egypt
(Mady, Allam) Faculty of Medicine, Al-Azhar University, Cairo, Egypt
Abstract
INTRODUCTION: New-onset postoperative atrial fibrillation (POAF) is a
common complication following cardiac surgeries. N-acetylcysteine (NAC)
showed a significant reduction in the incidence of POAF. This review aimed
to systematically summarize and Meta-analyze data from previously
published Randomized Controlled Trials (RCTs). EVIDENCE ACQUISITION:
Electronic databases: PubMed, Cochrane, Embase, Scopus, and Web of Science
were searched. Data was extracted and the quality of the included studies
was assessed. A random-effects DerSimonian Laird model was employed for
meta-analysis. EVIDENCE SYNTHESIS: Fifteen RCTs were included in this
study (NAC, N.=940; control, N.=935). In the NAC group, 16.38% developed
POAF compared with 23.53% in the control group. NAC supplementation was
associated with a decreased incidence of POAF in patients undergoing
cardiothoracic surgery (RR 0.69; 95% CI 0.52, 0.91; P=0.008).
Meta-regression of randomized trial data showed that the incidence of POAF
was not related to the NAC dose (P=0.439). A subgroup analysis in terms of
the time of NAC administration revealed that preoperative and
postoperative NAC administration was the only subgroup that demonstrated a
statistically significant difference (RR 0.48, 95% CI 0.32, 0.71;
P=0.0003) compared with placebo and showed no heterogeneity.
 CONCLUSION(S): Atrial fibrillation is a significant postoperative
complication, particularly in cardiothoracic surgery. This study
highlights the need for further research on optimal NAC dosing and timing,
with evidence suggesting that preoperative and postoperative NAC
administration may significantly decrease postoperative atrial
fibrillation in cardiothoracic surgery patients, although limitations and
variability in study designs need to be considered.

<56>
Accession Number
644447146
Title
Vitamin C for all?.
Source
Current opinion in critical care. (no pagination), 2024. Date of
Publication: 21 May 2024.
Author
de Man A.; Long M.T.; Stoppe C.
Institution
(de Man) Amsterdam UMC, location Vrije Universiteit, Department of
Intensive Care, Amsterdam, the Netherlands; Amsterdam Cardiovascular
Sciences, Amsterdam, The Netherland
(Long) Departments of Anesthesiology, Internal Medicine & Emergency
Medicine, University of Wisconsin Hospitals & Clinics, Madison, WI, United
States
(Stoppe) University Hospital Wuerzburg, Department of Anaesthesiology,
Intensive Care, Emergency, Pain Medicine, Wuerzburg, Germany
(Stoppe) German Heart Center Charite Berlin, Department of Cardiac
Anesthesiology and Intensive Care Medicine, Berlin, Germany
Abstract
PURPOSE OF REVIEW: Vitamin C can be a potential adjunctive treatment
option for critically ill individuals due to its pleiotropic effects as
electron donor in many enzymatic reactions throughout the body. Recently,
several important randomized controlled trials (RCTs) investigating
vitamin C in critically ill patients have been published. RECENT FINDINGS:
Two recent large RCTs administering high-dose vitamin C to patients with
sepsis and COVID-19 showed signs of harm. Though performed at high
standard, these trials had several limitations. Recent studies in cardiac
surgery and burns showed decreased cardiac enzymes and improved clinical
outcomes after cardiac surgery, and decreased fluid requirements, reduced
wound healing time and in-hospital mortality after burns. Vitamin C may
hold benefit in the management of other ischemia/reperfusion injury
populations, including postcardiac arrest patients and after solid organ
transplantation. Currently, covering basal vitamin C requirements during
critical illness is recommended, though the exact dose remains to be
determined. SUMMARY: Future work should address optimal vitamin C timing,
since early versus late drug administration are likely distinct, and
duration of therapy, where withdrawal-induced injury is possible.
Additionally accurate assessment of body stores with determination of
individual vitamin requirements is crucial to ascertain patient and
subgroups most likely to benefit from vitamin C. Copyright © 2024
Wolters Kluwer Health, Inc. All rights reserved.

<57>
Accession Number
644445889
Title
A Systematic Review and Meta-Analysis of the Effects of Statin Therapy on
Heart Transplantation.
Source
Reviews on recent clinical trials. (no pagination), 2024. Date of
Publication: 04 Jun 2024.
Author
Mardani-Nafchi H.; Rafsanjani S.M.R.H.; Heidari-Soureshjani S.; Abbaszadeh
S.; Gholamine B.; Naghdi N.
Institution
(Mardani-Nafchi) Student of Pharmacology, Shahid Beheshti University of
Medical Sciences, Tehran, Iran, Islamic Republic of
(Rafsanjani) Faculty of Medicine, Tehran Medical Sciences, Islamic Azad
University, Tehran, Iran, Islamic Republic of
(Heidari-Soureshjani) Modeling in Health Research Center, Shahrekord
University of Medical Sciences, Iran, Islamic Republic of
(Abbaszadeh) Department of Biochemistry and Genetics, School of Medicine,
Lorestan University of Medical Sciences, Khorramabad, Iran, Islamic
Republic of
(Gholamine, Naghdi) Department of Pharmacology, School of Medicine, Shahid
Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of
Abstract
BACKGROUND: Most of the mortality after Heart Transplantation (HT) is
attributed to severe cardiac allograft vasculopathy (CAV) and rejection.
 OBJECTIVE(S): This meta-analysis aimed to investigate the effects of
postoperative statin therapy on outcomes (mortality, rejection, and CAV in
HT patients). METHOD(S): This systematic review and meta-analysis was
performed on publications between 1980 and October 2023 in Web of Science,
Scopus, PubMed, Cochrane, Science Direct, Google Scholar, and Embase
databases. Heterogeneity was assessed using Chi-square, I2, and forest
plots. Publication bias was evaluated using Begg's and Egger's tests.
Analyses were performed in Stata 15 with significance at p < 0.05.
 RESULT(S): This meta-analysis included 17 studies comprising 4,627
participants and conducted between 1995 to 2021. Compared to non-users,
the odds of mortality were lower among statin users (OR= 0.49, 95% CI:
0.32-0.75, p < 0.001). The odds of CAV were also reduced with statin use
(OR= 0.71, 95% CI: 0.53-0.96, p = 0.027). The odds of rejection were not
significantly different (OR= 0.69, 95% CI: 0.41-1.15, p = 0.152). However,
rejection odds were lower with statins in RCTs (OR= 0.42, 95% CI:
0.21-0.82, p = 0.012) but not in case-control studies (OR= 0.87, 95% CI:
0.49-1.52, p = 0.615). No publication bias was observed with Begg's test,
but Egger's test showed possible bias. CONCLUSION(S): This
meta-analysis found postoperative statin use associated with lower
mortality and CAV, but not overall rejection, though RCT subgroup analysis
showed decreased rejection with statins. Statin therapy may improve
prognosis in HT patients. Copyright© Bentham Science Publishers;
For any queries, please email at epub@benthamscience.net.

<58>
Accession Number
2029021195
Title
Systematic Review of Literature Citing the ISCHEMIA Trial.
Source
Current Cardiology Reports. 26(5) (pp 325-329), 2024. Date of Publication:
May 2024.
Author
King D.J.; Eskander C.; Ricci J.; Gittess D.; Patel R.; Bourne M.; Budweg
J.; Winchester D.E.
Institution
(King, Eskander, Gittess, Patel, Bourne) Department of Medicine,
University of Florida, Gainesville, FL, United States
(Ricci) College of Medicine, University of Florida, Gainesville, FL,
United States
(Budweg, Winchester) Division of Cardiovascular Medicine, University of
Florida, Gainesville, FL, United States
Publisher
Springer
Abstract
Purpose of Review: Optimal therapy for patients with chronic coronary
artery disease (CCD) has long been a topic under investigation and a
subject of debate. Seeking to clarify appropriate management, the
International Study of Comparative Health Effectiveness with Medical and
Invasive Approaches (ISCHEMIA) trial compared medical management versus
coronary angiography for patients with stable ischemic heart disease. Its
reception in the medical community has been met with both acclaim and
criticism. In light of such disparate views of this trial, a systematic
review of the literature citing the ISCHEMIA trial was performed. Recent
Findings: All articles citing the ISCHEMIA trial on PubMed as of July 21,
2023, were compiled and underwent qualitative analysis. A total of 430
articles were evaluated; 109 (25.3%) did not offer substantial commentary
on ISCHEMIA and cite it as background evidence for further study. Of the
commentary articles, the majority (224, 52.1%) gave balanced, honest
appraisals of the ISCHEMIA trial. A total of 46 (10.7%) strongly praised
the trial while another 39 (9.1%) were strongly critical of the results.
 Summary: Almost three-quarters of the literature citing the ISCHEMIA
trial was commentary in nature, with roughly equal distribution across the
spectrum of praise and criticism. Despite being one of the largest studies
on CCD and coronary revascularization ever conducted, the impact of
ISCHEMIA on the cardiology community appears to be mixed. Copyright
© This is a U.S. Government work and not under copyright protection
in the US; foreign copyright protection may apply 2024.

<59>
Accession Number
2029563211
Title
Global Cardiac Surgery in Brazil: A Call to Action.
Source
Brazilian Journal of Cardiovascular Surgery. 39(2) (no pagination), 2024.
Article Number: e20230408. Date of Publication: 2024.
Author
Faleiro M.D.; Fernandez M.G.; Feitosa K.I.B.; Vervoort D.
Institution
(Faleiro, Fernandez, Feitosa) International Student Surgical Network
(InciSioN), Minas Gerais, Belo Horizonte, Brazil
(Faleiro) Faculdade de Medicina, Universidade Federal de Minas Gerais,
Minas Gerais, Belo Horizonte, Brazil
(Fernandez) Escola Bahiana de Medicina e Saude Publica, Bahia, Salvador,
Brazil
(Feitosa) Faculdade de Medicina, Universidade Positivo, Parana, Curitiba,
Brazil
(Vervoort) Division of Cardiac Surgery, University of Toronto, Toronto,
ON, Canada
(Vervoort) Institute of Health Policy, Management and Evaluation,
University of Toronto, Toronto, ON, Canada
Publisher
Sociedade Brasileira de Cirurgia Cardiovascular
Abstract
Global Cardiac Surgery is an innovative initiative with a focus on
improving health outcomes and achieving healthcare equity for individuals
worldwide affected by cardiac surgical conditions or in need of cardiac
surgical care. Considering the existing disparities in access to cardiac
surgery and the substantial burden of cardiac conditions amenable to
surgical procedures in Brazil, it is imperative to support and scale
Global Cardiac Surgery initiatives and leave no Brazilian patient behind.
Here, we advocate for national initiatives within this field and highlight
opportunities and challenges to support their development. Copyright
© 2024, Sociedade Brasileira de Cirurgia Cardiovascular. All rights
reserved.

<60>
Accession Number
2029545741
Title
Comparison of the Effects of Full Median Sternotomy vs. Mini-Incision on
Postoperative Pain in Cardiac Surgery: A Meta-Analysis.
Source
Brazilian Journal of Cardiovascular Surgery. 39(4) (no pagination), 2024.
Article Number: e20230154. Date of Publication: 2024.
Author
Junior A.J.C.; Avelino P.S.; Lopes J.B.
Institution
(Junior) Faculdade de Medicina da Bahia, Universidade Federal da Bahia
(FMB/UFBA), Bahia, Salvador, Brazil
(Avelino) Faculdade de Medicina, Universidade Salvador (UNIFACS), Bahia,
Salvador, Brazil
(Lopes) Department of Anesthesiology and Surgery, Faculdade de Medicina da
Bahia, Universidade Federal da Bahia (FMB/UFBA), Bahia, Salvador, Brazil
Publisher
Sociedade Brasileira de Cirurgia Cardiovascular
Abstract
Introduction: It is not yet clear whether cardiac surgery by mini-incision
(minimally invasive cardiac surgery [MICS]) is overall less painful than
the conventional approach by full sternotomy (FS). A meta-analysis is
necessary to investigate polled results on this topic. Method(s):
PubMed/MEDLINE, Cochrane CENTRAL, Latin American and Caribbean Health
Sciences Literature (or LILACS), and Scientific Electronic Library Online
(or SciELO) were searched for all clinical trials, reported until 2022,
comparing FS with MICS in coronary artery bypass grafting (CABG), mitral
valve surgery (MVS), and aortic valve replacement (AVR), and postoperative
pain outcome was analyzed. Main summary measures were the method of
standardized mean differences (SMD) with a 95% confidence interval (CI)
and P-values (considered statistically significant when < 0.05).
 Result(s): In AVR, the general estimate of postoperative pain effect
favored MICS (SMD 0.87 [95% CI 0.04 to 1.71], P=0.04). However, in the
sensitivity analysis, there was no difference between the groups (SMD 0.70
[95% CI-0.69 to 2.09], P=0.32). For MVS, it was not possible to perform a
meta-analysis with the included studies, because they had different
methodologies. In CABG, the general estimate of the effect of
postoperative pain did not favor any of the approaches (SMD-0.40 [95%
CI-1.07 to 0.26], P=0.23), which was confirmed by sensitivity analysis
(SMD-0.02 [95% CI-0.71 to 0.67], P=0.95). Conclusion(s): MICS was not
globally less painful than the FS approach. It seems that postoperative
pain is more related to the degree of tissue retraction than to the size
of the incision. Copyright © 2024, Sociedade Brasileira de
Cirurgia Cardiovascular. All rights reserved.

<61>
Accession Number
2029520676
Title
Outcomes of Percutaneous Revascularization in Severe Ischemic Left
Ventricular Dysfunction.
Source
Current Cardiology Reports. 26(5) (pp 435-442), 2024. Date of Publication:
May 2024.
Author
Bista R.; Zghouzi M.; Jasti M.; Lichaa H.; Kerrigan J.; Haddad E.; Alraies
M.C.; Paul T.K.
Institution
(Bista, Zghouzi, Jasti, Lichaa, Kerrigan, Haddad, Paul) University of
Tennessee Health Science Center, Nashville, TN, United States
(Bista, Zghouzi, Jasti, Lichaa, Kerrigan, Haddad, Paul) Ascension St.,
Thomas Hospital, Nashville, TN, United States
(Alraies) Detroit Medical Center, Cardiovascular Institute, Heart
Hospital, Detroit, MI, United States
Publisher
Springer
Abstract
Purpose of Review: This article presents a comprehensive review of
coronary revascularization versus optimal medical therapy (OMT) in
patients with severe ischemic left ventricular dysfunction. Recent
Findings: The REVIVED-BCIS2 trial randomized 700 patients with extensive
coronary artery disease and left ventricular (LV) ejection fraction (LVEF)
<= 35% and viability in more than four dysfunctional myocardial segments
to percutaneous coronary intervention (PCI) plus OMT versus OMT alone.
Over a median duration of 41 months, there was no difference in the
composite of all-cause mortality, heart failure hospitalization, or
improvement in LVEF with PCI plus OMT versus OMT alone at 6 and 12 months,
quality of life scores at 24 months, or fatal ventricular arrhythmia. The
STICH randomized trial was conducted between 2002 and 2007, involving
patients with LV dysfunction and coronary artery disease. The patients
were assigned to either CABG plus medical therapy or medical therapy
alone. At the 5-year follow-up, the trial showed that CABG plus medical
therapy reduced cardiovascular disease-related deaths and hospitalizations
but no reduction in all-cause mortality. However, a 10-year follow-up
showed a significant decrease in all-cause mortality with CABG.
 Summary: The currently available evidence showed no apparent benefit
of PCI in severe ischemic cardiomyopathy as compared to OMT, but that CABG
improves outcomes in this patient population. The paucity of data on the
advantages of PCI in this patient population underscores the critical need
for optimization of medical therapy for better survival and quality of
life until further evidence from RCTs is available. Copyright ©
The Author(s) 2024.

<62>
Accession Number
2029393548
Title
Effect of an intravenous acetaminophen/ibuprofen fixed-dose combination on
postoperative opioid consumption and pain after video-assisted thoracic
surgery: a double-blind randomized controlled trial.
Source
Surgical Endoscopy. 38(6) (pp 3061-3069), 2024. Date of Publication: June
2024.
Author
Lee H.-J.; Choi S.; Yoon S.; Bahk J.-H.
Institution
(Lee, Choi, Yoon, Yoon, Bahk) Department of Anesthesiology and Pain
Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu,
Seoul 03080, South Korea
(Lee, Yoon, Bahk) Department of Anesthesiology and Pain Medicine, Seoul
National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul
03080, South Korea
Publisher
Springer
Abstract
Background: Video-assisted thoracoscopic surgery (VATS) often induces
significant postoperative pain, potentially leading to chronic pain and
decreased quality of life. This study aimed to evaluate the
acetaminophen/ibuprofen combination effectiveness in reducing analgesic
requirements and pain intensity in patients undergoing VATS. Study design:
This is a double-blinded randomized controlled trial. Method(s):
Adult patients scheduled for elective VATS for lung resection were
randomized to receive either intravenous acetaminophen and ibuprofen
(intervention group) or 100 mL normal saline (control group). Treatments
were administered post-anesthesia induction and every 6 h for three
cycles. The primary outcome was total analgesic consumption at 24 h
postoperatively. Secondary outcomes were cumulative analgesic consumption
at 2 and 48 h; analgesic-related side effects at 2, 24, and 48 h; quality
of recovery at 24 h and 48 h postoperatively; pain intensity at rest and
during coughing; and rescue analgesics use. Chronic postsurgical pain
(CPSP) was assessed through telephone interviews 3 months postoperatively.
 Result(s): The study included 96 participants. The intervention group
showed significantly lower analgesic consumption at 24 h and 48 h
postoperatively (24 h: median difference: - 100 microg equivalent
intravenous fentanyl [95% confidence interval (CI) - 200 to - 5 mug], P =
0.037; 48 h: median difference: - 140 mug [95% CI - 320 to - 20 mug], P =
0.035). Compared to the controls, the intervention group exhibited a
significantly lower quality of recovery 24 h post-surgery, with no
significant difference at 48 h. All pain scores except for coughing at 48
h post-surgery were significantly lower in the intervention group compared
to the controls. No significant differences were observed between the
groups in postoperative nausea and vomiting occurrence, hospital stay
length, and CPSP. Conclusion(s): Perioperative administration of
acetaminophen/ibuprofen significantly decreased analgesic needs in
patients undergoing VATS, providing an effective postoperative pain
management strategy, and potentially minimizing the need for stronger
analgesics. Copyright © The Author(s) 2024.

<63>
Accession Number
2029294978
Title
Insights into the Inherited Basis of Valvular Heart Disease.
Source
Current Cardiology Reports. 26(5) (pp 381-392), 2024. Date of Publication:
May 2024.
Author
Yu M.; Bouatia-Naji N.
Institution
(Yu) Shanghai Pudong Hospital, Human Phenome Institute, Fudan University
Pudong Medical Center, Zhangjiang Fudan International Innovation Center,
Fundan University, 825 Zhangheng Road, Pudong District, Shanghai 201203,
China
(Bouatia-Naji) Universite Paris Cite, PARCC, INSERM, Paris, France
Publisher
Springer
Abstract
Purpose of Review: Increases in the availability of genetic data and
advances in the tools and methods for their analyses have enabled
well-powered genetic association studies that have significantly enhanced
our understanding of the genetic factors underlying both rare and common
valve diseases. Valvular heart diseases, such as congenital valve
malformations and degenerative valve lesions, increase the risk of heart
failure, arrhythmias, and sudden death. In this review, we provide an
updated overview of our current understanding of the genetic mechanisms
underlying valvular heart diseases. With a focus on discoveries from the
past 5 years, we describe recent insights into genetic risk and underlying
biological pathways. Recent Findings: Recently acquired knowledge around
valvular heart disease genetics has provided important insights into novel
mechanisms related to disease pathogenesis. Newly identified risk loci
associated valvular heart disease mainly regulate the composition of the
extracellular matrix, accelerate the endothelial-to-mesenchymal
transition, contribute to cilia formation processes, and play roles in
lipid metabolism. Summary: Large-scale genomic analyses have
identified numerous risk loci, genes, and biological pathways associated
with degenerative valve disease and congenital valve malformations. Shared
risk genes suggest common mechanistic pathways for various valve
pathologies. More recent studies have combined cardiac magnetic resonance
imaging and machine learning to offer a novel approach for exploring
genotype-phenotype relationships regarding valve disease. Progress in the
field holds promise for targeted prevention, particularly through the
application of polygenic risk scores, and innovative therapies based on
the biological mechanisms for predominant forms of valvular heart
diseases. Copyright © The Author(s), under exclusive licence to
Springer Science+Business Media, LLC, part of Springer Nature 2024.

<64>
Accession Number
2029135412
Title
Transcatheter valve-in-valve interventions after aortic root replacement:
A systematic review.
Source
Catheterization and Cardiovascular Interventions. 103(7) (pp 1101-1110),
2024. Date of Publication: 01 Jun 2024.
Author
Baudo M.; Cuko B.; Ternacle J.; Sicouri S.; Torregrossa G.; Pernot M.;
Busuttil O.; Beurton A.; Alaux A.; Ouattara A.; Lafitte S.; Bonnet G.;
Leroux L.; De Vincentiis C.; Labrousse L.; Ramlawi B.; Modine T.
Institution
(Baudo, Torregrossa, Ramlawi) Department of Cardiac Surgery, Lankenau
Heart Institute, Lankenau Medical Center, Main Line Health, Wynnewood, PA,
United States
(Baudo, Sicouri, Torregrossa, Ramlawi) Department of Cardiac Surgery
Research, Lankenau Institute for Medical Research, Main Line Health,
Wynnewood, PA, United States
(Cuko, Ternacle, Pernot, Busuttil, Lafitte, Bonnet, Leroux, Labrousse,
Modine) Department of Cardiology and Cardio-Vascular Surgery, Hopital
Cardiologique de Haut-Leveque, Bordeaux University Hospital, Pessac,
France
(Beurton, Alaux, Ouattara) Department of Cardiovascular Anesthesia and
Critical Care, Hopital Cardiologique de Haut-Leveque, Bordeaux University
Hospital, Pessac, France
(Bonnet) Cardiovascular Research Foundation, New York, NY, United States
(De Vincentiis) Department of Cardiac Surgery, IRCCS Policlinico San
Donato, Milan, Italy
Publisher
John Wiley and Sons Inc
Abstract
Structural valve deterioration after aortic root replacement (ARR) surgery
may be treated by transcatheter valve-in-valve (ViV-TAVI) intervention.
However, several technical challenges and outcomes are not well described.
The aim of the present review was to analyze the outcomes of ViV-TAVI in
deteriorated ARR. This review included studies reporting any form of
transcatheter valvular intervention in patients with a previous ARR. All
forms of ARR were considered, as long as the entire root was replaced.
Pubmed, ScienceDirect, SciELO, DOAJ, and Cochrane library databases were
searched until September 2023. Overall, 86 patients were included from 31
articles that met our inclusion criteria out of 741 potentially eligible
studies. In the entire population, the mean time from ARR to
reintervention was 11.0 years (range: 0.33-22). The most frequently
performed techniques/grafts for ARR was homograft (67.4%) and the main
indication for intervention was aortic regurgitation (69.7%). Twenty-three
articles reported no postoperative complications. Six (7.0%) patients
required permanent pacemaker implantation (PPI) after the ViV-TAVI
procedure, and 4 (4.7%) patients had a second ViV-TAVI implant. There were
three device migrations (3.5%) and 1 stroke (1.2%). Patients with previous
ARR present a high surgical risk. ViV-TAVI can be considered in selected
patients, despite unique technical challenges that need to be carefully
addressed according to the characteristics of the previous surgery and on
computed tomography analysis. Copyright © 2024 Wiley Periodicals
LLC.

<65>
Accession Number
2032613186
Title
Effect of a multicomponent quality improvement strategy on sustained
achievement of diabetes care goals and macrovascular and microvascular
complications in South Asia at 6.5 years follow-up: Post hoc analyses of
the CARRS randomized clinical trial.
Source
PLoS Medicine. 21(6 JUNE) (no pagination), 2024. Article Number: e1004335.
Date of Publication: June 2024.
Author
Ali M.K.; Singh K.; Kondal D.; Devarajan R.; Patel S.A.; Menon V.U.;
Varthakavi P.K.; Vishwanathan V.; Dharmalingam M.; Bantwa G.; Sahay R.K.;
Masood M.Q.; Khadgawat R.; Desai A.; Prabhakaran D.; Narayan K.M.V.;
Tandon N.
Institution
(Ali) Emory Global Diabetes Research Center, Woodruff Health Sciences
Center, Department of Family and Preventive Medicine, School of Medicine,
Emory University, Atlanta, GA, United States
(Singh) Heidelberg Institute of Global Health, Heidelberg University,
Heidelberg, Germany
(Singh, Kondal, Devarajan) Public Health Foundation of India, Gurgaon,
India
(Patel) Emory University, Rollins School of Public Health, Atlanta, GA,
United States
(Menon) Amrita Institute of Medical Sciences, Department of Endocrinology
& Diabetes, AIMS Ponekkara, Kochi, India
(Varthakavi) TNM College, BYL Nair Charity Hospital, Department of
Endocrinology, Mumbai, India
(Vishwanathan) MV Hospital for Diabetes & Diabetes Research Centre,
Chennai, India
(Dharmalingam) Bangalore Endocrinology & Diabetes Research Centre,
Bangalore, India
(Bantwa) St. John's Medical College & Hospital, Department of
Endocrinology, Bangalore, India
(Sahay) Osmania General Hospital, Department of Endocrinology, Hyderabad,
India
(Masood) Aga Khan University, Department of Medicine, Section of
Endocrinology and Diabetes, Karachi, Pakistan
(Khadgawat, Tandon) All India Institute of Medical Sciences, Department of
Endocrinology & Metabolism, Biotechnology Block, New Delhi, India
(Desai) Goa Medical College, Department of Endocrinology, Bambolim, India
(Prabhakaran) Centre for Control of Chronic Conditions, Public Health
Foundation of India, Gurgaon, India
(Narayan) Emory Global Diabetes Research Center, Woodruff Health Sciences
Center, Emory University, Atlanta, GA, United States
Publisher
Public Library of Science
Abstract
Background Diabetes control is poor globally and leads to burdensome
microvascular and macrovascular complications. We aimed to assess post hoc
between-group differences in sustained risk factor control and
macrovascular and microvascular endpoints at 6.5 years in the Center for
cArdiovascular Risk Reduction in South Asia (CARRS) randomized trial.
Methods and findings This parallel group individual randomized clinical
trial was performed at 10 outpatient diabetes clinics in India and
Pakistan from January 2011 through September 2019. A total of 1,146
patients with poorly controlled type 2 diabetes (HbA1c >=8% and systolic
BP >=140 mm Hg and/or LDL-cholesterol >=130 mg/dl) were randomized to a
multicomponent quality improvement (QI) strategy (trained nonphysician
care coordinator to facilitate care for patients and clinical decision
support system for physicians) or usual care. At 2.5 years, compared to
usual care, those receiving the QI strategy were significantly more likely
to achieve multiple risk factor control. Six clinics continued, while 4
clinics discontinued implementing the QI strategy for an additional 4-year
follow-up (overall median 6.5 years followup). In this post hoc analysis,
using intention-to-treat, we examined between-group differences in
multiple risk factor control (HbA1c <7% plus systolic BP <130 mm Hg and/or
LDLcholesterol <100 mg/dl) and first macrovascular endpoints (nonfatal
myocardial infarction, nonfatal stroke, death, revascularization
[angioplasty or coronary artery bypass graft]), which were coprimary
outcomes. We also examined secondary outcomes, namely, single risk factor
control, first microvascular endpoints (retinopathy, nephropathy,
neuropathy), and composite first macrovascular plus microvascular events
(which also included amputation and all-cause mortality) by treatment
group and whether QI strategy implementation was continued over 6.5 years.
At 6.5 years, assessment data were available for 854 participants (74.5%;
n = 417 [intervention]; n = 437 [usual care]). In terms of
sociodemographic and clinical characteristics, participants in the
intervention and usual care groups were similar and participants at sites
that continued were no different to participants at sites that
discontinued intervention implementation. Patients in the intervention arm
were more likely to exhibit sustained multiple risk factor control than
usual care (relative risk: 1.79; 95% confidence interval [CI], 1.45,
2.20), p < 0.001. Cumulatively, there were 233 (40.5%) first microvascular
and macrovascular events in intervention and 274 (48.0%) in usual care
patients (absolute risk reduction: 7.5% [95% CI: -13.2, -1.7], p = 0.01;
hazard ratio [HR] = 0.72 [95% CI: 0.61, 0.86]), p < 0.001. Patients in the
intervention arm experienced lower incidence of first microvascular
endpoints (HR = 0.68 [95% CI: 0.56, 0.83), p < 0.001, but there was no
evidence of between-group differences in first macrovascular events.
Beneficial effects on microvascular and composite vascular outcomes were
observed in sites that continued, but not sites that discontinued the
intervention. Conclusions In urban South Asian clinics, a multicomponent
QI strategy led to sustained multiple risk factor control and
between-group differences in microvascular, but not macrovascular,
endpoints. Between-group reductions in vascular outcomes at 6.5 years were
observed only at sites that continued the QI intervention, suggesting that
practice change needs to be maintained for better population health of
people with diabetes. Copyright © 2024 Ali et al. This is an open
access article distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original author and source are
credited.

<66>
Accession Number
2032598487
Title
Stroke Risk After Mitral Valve Interventions: A Systematic Review and
Network Meta-Analysis.
Source
American Journal of Cardiology. 223 (pp 109-117), 2024. Date of
Publication: 15 Jul 2024.
Author
Kazemian S.; Bansal K.; Kuno T.; Gupta T.; Goel K.; Khera S.; Alkhouli M.;
Kolte D.
Institution
(Kazemian) Tehran Heart Center, Cardiovascular Diseases Research
Institute, Tehran University of Medical Sciences, Tehran, Iran, Islamic
Republic of
(Bansal) Department of Medicine, Saint Vincent Hospital, Worcester,
Massachusetts, United States
(Kuno) Division of Cardiology, Montefiore Medical Center, Albert Einstein
College of Medicine, New York, New York, United States
(Gupta) Division of Cardiology, University of Vermont Medical Center,
Burlington, Vermont, United States
(Goel) Division of Cardiology, Vanderbilt University Medical Center,
Nashville, TN, United States
(Khera) Division of Interventional Cardiology, Mount Sinai Hospital, New
York, New York, United States
(Alkhouli) Department of Cardiovascular Medicine, Mayo Clinic, Rochester,
Minnesota, United States
(Kolte) Cardiology Division, Massachusetts General Hospital and Harvard
Medical School, Boston, Massachusetts, United States
Publisher
Elsevier Inc.
Abstract
Previous research indicates varying stroke rates after mitral valve (MV)
interventions. This study aimed to compare postprocedural stroke risks
after transcatheter and surgical MV interventions. Electronic databases
were searched from inception to February 2024 for studies comparing stroke
rates after mitral transcatheter edge-to-edge repair (mTEER), surgical MV
repair/replacement, or guideline-directed medical therapy (GDMT). Primary
end points were all-time and early (<30 days) stroke. Secondary outcomes
included new-onset atrial fibrillation and 1-year all-cause mortality. A
frequentist network meta-analysis was employed to compare outcomes. The
network meta-analysis included 18 studies (3 randomized controlled trials
and 15 observational), with 51,703 patients. mTEER was associated with a
decreased risk of all-time (odds ratio [OR] 0.61, 95% confidence interval
[CI] 0.41 to 0.89) and early stroke (OR 0.41, 95% CI 0.33 to 0.51)
compared with surgery, and a similar risk of all-time (OR 1.54, 95% CI
0.76 to 3.12) and early stroke (OR 2.12, 95% CI 0.53 to 8.47) compared
with GDMT. Conversely, surgery was associated with an increased risk of
all-time (OR 2.55, 95% CI 1.17 to 5.57) and early stroke (OR 5.15, 95% CI
1.27 to 20.84) compared with GDMT. There were no statistically significant
differences in the risk of new-onset atrial fibrillation (OR 0.38, 95% CI
0.11 to 1.31) and 1-year all-cause mortality (OR 1.43, 95% CI 0.91 to
2.24) between mTEER versus surgery. In conclusion, mTEER was associated
with a lower risk of stroke and similar risks of new-onset atrial
fibrillation and 1-year mortality compared with surgical MV interventions.
Further studies are needed to understand the mechanisms of stroke and to
determine strategies to reduce stroke risk after MV
interventions. Copyright © 2024 Elsevier Inc.

<67>
Accession Number
2032559937
Title
How to harvest the left internal mammary artery-a randomized controlled
trial.
Source
Interdisciplinary Cardiovascular and Thoracic Surgery. 38(5) (no
pagination), 2024. Article Number: ivae102. Date of Publication: 01 May
2024.
Author
Laugesen S.; Krasniqi L.; Benhassen L.L.; Mortensen P.E.; Pallesen P.A.;
Bak S.; Kjelsen B.J.; Riber L.P.
Institution
(Laugesen, Krasniqi, Mortensen, Pallesen, Bak, Kjelsen, Riber) Department
of Cardio, Vascular and Thoracic Surgery, Odense University Hospital,
Odense, Denmark
(Laugesen, Krasniqi, Riber) Department of Clinical Medicine, Faculty of
Health, Odense University, Odense, Denmark
(Benhassen) Department of Clinical Medicine, Faculty of Health, Aarhus
University, Aarhus, Denmark
(Benhassen) Department of Cardiothoracic and Vascular Surgery, Aarhus
University Hospital, Aarhus, Denmark
Publisher
Oxford University Press
Abstract
OBJECTIVES: It is uncertain whether Thunderbeat has a place in harvesting
the left internal mammary artery (LIMA) and whether skeletonization is
superior to pedicle-harvested LIMA. Some investigations have shown
improved flowrates in the skeletonized graft. The aim of this study was to
compare 3 groups of harvesting techniques: Pedicled, surgical skeletonized
and skeletonized with Thunderbeat in terms of flow rates in the LIMA and
postoperative in-hospital outcomes. METHOD(S): Patients undergoing
coronary artery bypass grafting with the LIMA to the anterior descending
artery were randomized to pedicled (n 1/4 56), surgical skeletonized (n
1/4 55) and skeletonized with Thunderbeat (n 1/4 54). Main outcomes were
blood flow and pulsatility index in the graft. RESULT(S): No
statistical difference between groups regarding flow in LIMA or
pulsatility index. Similarly, no difference in postoperative bleeding or
days of hospitalization. The duration of harvesting was faster for the
pedicled technique compared with surgical skeletonized and skeletonized
with Thunderbeat [mean total min: pedicled 20.2 min standard deviation
(SD) +/- 5.4; surgical skeletonized 28.6 min SD +/- 8.7; skeletonized with
Thunderbeat 28.3 min SD +/- 9.11, P < 0.001]. No grafts discarded due to
faulty harvesting and there was no graft failure within hospital stay.
 CONCLUSION(S): We found no difference between the harvesting methods
except for a significantly faster harvesting time with the pedicled
technique. However, non-touch skeletonized LIMA harvesting with
Thunderbeat seems to be an effective alternative to traditional surgical
skeletonized LIMA. The future will reveal whether patency is harvesting
dependent. Copyright # The Author(s) 2024. Published by Oxford
University Press on behalf of the European Association for Cardio-Thoracic
Surgery.

<68>
Accession Number
2032557733
Title
More than just teeth: How oral health can affect the heart.
Source
American Heart Journal Plus: Cardiology Research and Practice. 43 (no
pagination), 2024. Article Number: 100407. Date of Publication: July 2024.
Author
Hopkins S.; Gajagowni S.; Qadeer Y.; Wang Z.; Virani S.S.; Meurman J.H.;
Leischik R.; Lavie C.J.; Strauss M.; Krittanawong C.
Institution
(Hopkins, Gajagowni, Qadeer) Department of Medicine, Baylor College of
Medicine, Houston, TX, United States
(Wang) Robert D. and Patricia E. Kern Center for the Science of Health
Care Delivery, Mayo Clinic, Rochester, MN, United States
(Wang) Division of Health Care Policy and Research, Department of Health
Sciences Research, Mayo Clinic, Rochester, MN, United States
(Virani) Section of Cardiology and Cardiovascular Research, Department of
Medicine, Baylor College of Medicine, Houston, TX 77030, United States
(Virani) Office of the Vice Provost (Research), The Aga Khan University,
Karachi 74800, Pakistan
(Meurman) Department of Oral and Maxillofacial Diseases, University of
Helsinki and Helsinki University Hospital, Helsinki, Finland
(Leischik, Strauss) Department of Cardiology, Sector Preventive Medicine,
Health Promotion, Faculty of Health, School of Medicine, University
Witten/Herdecke, Hagen 58095, Germany
(Lavie) John Ochsner Heart and Vascular Institute, Ochsner Clinical
School, The University of Queensland School of Medicine, New Orleans, LA
70121, United States
(Strauss) Department of Cardiology I- Coronary and Periphal Vascular
Disease, Heart Failure Medicine, University Hospital Muenster, Cardiol,
Muenster 48149, Germany
(Krittanawong) Cardiology Division, NYU Langone Health and NYU School of
Medicine, New York, NY, United States
Publisher
Elsevier Inc.
Abstract
Epidemiological evidence has revealed a potential relationship between
periodontal disease and cardiovascular disease (CVD). Consensus regarding
a link between these pathologies remains elusive, however, largely
secondary to the considerable overlap between risk factors and
comorbidities common to both disease processes. This review article aims
to update the evidence for an association by summarizing the evidence for
causality between periodontitis and comorbidities linked to CVD, including
endocarditis, hypertension (HTN), atrial fibrillation (AF), coronary
artery disease (CAD), diabetes mellitus (DM) and hyperlipidemia (HLD).
This article additionally discusses the role for periodontal therapy to
improved management of the comorbidities, with the larger goal of
examining the value of periodontal therapy on reduction of CVD risk. In
doing so, we endeavor to further the understanding of the commonality
between periodontitis, and CVD. Copyright © 2024 The Authors

<69>
Accession Number
2032548755
Title
Quality of Life in Older Adults With Stable Ischemic Heart Disease and
Diabetes Mellitus: A Post Hoc Analysis of the BARI 2D Trial.
Source
American Journal of Cardiology. 223 (pp 58-69), 2024. Date of Publication:
15 Jul 2024.
Author
Park D.Y.; Jamil Y.; Moumneh M.B.; Batchelor B. W.; Nanna M.G.; Damluji
A.A.
Institution
(Park) Department of Medicine, Cook County Health, Chicago, Illinois,
United States
(Jamil) Department of Medicine, Yale School of Medicine, New Haven,
Connecticut, United States
(Moumneh, Batchelor B., Damluji) Inova Center of Outcomes Research, Falls
Church, VA, United States
(Nanna) Section of Cardiovascular Medicine, Yale School of Medicine, New
Haven, Connecticut, United States
(Damluji) Johns Hopkins University School of Medicine, Baltimore,
Maryland, United States
Publisher
Elsevier Inc.
Abstract
Studies on the long-term differences in quality-of-life (QoL) metrics
after treatment for stable ischemic heart disease (SIHD) in older adults
with diabetes mellitus are lacking. Older patients (age >=65 years) in the
Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D)
trial were stratified into those who received intensive medical therapy
(IMT) only versus revascularization (percutaneous coronary intervention
[PCI] vs coronary artery bypass graft surgery [CABG]) with Optimal Medical
Therapy (OMT). Self-health score, Duke activity status index (DASI),
energy rating, and health distress rating at 5 years were compared using
multivariable linear regression. A total of 929 older adults were
included, of whom 469 (50.5%) underwent medical therapy alone, 302 (32.5%)
underwent PCI, and 158 (17.0%) had CABG. Patients who underwent CABG were
more likely to have proximal left anterior descending coronary artery
disease, chronic total occlusion, and higher myocardial jeopardy index. At
5 years of follow-up, no differences in self-health score, DASI, energy
rating, and health distress rating were observed between PCI and IMT.
There are also no differences in the 4 QoL measures between CABG and IMT
alone. However, the DASI was marginally higher with CABG but not
statistically significant (mean difference 3.88, 95% confidence interval
-0.10 to -7.86, p = 0.057). At 5 years of follow-up, no differences in QoL
measures were observed between PCI and CABG with OMT versus OMT alone in
older adult patients with diabetes mellitus and SIHD. Future blinded
randomized trials are necessary to investigate the impact of SIHD
treatment in the older adult population, considering the risks associated
with multimorbidity, polypharmacy, frailty, and cognitive
impairment. Copyright © 2024 Elsevier Inc.

<70>
Accession Number
2032508996
Title
In patients with type 2 diabetes and recent MI, colchicine reduced a
composite CV outcome at 23 mo.
Source
Annals of Internal Medicine. 177(5) (pp JC54), 2024. Date of Publication:
01 May 2024.
Author
Bates E.R.
Institution
(Bates) University of Michigan, Ann Arbor, MI, United States
Publisher
American College of Physicians

<71>
[Use Link to view the full text]
Accession Number
2032461457
Title
Effect of Empagliflozin on Heart Failure Outcomes after Acute Myocardial
Infarction: Insights from the EMPACT-MI Trial.
Source
Circulation. 149(21) (pp 1627-1638), 2024. Date of Publication: 21 May
2024.
Author
Hernandez A.F.; Udell J.A.; Jones W.S.; Anker S.D.; Petrie M.C.;
Harrington J.; Mattheus M.; Seide S.; Zwiener I.; Amir O.; Bahit M.C.;
Bauersachs J.; Bayes-Genis A.; Chen Y.; Chopra V.K.; Figtree G.A.; Ge J.;
Goodman S.G.; Gotcheva N.; Goto S.; Gasior T.; Jamal W.; Januzzi J.L.;
Jeong M.H.; Lopatin Y.; Lopes R.D.; Merkely B.; Parikh P.B.; Parkhomenko
A.; Ponikowski P.; Rossello X.; Schou M.; Simic D.; Steg P.G.;
Szachniewicz J.; Van Der Meer P.; Vinereanu D.; Zieroth S.; Brueckmann M.;
Sumin M.; Bhatt D.L.; Butler J.
Institution
(Hernandez, Jones, Harrington, Lopes) Duke Clinical Research Institute,
300 W Morgan Street, Durham, NC 27701, United States
(Udell) Women's College Hospital and Peter Munk Cardiac Centre, Toronto
General Hospital, University of Toronto, Canada
(Anker) Department of Cardiology (CVK) of German Heart Center Charite,
Berlin Institute of Health Center for Regenerative Therapies (BCRT),
German Centre for Cardiovascular Research (DZHK) Partner Site Berlin,
Charite Universitatsmedizin, Berlin, Germany
(Petrie) School of Cardiovascular and Medical Sciences, British Heart
Foundation Glasgow Cardiovascular Research Centre, University of Glasgow,
United Kingdom
(Mattheus, Seide, Zwiener) Boehringer Ingelheim Pharma GmbH & Co KG,
Ingelheim, Germany
(Amir) Heart Institute, Hadassah Medical Center, Hebrew University of
Jerusalem, Israel
(Bahit) INECO Neurociencias Orono, Fundacion INECO, Rosario, Santa Fe,
Argentina
(Bauersachs) Department of Cardiology and Angiology, Hannover Medical
School, Germany
(Bayes-Genis) Heart Institute, Hospital Universitari Germans Trias i
Pujol, Barcelona, Spain
(Bayes-Genis) Department of Medicine, Universitat Autonomoa de Barcelona,
Spain
(Chen) Department of Cardiology, First Medical Center of Chinese PLA
General Hospital, Beijing, China
(Chopra) Max Super Speciality Hospital, Saket, New Delhi, India
(Figtree) Faculty of Medicine and Health, University of Sydney, Australia
(Ge) Department of Cardiology, Zhongshan Hospital, Fudan University,
Shanghai Institute of Cardiovascular Diseases, National Clinical Research
Center for Interventional Medicine, Shanghai, China
(Goodman) Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada
(Goodman) Division of Cardiology, Department of Medicine, St Michael's
Hospital, Unity Health Toronto and Peter Munk Cardiac Centre, University
Health Network, University of Toronto, Canada
(Gotcheva) Department of Cardiology, MHAT "national Cardiology Hospital"
EAD, Sofia, Bulgaria
(Goto) Department of Medicine (Cardiology), Tokai University School of
Medicine, Isehara, Japan
(Gasior, Jamal, Brueckmann, Sumin) Boehringer Ingelheim International
GmbH, Ingelheim, Germany
(Gasior) Collegium Medicum, Faculty of Medicine, WSB University, Dabrowa
Gornicza, Poland
(Januzzi) Division of Cardiology, Harvard Medical School and Massachusetts
General Hospital, Boston, United States
(Jeong) Chonnam National University Hospital and Medical School, Gwangju,
South Korea
(Lopatin) Volgograd State Medical University, Russian Federation
(Merkely) Heart and Vascular Center, Semmelweis University, Budapest,
Hungary
(Parikh) Division of Cardiovascular Medicine, Department of Medicine,
State University of New York at Stony Brook, United States
(Parkhomenko) Ukrainian Institute of Cardiology Na MD Strazhesko, AMS
Ukraine, Kyiv, Ukraine
(Ponikowski) Institute of Heart Diseases, Wroclaw Medical University,
Poland
(Rossello) Hospital Universitari Son Espases, Health Research Institute of
the Balearic Islands, University of the Balearic Islands, Palma de
Mallorca, Spain
(Schou) Department of Cardiology, Herlev and Gentofte University Hospital,
Copenhagen, Denmark
(Simic) Department of Cardiovascular Diseases, University Clinical Center
Belgrade, Serbia
(Steg) Universite Paris-Cite, FACT (French Alliance for Cardiovascular
Trials), INSERM U-1148, AP-HP, Hopital Bichat, Paris, France
(Szachniewicz) Jan Mikulicz-Radecki University Clinical Hospital, Wroclaw,
Poland
(Van Der Meer) Department of Cardiology, University of Groningen,
University Medical Centre Groningen, Netherlands
(Vinereanu) University of Medicine and Pharmacy Carol Davila, University
and Emergency Hospital, Bucharest, Romania
(Zieroth) Section of Cardiology, Max Rady College of Medicine, University
of Manitoba, Winnipeg, Canada
(Brueckmann) First Department of Medicine, Faculty of Medicine Mannheim,
University of Heidelberg, Mannheim, Germany
(Bhatt) Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at
Mount Sinai, New York, United States
(Butler) Baylor Scott and White Research Institute, Dallas, TX, United
States
(Butler) Department of Medicine, University of Mississippi, Jackson,
United States
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) events in
patients with type 2 diabetes at high cardiovascular risk, chronic kidney
disease, or prevalent HF irrespective of ejection fraction. Whereas the
EMPACT-MI trial (Effect of Empagliflozin on Hospitalization for Heart
Failure and Mortality in Patients With Acute Myocardial Infarction) showed
that empagliflozin does not reduce the risk of the composite of
hospitalization for HF and all-cause death, the effect of empagliflozin on
first and recurrent HF events after myocardial infarction is unknown.
 METHOD(S): EMPACT-MI was a double-blind, randomized,
placebo-controlled, event-driven trial that randomized 6522 patients
hospitalized for acute myocardial infarction at risk for HF on the basis
of newly developed left ventricular ejection fraction of <45% or signs or
symptoms of congestion to receive empagliflozin 10 mg daily or placebo
within 14 days of admission. In prespecified secondary analyses, treatment
groups were analyzed for HF outcomes. RESULT(S): Over a median
follow-up of 17.9 months, the risk for first HF hospitalization and total
HF hospitalizations was significantly lower in the empagliflozin compared
with the placebo group (118 [3.6%] versus 153 [4.7%] patients with events;
hazard ratio, 0.77 [95% CI, 0.60, 0.98]; P=0.031, for first HF
hospitalization; 148 versus 207 events; rate ratio, 0.67 [95% CI, 0.51,
0.89]; P=0.006, for total HF hospitalizations). Subgroup analysis showed
consistency of empagliflozin benefit across clinically relevant patient
subgroups for first and total HF hospitalizations. The need for new use of
diuretics, renin-Angiotensin modulators, or mineralocorticoid receptor
antagonists after discharge was less in patients randomized to
empagliflozin versus placebo (all P<0.05). CONCLUSION(S):
Empagliflozin reduced the risk of HF in patients with left ventricular
dysfunction or congestion after acute myocardial infarction. REGISTRATION:
URL: https://www.clinicaltrials.gov; Unique identifier:
NCT04509674. Copyright © 2024 The Authors.

<72>
Accession Number
2029570665
Title
Is the combination of conventional ultrafiltration and modified
ultrafiltration superior to modified ultrafiltration in pediatric
open-heart surgery?.
Source
JMS - Journal of Medical Society. 37(3) (pp 159-166), 2023. Date of
Publication: Sep-Dec 2023.
Author
Singh S.; Singh A.; Rahman M.M.A.; Mahrous D.E.; Singh L.C.
Institution
(Singh) Department of Anaesthesiology and Intensive Care, Kwame Nkrumah
University of Science and Technology, Kumasi, Ghana
(Singh) Department of Public Health, School of Public Health, Kwame
Nkrumah University of Science and Technology, Kumasi, Ghana
(Rahman) Department of Cardiac Surgery, Almana General Hospital, Khobar,
Saudi Arabia
(Mahrous) Center of Surgery, Marie Lannelongue, University Paris-South, Le
Plessis-Robinson, France
(Singh) Department of Anaesthesia, RIMS, Manipur, Imphal, India
Publisher
Regional Institute of Medical Sciences
Abstract
Background: Cardiopulmonary bypass (CPB) during open-heart surgery is
associated with increased body fluids as a consequence of hemodilution due
to the use of CPB. Ultrafiltration (UF) is a method used to decrease the
body fluid volume on CPB. Aims and Objectives: This study aimed to compare
the effects of combined conventional UF (CUF) and modified UF (MUF) versus
MUF on the clinical outcomes of pediatric patients undergoing open-heart
surgery for congenital heart disease. Material(s) and Method(s): This
was a prospective, single-center, randomized, and double-blinded clinical
study that involved 74 pediatric patients undergoing open-heart surgery on
CPB. Patient management was standardized. Preoperative Aristotle
comprehensive complexity level, ultrafiltrate volumes, hematocrit,
hemodynamic data, transesophageal echocardiographically (TEE) determined
ejection fraction (EF), fractional area change (FAC), temperature drift,
arterial oxygenation, time of extubation, ventilation, comparison of
inotropic drugs, postoperative chest tube drainage, cardiac care unit
(CCU), and hospital length of stay (LOS) were recorded in both groups. The
analysis was conducted using SPSS-23.0, IBM, Armonk, NY, USA.
 Result(s): There was no mortality in both groups. Technical
difficulties prevented the completion of MUF in two patients out of 37 in
the CUF + MUF group. In this study, there were 43.26% of females and
56.75% of males, with a median age of 439 days, a mean weight of 9.98 kg,
and an Aristotle Comprehensive Complexity score of level 2. Group CUF +
MUF had a greater ultrafiltrate volume of 122 +/- 39.7 ml (P = 0.036). The
duration of ventilatory support was 11.2 +/- 6.4 h versus 34.4 +/- 5.7 h
(P = 0.013), average CCU LOS was 4.3 +/- 3.5 days versus 7.2 +/- 3.6 days
(P = 0.008), and chest tube drain in the first 48 h was 89.76 +/- 34.82 ml
versus 106.65 +/- 47.29 ml (P = 0.029) in groups CUF + MUF and MUF,
respectively. Inotropic infusion requirements were significantly lower in
the CUF + MUF group compared to the MUF group. EF and FAC were 14% and 5%
higher at 45 min in group CUF + MUF, respectively. Conclusion(s): The
advantage of combining CUF and MUF over MUF is the significant improvement
in the hemodynamic status of patients, which significantly decreases the
duration of mechanical ventilation, average CCU LOS, inotrope requirements
after surgery, and chest tube drain in the first 48 h. Copyright
© 2024 Journal of Medical Society Published by Wolters
Kluwer-Medknow.

<73>
Accession Number
2030104186
Title
Ultrasound-guided erector spinae plane block versus thoracic epidural
block for postoperative analgesia in pediatric Nuss surgery: a randomized
noninferiority trial.
Source
Journal of Anesthesia. (no pagination), 2024. Date of Publication: 2024.
Author
Ren Y.; Nie X.; Zhang F.; Ma Y.; Hua L.; Zheng T.; Xu Z.; Gao J.; Zhang J.
Institution
(Ren, Zhang, Ma, Hua, Zheng, Xu, Gao, Zhang) Department of Anesthesiology,
Beijing Children's Hospital, National Center for Children's Health,
Capital Medical University, No. 56, South Lishi Road, Beijing 100045,
China
(Nie) Center for Clinical Epidemiology and Evidence-Based Medicine,
Beijing Children's Hospital, National Center for Children's Health,
Capital Medical University, Beijing 100045, China
Publisher
Springer
Abstract
Purpose: Thoracic epidural anesthesia (TEA) is often used for analgesia
after thoracic surgery. Erector spinae plane block (ESPB) has been
proposed to provide adequate analgesia. We hypothesized that ESPB would be
noninferior to TEA as a part of multimodal analgesia in pediatric patients
undergoing the Nuss procedure. Method(s): Patients aged 7-18 years
and scheduled for the Nuss procedure were randomly allocated to receive
bilateral single-shot ESPB or TEA and a multimodal analgesic regimen
including parent-controlled intravenous analgesia (PCIA). At 6 h, 12 h, 18
h, and 24 h postoperatively, pain was evaluated using the numeric rating
scale (NRS) and opioid consumption was assessed by counting the number of
PCIA boluses. The joint primary outcomes were the average pain score and
opioid consumption at 24 h after surgery. The secondary outcomes were the
NRS scores and the number of opioid boluses administered at different
postoperative time points, adverse events, and recovery quality.
 Result(s): Three hundred patients underwent randomization, and 286
received ESPB (147 patients) or TEA (139 patients). At 24 h
postoperatively, ESPB was noninferior to TEA in terms of the average NRS
score (mean difference, - 0.1, 95% confidence interval [CI], - 0.3-0.1,
margin = 1, P for noninferiority < 0.001) and the number of opioid boluses
administered (mean difference, - 1.1, 95% CI, - 2.8-0.6, margin = 7, P for
noninferiority < 0.001). Adverse events and patient recovery were
comparable between groups. Conclusion(s): The results demonstrate
that combined with a multimodal analgesia, ESPB provides noninferior
analgesia compared to TEA with respect to pain score and opioid
consumption among pediatric patients undergoing the Nuss
procedure. Copyright © The Author(s) under exclusive licence to
Japanese Society of Anesthesiologists 2024.

<74>
Accession Number
644429615
Title
Supplementing Randomized Trial Data to Answer a Real World Question:
Discharge to Home Status as a Heuristic for Stroke Severity After
Transcatheter Aortic Valve Replacement.
Source
Circulation. Cardiovascular interventions. (no pagination), 2024. Date of
Publication: 05 Jun 2024.
Author
Kumbhani D.J.; Welt F.G.
Institution
(Kumbhani) University of Texas Southwestern Medical Center, Dallas, TX,
United States
(Welt) University of Utah Health Sciences Center, Salt Lake City, UT,
United States

<75>
Accession Number
2032574776
Title
Optimizing the treatment of severe aortic stenosis.
Source
European Heart Journal. 45(21) (pp 1861-1865), 2024. Date of Publication:
01 Jun 2024.
Author
Crea F.
Institution
(Crea) Center of Excellence of Cardiovascular Sciences, Ospedale Isola
Tiberina - Gemelli Isola, Rome, Italy
(Crea) Catholic University of the Sacred Heart, Rome, Italy
Publisher
Oxford University Press

<76>
Accession Number
2032491168
Title
Cytomegalovirus infection and cardiovascular outcomes in abdominal organ
transplant recipients: A systematic review and meta-analysis.
Source
Transplantation Reviews. 38(4) (no pagination), 2024. Article Number:
100860. Date of Publication: December 2024.
Author
Arvanitis P.; Davis M.R.; Farmakiotis D.
Institution
(Arvanitis, Farmakiotis) Division of Infectious Diseases, The Warren
Alpert Medical School of Brown University, Providence, RI, United States
(Davis) The Warren Alpert Medical School of Brown University, Providence,
RI, United States
Publisher
Elsevier Inc.
Abstract
Introduction: Despite advancements in Cytomegalovirus (CMV) management,
its impact on graft function, mortality, and cardiovascular (CV) health of
organ transplant recipients (OTR) remains a significant concern. We
investigated the association between CMV infection and CV events (CVE) in
organ (other than heart) transplant recipients. Method(s): We
conducted a comprehensive literature search in PubMed and EMBASE,
including studies that reported on CMV infection or disease and
post-transplantation CVE. Studies of heart transplant recipients were
excluded. Result(s): We screened 3875 abstracts and 12 clinical
studies were included in the final analysis, mainly in kidney and liver
transplant recipients. A significant association was observed between CMV
infection and an increased risk of CVE, with a pooled unadjusted hazard
ratio (HR) of 1.99 (95% Confidence Intervals [CI] 1.45-2.73) for CMV
infection and 1.59 (95% CI 1.21-2.10) for CMV disease. Pooled adjusted HR
were 2.17 (95% CI 1.47-3.20) and 1.77 (95% CI 0.83-3.76), respectively.
Heterogeneity was low (I2 = 0%) for CMV infection, suggesting
consistent association across studies, and moderate-to-high for CMVdisease
(I2 = 50% for unadjusted, 53% for adjusted HR).
 Discussion(s): We found a significant association between CMV
infection and CV risk in abdominal OTR, underscoring the importance of
proactive CMV surveillance and early treatment. Future research should aim
for more standardized methodologies to fully elucidate the relationship
between CMV and CV outcomes, potentially informing novel preventive and
therapeutic strategies that could benefit the CV health of
OTR. Copyright © 2024 Elsevier Inc.

<77>
Accession Number
2024153766
Title
The effect of head and facial massage on sleep condition after coronary
artery bypass graft surgery.
Source
Traditional Medicine Research. 8(4) (no pagination), 2023. Article Number:
24. Date of Publication: 01 Apr 2023.
Author
Ozudi M.R.; Bagheri-Nesami M.; Setareh J.; Moosazadeh M.; Habibi V.;
Saatchi K.
Institution
(Ozudi) Student Research Committee, Mazandaran University of Medical
Sciences, Sari 4816715793, Iran, Islamic Republic of
(Bagheri-Nesami) Traditional and Complementary Medicine Research Center,
Addiction Institute, Mazandaran University of Medical Sciences, Sari
4816715793, Iran, Islamic Republic of
(Bagheri-Nesami) World Federation of Acupuncture-Moxibustion Societies
(WFAS), Beijing 100000, China
(Setareh) Psychiatry and Behavioral Sciences Research Center, Addiction
Institute, Mazandaran University of Medical Sciences, Sari 4816715793,
Iran, Islamic Republic of
(Moosazadeh) Gastrointestinal Cancer Research Center, Non-communicable
Diseases Institute, Mazandaran University of Medical Sciences, Sari
4816715793, Iran, Islamic Republic of
(Habibi) Department of Cardiac Surgery, Fatemeh Zahra Hospital, Mazandaran
University of Medical Sciences, Sari 4816715793, Iran, Islamic Republic of
(Saatchi) Board of Directors of Acupuncture Society of Iran, Tehran
1414734117, Iran, Islamic Republic of
Publisher
TMR Publishing Group
Abstract
Background: Sleep disorders after heart surgery lead to increased heart
rate, myocardial oxygen demand, and cause dysrhythmia that worsens heart
ischemia. The purpose of this study was to determine the effect of head
and facial massage on sleep conditions following coronary artery bypass
graft surgery. Material(s) and Method(s): A randomized controlled
trial was performed on 72 patients. They were randomly divided into
interventional (n = 36) and control groups (n = 36). On the third to fifth
day after the operation, head and the facial massage were done for 15 min
in the intervention group. The patients in the control group received only
routine care. Richard Campbell's Sleep Questionnaire was completed for
four consecutive days for each group. Data were analyzed in SPSS V26.
 Result(s): Mean scores for sleep conditions before the intervention
no statistically significant difference seen between the two groups (P >
0.05). After the intervention, there was a statistically significant
difference between mean scores for sleep conditions of the interventional
and control groups (P < 0.001). Also with general estimated equation test
compared mean scores for sleep conditions between two groups. That
revealed sleep condition total score in the intervention group was more
than the control group and the trend of changes over time was
statistically significant (P < 0.001). Conclusion(s): Head and facial
massage is an effective nursing intervention in improving the sleep
condition of patients after coronary artery bypass graft. Due to the fact
that head and face massage is an easy method and brings patient
satisfaction, it is recommended to use this method as a suitable
supplement for drug therapy and postoperative interventions in these
patients. Copyright © 2023 By Author(s). Published by TMR
Publishing Group Limited.

<78>
Accession Number
2032610485
Title
Impact of simulation-based training on transesophageal echocardiography
learning: A systemic review and meta-analysis of randomized controlled
trials.
Source
Current Problems in Cardiology. 49(8) (no pagination), 2024. Article
Number: 102679. Date of Publication: August 2024.
Author
Salim N.; Shoaib A.; Amir M.A.; Shiraz M.I.; Ayaz A.; Shahid A.R.
Institution
(Salim, Shoaib, Ayaz) Department of Medicine, Karachi Medical and Dental
College, Block M, North Nazimabad Town, Sindh, Karachi 74700, Pakistan
(Amir, Shiraz, Shahid) Department of Medicine, Dow International Medical
College, Dow University of Health Sciences, Sindh, Karachi, Pakistan
Publisher
Elsevier Inc.

<79>
Accession Number
2032558987
Title
Peripheral nerve block and cognitive impairment after thoracic surgery: a
systematic review and meta-analysis.
Source
Minerva Anestesiologica. 90(5) (pp 417-426), 2024. Date of Publication:
May 2024.
Author
Zhang Y.; Liu M.; He J.; Zhang H.; Zhang M.; Li J.
Institution
(Zhang, Liu, He, Zhang, Zhang, Li) Department of anesthesiology, Hebei
general Hospital, Hebei, shijiazhuang, China
(Zhang) North china University of science and technology, Hebei, tangshan,
China
Publisher
Edizioni Minerva Medica
Abstract
iNtroDUctioN: Postoperative cognitive impairment is common in surgical
patients, including postoperative delirium and postoperative cognitive
dysfunction. several studies investigating the association between
peripheral nerve block and the risk of cognitive impairment after thoracic
surgery showed conflicting results. Therefore, we conducted the current
systematic review and meta-analysis to determine the effects of peripheral
nerve block on postoperative cognitive impairment in thoracic surgical
patients. eViDeNce acQUisitioN: eligible randomized controlled trials were
retrieved from PubMed, cochrane library, Web of science and embase
databases. the primary outcomes were the incidence of postoperative
delirium or cognitive dysfunction and the MMSE scores. Furthermore, VAS
scores, levels of TNF-alpha and IL-6, as well as the duration of
hospitalization were analyzed as secondary outcomes. eViDeNce sYNtHesis:
ten articles including 1279 participants were selected for this
meta-analysis. the results showed that peripheral nerve block could lessen
the incidence of postoperative delirium or cognitive dysfunction (OR=0.39,
95% CI [0.27 to 0.56]), the scores of VAS (MD=-1.35 [95% CI: -2.30 to
-0.40]), the values of TNF-alpha (SMD=-1.13 [95% ci: -1.49 to -0.76]) and
il-6 (sMD=-1.65 [95% ci: -1.87 to -1.42]), as well as the length of
hospitalization (MD=-0.70 [95% CI: -0.96 to -0.43]). In addition,
peripheral nerve block was linked to a significant increase in MMSE scores
(MD=2.16 [95% ci: 1.40 to 2.91]). coNclUsioNs: this meta-analysis revealed
positive effects of peripheral nerve block on improving postoperative
cognitive impairment in patients following thoracic surgery. Copyright
© 2024 Edizioni Minerva Medica. All rights reserved.

<80>
Accession Number
2032520589
Title
Sevoflurane multiple Wash In/Wash Out at the end of anesthesia to reduce
agitation: A multicenter double-blind randomized controlled trial.
Source
Contemporary Clinical Trials Communications. 39 (no pagination), 2024.
Article Number: 101316. Date of Publication: June 2024.
Author
Landoni G.; Likhvantsev V.V.; Berikashvili L.B.; Yavorovsky A.G.;
Bagdasarov P.S.; Smirnova A.V.; Serkova T.S.; Subbotin V.V.; Kadantseva
K.K.; Ovezov A.M.; Yadgarov M.Y.; Yakovlev A.A.; Lamacchia A.; Gallo L.;
Gracheva N.D.; Ryzhkov P.V.; Zilocchi R.; Vecchi J.D.; Aleinikov M.A.;
Mayuk P.S.; Pivovarova A.A.; Shemetova M.M.
Institution
(Landoni, Lamacchia, Gallo, Zilocchi, Vecchi) Department of Anaesthesia
and Intensive Care, IRCCS San Raffaele Scientific Institute, Italy
(Landoni) Vita-Salute San Raffaele University, Milan, Italy
(Likhvantsev, Berikashvili, Smirnova, Kadantseva, Yadgarov, Yakovlev,
Gracheva, Ryzhkov, Shemetova) Federal Research and Clinical Center of
Intensive Care Medicine and Rehabilitology, Moscow, Russian Federation
(Likhvantsev, Yavorovsky, Bagdasarov, Serkova, Aleinikov, Mayuk) First
University Clinical Federal State Autonomous Educational Institution of
Higher Education I.M. Sechenov First Moscow State Medical University of
the Ministry of Health of the Russian Federation, Moscow, Russian
Federation
(Subbotin, Kadantseva) A. Loginov Moscow Scientific Clinical Center,
Moscow, Russian Federation
(Ovezov, Pivovarova) M. Vladimirsky Moscow Regional Research and Clinical
Institute, Moscow, Russian Federation
(Shemetova) Moscow City Oncological Hospital No.1, Moscow, Russian
Federation
Publisher
Elsevier Inc.
Abstract
Background: Postoperative agitation is common after non-cardiac surgery.
It is associated with postoperative delirium and cognitive dysfunction,
leading to prolonged hospital stay and delayed social readjustment.
Prevention and treatment strategies are lacking. We assessed the efficacy
of a novel approach, the Wash In/Wash Out procedure, in reducing
post-anesthetic agitation. Method(s): This multicenter,
parallel-group, double-blind randomized controlled trial is enrolling 200
patients undergoing open abdominal surgery. Participants are randomly
assigned to either a control group receiving standard recovery methods or
an investigational group undergoing the Wash In/Wash Out procedure. In the
Wash In/Wash Out procedure group, sevoflurane is stopped and then promptly
restarted when the patient shows the first signs of awakening to achieve
an end-tidal concentration of 1 minimum alveolar concentration (MAC) for 5
min. This stop-and-restart cycle is performed three times. The trial's
primary outcome is the rate of postoperative agitation. Secondary outcomes
include rate of postoperative delirium and cognitive dysfunction,
postoperative nausea and vomiting, and length of intensive care and
hospital stay. Discussion(s): The OPERA trial investigates the effect
of the Wash In/Wash Out procedure to reduce post-anesthetic agitation in
non-cardiac surgery. This study could offer a significant contribution to
improving patient outcomes and optimizing recovery protocols in surgical
settings. Copyright © 2024

<81>
Accession Number
2032506252
Title
Central (Aortic) Cannulation versus Peripheral (Axillary or Femoral)
Cannulation in Acute Type A Aortic Dissections: A Meta-Analysis of
Comparative Studies.
Source
Reviews in Cardiovascular Medicine. 25(5) (no pagination), 2024. Article
Number: 156. Date of Publication: May 2024.
Author
Ma J.; Wang H.; Wang X.; Hou X.
Institution
(Ma, Wang, Wang, Hou) Center for Cardiac Intensive Care, Beijing Anzhen
Hospital, Capital Medical University, Beijing 100054, China
Publisher
IMR Press Limited
Abstract
Background: There has been an increased interest in using antegrade
cannulation techniques during surgery for type A aortic dissection. While
the utilization of central artery cannulation has been on the rise in
recent times, its effectiveness and safety still require thorough
examination. This study aimed to explore both the efficiency and safety of
central arterial cannulation. Method(s): A meta-analysis was
conducted on studies that evaluated surgical outcomes when using central
artery cannulation (CAC) in comparison to axillary artery cannulation
(AXC) or femoral artery cannulation (FAC). Result(s): 10
retrospective observational studies were included, enrolling 3022 patients
(CAC = 1208 vs. FAC = 606; CAC = 1051 vs. AXC = 1119). Among these, 4
articles involved axillary artery cannulation, femoral artery cannulation,
and central artery cannulation. Central cannulation was linked to
decreased short-term mortality [odds ratio, 0.66, 95% confidence interval
(CI) (0.48, 0.89), ?2 = 3.27, p = 0.007; I2 = 0; p =
0.86] compared to femoral cannulation. Additionally, central cannulation
was associated with a lower occurrence of temporary neurological
dysfunction (TND) [odds ratio, 0.57, 95% CI (0.38, 0.85), ?2 =
0.88, p = 0.006; I2 = 0%, p = 0.83] when compared with femoral
cannulation. However, there was no statistical significance in mortality
and TND between the central cannulation and axillary cannulation groups.
 Conclusion(s): This meta-analysis reveals that central cannulation
surpasses femoral cannulation in lowering short-term mortality and the
occurrence of TND among patients undergoing surgery for type A acute
aortic dissection. However, central cannulation does not exhibit a higher
mortality and TND compared to axillary cannulation. Copyright ©
2024 The Author(s).

<82>
Accession Number
2032499658
Title
Comparison of downsizing strategy (HANGZHOU Solution) and standard annulus
sizing strategy in type 0 bicuspid aortic stenosis patients undergoing
transcatheter aortic valve replacement: Rationale and design of a
randomized clinical trial.
Source
American Heart Journal. 274 (pp 65-74), 2024. Date of Publication: August
2024.
Author
Guo Y.; Liu X.; Li R.; Ng S.; Liu Q.; Wang L.; Hu P.; Ren K.; Jiang J.;
Fan J.; He Y.; Zhu Q.; Lin X.; Li H.; Wang J.
Institution
(Guo, Liu, Li, Ng, Liu, Wang, Hu, Ren, Jiang, Fan, He, Zhu, Lin, Li, Wang)
Department of Cardiology, Second Affiliated Hospital, School of Medicine,
Zhejiang University, Hangzhou 310009, China
(Guo, Liu, Li, Ng, Liu, Wang, Hu, Ren, Jiang, Fan, He, Zhu, Lin, Li, Wang)
State Key Laboratory of Transvascular Implantation Devices, Hangzhou
310009, China
(Guo, Liu, Li, Ng, Liu, Wang, Hu, Ren, Jiang, Fan, He, Zhu, Lin, Li, Wang)
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China
(Liu, Wang) Research Center for Life Science and Human Health, Binjiang
Institute of Zhejiang University, Hangzhou 310053, China
Publisher
Elsevier Inc.
Abstract
Background: There has not been a consensus on the prothesis sizing
strategy in type 0 bicuspid aortic stenosis (AS) patients undergoing
transcatheter aortic valve replacement (TAVR). Modifications to standard
annular sizing strategies might be required due to the distinct anatomical
characteristics. We have devised a downsizing strategy for TAVR using a
self-expanding valve specifically for patients with type 0 bicuspid AS.
The primary aim of this study is to compare the safety and efficacy of
downsizing strategy with the Standard Annulus Sizing Strategy in TAVR for
patients with type 0 bicuspid AS. Trial design: It is a prospective,
multi-center, superiority, single-blinded, randomized controlled trial
comparing the Down Sizing and Standard Annulus Sizing Strategy in patients
with type 0 bicuspid aortic stenosis undergoing transcatheter aortic valve
replacement. Eligible participants will include patients with severe type
0 bicuspid AS, as defined by criteria such as mean gradient across aortic
valve >=40 mmHg, peak aortic jet velocity >=4.0 m/s, aortic valve area
(AVA) <=1.0 cm2, or AVA index <=0.6 cm2/m2. These
patients will be randomly assigned, in a 1:1 ratio, to either the Down
Sizing Strategy group or the Standard Sizing Strategy group. In the Down
Sizing Strategy group, a valve one size smaller will be implanted if the
"waist sign" manifests along with less than mild regurgitation during
balloon pre-dilatation. The primary end point of the study is a composite
of VARC-3 defined device success, absence of both permanent pacemaker
implantation due to high-degree atrioventricular block and new-onset
complete left bundle branch block. Conclusion(s): This study will
compare the safety and efficacy of Down Sizing Strategy with the Standard
Annulus Sizing Strategy and provide valuable insights into the optimal
approach for sizing in TAVR patients with type 0 bicuspid AS. We
hypothesize that the Down Sizing Strategy will demonstrate superiority
when compared to the Standard Annulus Sizing Strategy. (Down Sizing
Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid
Aortic Stenosis (Type 0) (TAILOR-TAVR), NCT05511792). Copyright ©
2024 Elsevier Inc.

<83>
[Use Link to view the full text]
Accession Number
2032464436
Title
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment
Options: A Scientific Statement from the American Heart Association.
Source
Circulation. 149(22) (pp E1223-E1238), 2024. Date of Publication: 28 May
2024.
Author
Davidson L.J.; Tang G.H.L.; Ho E.C.; Fudim M.; Frisoli T.; Camaj A.;
Bowers M.T.; Masri S.C.; Atluri P.; Chikwe J.; Mason P.J.; Kovacic J.C.;
Dangas G.D.
Publisher
Lippincott Williams and Wilkins
Abstract
Tricuspid valve disease is an often underrecognized clinical problem that
is associated with significant morbidity and mortality. Unfortunately,
patients will often present late in their disease course with severe
right-sided heart failure, pulmonary hypertension, and life-limiting
symptoms that have few durable treatment options. Traditionally, the only
treatment for tricuspid valve disease has been medical therapy or surgery;
however, there have been increasing interest and success with the use of
transcatheter tricuspid valve therapies over the past several years to
treat patients with previously limited therapeutic options. The tricuspid
valve is complex anatomically, lying adjacent to important anatomic
structures such as the right coronary artery and the atrioventricular
node, and is the passageway for permanent pacemaker leads into the right
ventricle. In addition, the mechanism of tricuspid pathology varies widely
between patients, which can be due to primary, secondary, or a combination
of causes, meaning that it is not possible for 1 type of device to be
suitable for treatment of all cases of tricuspid valve disease. To best
visualize the pathology, several modalities of advanced cardiac imaging
are often required, including transthoracic echocardiography,
transesophageal echocardiography, cardiac computed tomography, and cardiac
magnetic resonance imaging, to best visualize the pathology. This detailed
imaging provides important information for choosing the ideal
transcatheter treatment options for patients with tricuspid valve disease,
taking into account the need for the lifetime management of the patient.
This review highlights the important background, anatomic considerations,
therapeutic options, and future directions with regard to treatment of
tricuspid valve disease. Copyright © 2024 Lippincott Williams and
Wilkins. All rights reserved.

<84>
Accession Number
2030025831
Title
Effects of Chinese traditional five-element music intervention on
postoperative delirium and sleep quality in elderly patients after
non-cardiac surgery: a randomized controlled trial.
Source
Perioperative Medicine. 13(1) (no pagination), 2024. Article Number: 47.
Date of Publication: December 2024.
Author
Han S.; Cai Z.; Cao L.; Li J.; Huang L.
Institution
(Han, Huang) Department of Anesthesiology, The Second Hospital of Hebei
Medical University, Hebei, Shijiazhuang 050061, China
(Han, Cao, Li) Department of Anesthesiology, Hebei General Hospital,
Hebei, Shijiazhuang 050051, China
(Cai) Department of Anesthesiology, Bethune International Peace Hospital,
Hebei, Shijiazhuang 050082, China
Publisher
BioMed Central Ltd
Abstract
Background: Postoperative delirium (POD) is a common neurologic disorder
among elderly patients after non-cardiac surgery, which leads to various
negative outcomes. Sleep disorder is considered an important cause of POD.
The objective of this study was to investigate whether the Chinese
traditional five-element music intervention could reduce POD by improving
sleep quality in elderly patients undergoing non-cardiac surgery.
 Method(s): A total of 132 patients aged 65 to 90 years who underwent
non-cardiac surgery were randomized to two groups: the intervention (n =
60) and the control group (n = 63). Patients in the intervention group
were subjected to the Chinese traditional five-element music intervention
during the perioperative, while patients in the control group had no music
intervention. POD was evaluated using the Confusion Assessment Method
(CAM) in the first 5 days after surgery. The Richards-Campbell Sleep
Questionnaire (RCSQ) was used to assess subjective sleep quality. The
levels of nocturnal melatonin and cortisol in saliva were measured on the
preoperative and the first 2 postoperative days. Result(s): The
incidence of POD within 5 days was 27.0% in the control group and 11.7% in
the intervention group. Preoperative PSQI and MMSE scores were associated
with POD. The RCSQ scores on the first postoperative day were
significantly decreased in the two groups compared to the preoperative
day. Compared to the control group, the RCSQ scores showed a significant
improvement in the intervention group on the first postoperative day.
Compared to the control group, the level of saliva melatonin in the
intervention group showed a significant increase on the first
postoperative day. However, there was no statistical difference in
cortisol levels between the two groups. Conclusion(s): Chinese
traditional five-element music intervention decreased the incidence of POD
in elderly patients who underwent noncardiac surgery via improving sleep
quality, which may be associated with increased levels of
melatonin. Copyright © The Author(s) 2024.

<85>
Accession Number
2030001106
Title
Hemodynamic changes in the prone position according to fluid loading after
anaesthesia induction in patients undergoing lumbar spine surgery: a
randomized, assessor-blind, prospective study.
Source
Annals of Medicine. 56(1) (no pagination), 2024. Article Number: 2356645.
Date of Publication: 2024.
Author
Lee S.; Kim D.Y.; Han J.; Kim K.; You A.H.; Kang H.Y.; Park S.W.; Kim
M.K.; Kim J.E.; Choi J.-H.
Institution
(Lee, Kim, Han, You, Kang, Park, Kim, Choi) Department of Anesthesiology
and Pain Medicine, Kyung Hee University College of Medicine, Kyung Hee
University Hospital, Seoul, South Korea
(Kim) Department of Anesthesiology and Pain Medicine, Korea University
Anam Hospital, Seoul, South Korea
(Kim) Department of Anesthesiology and Pain Medicine, Kangnam Sacred Heart
Hospital, Hallym University College of Medicine, Seoul, South Korea
Publisher
Taylor and Francis Ltd.
Abstract
Introduction: A change from the supine to prone position causes
hemodynamic alterations. We aimed to evaluate the effect of fluid
preloading in the supine position, the subsequent hemodynamic changes in
the prone position and postoperative outcomes. Patients and Methods:
This prospective, assessor-blind, randomized controlled trial was
conducted between March and June 2023. Adults scheduled for elective
orthopaedic lumbar surgery under general anaesthesia were enrolled. In
total, 80 participants were randomly assigned to fluid maintenance (M) or
loading (L) groups. Both groups were administered intravenous fluid at a
rate of 2 ml/kg/h until surgical incision; Group L was loaded with an
additional 5 ml/kg intravenous fluid for 10 min after anaesthesia
induction. The primary outcome was incidence of hypotension before
surgical incision. Secondary outcomes included differences in the mean
blood pressure (mBP), heart rate, pleth variability index (PVi), stroke
volume variation (SVV), pulse pressure variation (PPV), stroke volume
index and cardiac index before surgical incision between the two groups.
Additionally, postoperative complications until postoperative day 2 and
postoperative hospital length of stay were investigated. Result(s):
Hypotension was prevalent in Group M before surgical incision and could be
predicted by a baseline PVi >16. The mBP was significantly higher in Group
L immediately after fluid loading. The PVi, SVV and PPV were lower in
Group L after fluid loading, with continued differences at 2-3 time points
for SVV and PPV. Other outcomes did not differ between the two groups.
 Conclusion(s): Fluid loading after inducing general anaesthesia could
reduce the occurrence of hypotension until surgical incision in patients
scheduled for surgery in the prone position. Additionally, hypotension
could be predicted in patients with a baseline PVi >16. Therefore,
intravenous fluid loading is strongly recommended in patients with high
baseline PVi to prevent hypotension after anaesthesia induction and in the
prone position. Trial number: KCT0008294 (date of registration: 16 March
2023). Copyright © 2024 The Author(s). Published by Informa UK
Limited, trading as Taylor & Francis Group.

<86>
Accession Number
2029991284
Title
Klotho as an Early Marker of Acute Kidney Injury Following Cardiac
Surgery: A Systematic Review.
Source
Journal of Cardiovascular Development and Disease. 11(5) (no pagination),
2024. Article Number: 135. Date of Publication: May 2024.
Author
Mylonas K.S.; Karakitsos P.; Tajik A.; Pagliuso D.; Emadzadeh H.; Soukouli
I.; Hemmati P.; Avgerinos D.V.; Stavridis G.T.; Boletis J.N.
Institution
(Mylonas, Avgerinos, Stavridis) Department of Cardiac Surgery, Onassis
Cardiac Surgery Center, Athens 17674, Greece
(Karakitsos) Department of Cardiology, King's College Hospital, London SE5
9RS, United Kingdom
(Tajik, Emadzadeh) School of Medicine, St. George's University, True Blue,
Grenada
(Pagliuso) York University, Toronto, ON M3J 1P3, Canada
(Soukouli, Boletis) Department of Nephrology and Renal Transplantation,
Laiko General Hospital, National and Kapodistrian University of Athens,
Athens 11527, Greece
(Hemmati) Department of Cardiothoracic Surgery, Baptist Health Medical
Center, Little Rock, AR 72205, United States
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Acute kidney injury is a common complication following cardiac surgery
(CSA-AKI). Serum creatinine levels require a minimum of 24-48 h to
indicate renal injury. Nevertheless, early diagnosis remains critical for
improving patient outcomes. A PRISMA-compliant systematic review of the
PubMed and CENTRAL databases was performed to assess the role of Klotho as
a predictive biomarker for CSA-AKI (end-of-search date: 17 February 2024).
An evidence quality assessment of the four included studies was performed
with the Newcastle-Ottawa scale. Among the 234 patients studied, 119
(50.8%) developed CSA-AKI postoperatively. Serum Klotho levels above 120
U/L immediately postoperatively correlated with an area under the curve
(AUC) of 0.806 and 90% sensitivity. Additionally, a postoperative serum
creatinine to Klotho ratio above 0.695 showed 94.7% sensitivity and 87.5%
specificity, with an AUC of 92.4%, maintaining its prognostic validity for
up to three days. Urinary Klotho immunoreactivity was better maintained in
samples obtained via direct catheterization rather than indwelling
catheter collection bags. Storage at -80 degreeC was necessary for delayed
testing. Optimal timing for both serum and urine Klotho measurements was
from the end of cardiopulmonary bypass to the time of the first ICU lab
tests. In conclusion, Klotho could be a promising biomarker for the early
diagnosis of CSA-AKI. Standardization of measurement protocols and larger
studies are needed to validate these findings. Copyright © 2024
by the authors.

<87>
Accession Number
2029949288
Title
Is Cardiac Transplantation Still a Contraindication in Patients with
Muscular Dystrophy-Related End-Stage Dilated Cardiomyopathy? A Systematic
Review.
Source
International Journal of Molecular Sciences. 25(10) (no pagination), 2024.
Article Number: 5289. Date of Publication: May 2024.
Author
Politano L.
Institution
(Politano) Cardiomyology and Medical Genetics, University of Campania
Luigi Vanvitelli, Naples 80138, Italy
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Inherited muscular diseases (MDs) are genetic degenerative disorders
typically caused by mutations in a single gene that affect striated muscle
and result in progressive weakness and wasting in affected individuals.
Cardiac muscle can also be involved with some variability that depends on
the genetic basis of the MD (Muscular Dystrophy) phenotype. Heart
involvement can manifest with two main clinical pictures: left ventricular
systolic dysfunction with evolution towards dilated cardiomyopathy and
refractory heart failure, or the presence of conduction system defects and
serious life-threatening ventricular arrhythmias. The two pictures can
coexist. In these cases, heart transplantation (HTx) is considered the
most appropriate option in patients who are not responders to the
optimized standard therapeutic protocols. However, cardiac transplant is
still considered a relative contraindication in patients with inherited
muscle disorders and end-stage cardiomyopathies. High operative risk
related to muscle impairment and potential graft involvement secondary to
the underlying myopathy have been the two main reasons implicated in the
generalized reluctance to consider cardiac transplant as a viable option.
We report an overview of cardiac involvement in MDs and its possible
association with the underlying molecular defect, as well as a systematic
review of HTx outcomes in patients with MD-related end-stage dilated
cardiomyopathy, published so far in the literature. Copyright ©
2024 by the author.

<88>
Accession Number
2029937465
Title
Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care:
A Systematic Review.
Source
Journal of Clinical Medicine. 13(10) (no pagination), 2024. Article
Number: 2951. Date of Publication: May 2024.
Author
Levy B.; Slama M.; Lakbar I.; Maizel J.; Kato H.; Leone M.; Okada M.
Institution
(Levy) Service de Medecine Intensive et Reanimation Brabois, CHRU Nancy,
Pole Cardio-Medico-Chirurgical, Universite de Lorraine,
Vandoeuvre-les-Nancy 54511, France
(Slama, Maizel) Intensive Care Unit, Amiens Picardie University Hospital,
Amiens 80054, France
(Lakbar, Leone) Department of Anesthesiology and Intensive Care Unit,
Hopital Nord, Assistance Publique Hopitaux de Marseille, Aix Marseille
University, Marseille 13385, France
(Kato) Department of Anesthesiology and Intensive Care, Hopital Bicetre,
Assistance Publique Hopitaux de Paris, 78 rue du General, Leclerc, Le
Kremlin-Bicetre 94270, France
(Okada) Department of Emergency Medicine, Asahikawa Medical University,
Asahikawa 078-8510, Japan
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: new-onset atrial fibrillation remains a common complication in
critical care settings, often necessitating treatment when the correction
of triggers is insufficient to restore hemodynamics. The treatment
strategy includes electric cardioversion in cases of hemodynamic
instability and either rhythm control or rate control in the absence of
instability. Landiolol, an ultrashort beta-blocker, effectively controls
heart rate with the potential to regulate rhythm. Objectives This review
aims to compare the efficacy of landiolol in controlling heart rate and
converting to sinus rhythm in the critical care setting. Method(s):
We conducted a comprehensive review of the published literature from 2000
to 2022 describing the use of landiolol to treat atrial fibrillation in
critical care settings, excluding both cardiac surgery and medical cardiac
care settings. The primary outcome assessed was sinus conversion following
landiolol treatment. Result(s): Our analysis identified 17
publications detailing the use of landiolol for the treatment of 324
critical care patients. While the quality of the data was generally low,
primarily comprising non-comparative studies, landiolol consistently
demonstrated similar efficacy in controlling heart rate and facilitating
conversion to sinus rhythm in both non-surgical (75.7%) and surgical
(70.1%) settings. The incidence of hypotension associated with landiolol
use was 13%. Conclusion(s): The use of landiolol in critical care
patients with new-onset atrial fibrillation exhibited comparable efficacy
and tolerance in both non-surgical and surgical settings. Despite these
promising results, further validation through randomized controlled trials
is necessary. Copyright © 2024 by the authors.

<89>
Accession Number
2029937417
Title
The Enhanced Recovery after Surgery Approach in Heart Valve Surgery: A
Systematic Review of Clinical Studies.
Source
Journal of Clinical Medicine. 13(10) (no pagination), 2024. Article
Number: 2903. Date of Publication: May 2024.
Author
Malvindi P.G.; Bifulco O.; Berretta P.; Galeazzi M.; Alfonsi J.; Cefarelli
M.; Zingaro C.; Zahedi H.M.; Munch C.; Di Eusanio M.
Institution
(Malvindi, Bifulco, Berretta, Galeazzi, Alfonsi, Cefarelli, Zingaro, Di
Eusanio) Cardiac Surgery Unit, Lancisi Cardiovascular Center, Ospedali
Riuniti delle Marche Polytechnic University of Marche, Ancona 60121, Italy
(Zahedi, Munch) Cardiac Anaesthesia and Intensive Care Unit, Lancisi
Cardiovascular Center, Ospedali Riuniti delle Marche, Ancona 60121, Italy
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: Enhanced recovery after surgery (ERAS) protocols aim to reduce
postoperative complications and promote earlier recovery. Although it is
well established in noncardiac surgery fields, the ERAS approach has only
recently been adopted in cardiac surgery. The aim of this review is to
evaluate the status and implementation of ERAS protocols in patients
undergoing heart valve surgery and to summarise associated clinical
results. Method(s): A literature search for the period January 2015
and January 2024 was performed through online databases. Clinical studies
(randomised controlled trials and cohort studies) on patients undergoing
heart valve surgical procedures and comparing ERAS and conventional
approaches were included. The data extracted covered studies and
populations characteristics, early outcomes and the features of each ERAS
protocol. Result(s): There were 14 studies that fulfilled the final
search criteria and were ultimately included in the review. Overall, 5142
patients were identified in the 14 studies, with 2501 in ERAS groups and
2641 patients who were representative of control groups. Seven experiences
exclusively included patients who underwent heart valve surgery. Twelve
out of fourteen protocols involved multiple interventions from the
preoperative to postoperative phase, while two studies reported actions
limited to intraoperative and postoperative care. We found high
heterogeneity among the included protocols regarding key actions targeted
for improvement and measured outcomes. All the studies showed that ERAS
pathways can be safely adopted in cardiac surgery and in most of the
experiences were associated with shorter mechanical ventilation time,
reduced postoperative opioid use and reduced ICU and hospital stays.
 Conclusion(s): As demonstrated in noncardiac surgery, the adoption of
structured ERAS protocols has the potential to improve results in patients
undergoing heart valve surgery. Further evidence based on larger
populations is needed, including more homogenous pathways and reporting
further outcomes in terms of patient satisfaction, recovery and quality of
life after surgery. Copyright © 2024 by the authors.

<90>
Accession Number
2029544912
Title
Randomized investigation of the MitraClip device in heart failure: Design
and rationale of the RESHAPE-HF2 trial design.
Source
European Journal of Heart Failure. 26(4) (pp 984-993), 2024. Date of
Publication: April 2024.
Author
Anker S.D.; Friede T.; von Bardeleben R.S.; Butler J.; Fatima K.; Diek M.;
Heinrich J.; Hasenfuss G.; Schillinger W.; Ponikowski P.
Institution
(Anker, Diek) Department of Cardiology (CVK) of German Heart Center
Charite, German Centre for Cardiovascular Research (DZHK) partner site
Berlin, Charite Universitatsmedizin, Berlin, Germany
(Friede) Department of Medical Statistics, University Medical Center
Gottingen, German Centre for Cardiovascular Research (DZHK), partner site
Gottingen, Gottingen, Germany
(von Bardeleben) Zentrum fur Kardiologie, Johannes-Gutenberg-Universitat,
Mainz, Germany
(Butler) Department of Medicine, University of Mississippi Medical Center,
Jackson, MS, United States
(Butler) Baylor Scott and White Research Institute, Dallas, TX, United
States
(Fatima) Department of Research, Baylor Scott and White Research
Institute, Dallas, TX, United States
(Heinrich) Clinical Trial Unit, University Medical Center Gottingen,
Gottingen, Germany
(Hasenfus) Heart Research Center Gottingen, Clinic for Cardiology and
Pneumology, University Medical Center Gottingen, Gottingen, Germany
(Schillinger) Heart Center, Department of Cardiology,
Georg-August-University Gottingen, Gottingen, Germany
(Ponikowski) Institute of Heart Diseases, Wroclaw Medical University,
Wroclaw, Poland
Publisher
John Wiley and Sons Ltd
Abstract
Aims: The safety and effectiveness of the MitraClip device to treat
functional mitral regurgitation (FMR) has been tested in previous clinical
trials yielding somewhat heterogeneous results in heart failure (HF)
patients. Over time, the MitraClip device system has been modified and
clinical practice evolved to consider also less severely diseased HF
patients with FMR for this therapeutic option. The RESHAPE-HF2 trial aims
to assess the safety and effectiveness of the MitraClip device system on
top of medical therapy considered optimal in the treatment of clinically
significant FMR in symptomatic patients with chronic HF. Method(s):
The RESHAPE-HF2 is an investigator-initiated, prospective, randomized,
parallel-controlled, multicentre trial designed to evaluate the use of the
MitraClip device (used in the most up-to-date version as available at
sites) plus optimal standard of care therapy (device group) compared to
optimal standard of care therapy alone (control group). Eligible subjects
have signs and symptoms of HF (New York Heart Association [NYHA] class
II-IV despite optimal therapy), and have moderate-to-severe or severe FMR,
as confirmed by a central echocardiography core laboratory; have an
ejection fraction between >=20% and <=50% (initially 15-35% for NYHA class
II patients, and 15-45% for NYHA class III/IV patients); have been
adequately treated per applicable standards, and have received appropriate
revascularization and cardiac resynchronization therapy, if eligible; had
a HF hospitalization or elevated natriuretic peptides (B-type natriuretic
peptide [BNP] >=300 pg/ml or N-terminal proBNP >=1000 pg/ml) in the last
90 days; and in whom isolated mitral valve surgery is not a recommended
treatment option. The trial has three primary endpoints, which are these:
(i) the composite rate of total (first and recurrent) HF hospitalizations
and cardiovascular death during 24 months of follow-up, (ii) the rate of
total (i.e. first and recurrent) HF hospitalizations within 24 months, and
(iii) the change from baseline to 12 months in the Kansas City
Cardiomyopathy Questionnaire overall score. The three primary endpoints
will be analysed using the Hochberg procedure to control the familywise
type I error rate across the three hypotheses. Conclusion(s): The
RESHAPE-HF2 trial will provide sound evidence on the MitraClip device and
its effects in HF patients with FMR. The recruitment was recently
completed with 506 randomized patients. Copyright © 2024 The
Authors. European Journal of Heart Failure published by John Wiley & Sons
Ltd on behalf of European Society of Cardiology.

<91>
Accession Number
2029423356
Title
A review and analysis of outcomes in randomized clinical trials of plasma
transfusion in patients with bleeding or for the prevention of bleeding:
The BEST collaborative study.
Source
Transfusion. 64(6) (pp 1116-1131), 2024. Date of Publication: June 2024.
Author
Apelseth T.O.; Raza S.; Callum J.; Ipe T.; Blackwood B.; Akhtar A.; Hess
J.R.; Marks D.C.; Brown B.; Delaney M.; Wendel S.; Stanworth S.J.
Institution
(Apelseth) Department of Immunology and Transfusion Medicine, Haukeland
University Hospital, Bergen, Norway
(Apelseth) Faculty of Medicine, University of Bergen, Bergen, Norway
(Apelseth) Norwegian Armed Forces Joint Medical Services, Oslo, Norway
(Raza) Department of Laboratory Medicine and Pathobiology, University of
Toronto, Toronto, Canada
(Callum) Department of Pathology and Molecular Medicine, Kingston Health
Sciences Centre and Queen's University, Kingston, Canada
(Ipe) Our Blood Institute, Oklahoma City, OK, United States
(Ipe) Department of Pathology, University of Arkansas for Medical
Sciences, Little Rock, AR, United States
(Blackwood) Wellcome-Wolfson Institute for Experimental Medicine, Queen's
University, Belfast, United Kingdom
(Akhtar) Royal Victoria Hospital, Belfast, United Kingdom
(Hess) Department of Laboratory Medicine and Pathology, University of
Washington School of Medicine, Seattle, WA, United States
(Marks) Research and Development, Australian Red Cross Lifeblood, Sydney,
Australia
(Brown) American Red Cross, Medical and Scientific Office, Washington, DC,
United States
(Delaney) Childrens National Hospital, Washington, DC, United States
(Wendel) Hospital Sirio Libanes, Sao Paulo, Brazil
(Stanworth) NHSBT, Oxford University Hospitals NHS Trust; Blood
Transfusion Research Unit (BTRU), University of Oxford, Oxford, United
Kingdom
Publisher
John Wiley and Sons Inc
Abstract
Background: Previous systematic reviews have revealed an inconsistency of
outcome definitions as a major barrier in providing evidence-based
guidance for the use of plasma transfusion to prevent or treat bleeding.
We reviewed and analyzed outcomes in randomized controlled trials (RCTs)
to provide a methodology for describing and classifying outcomes. Study
Design and Methods: RCTs involving transfusion of plasma published after
2000 were identified from a prior review (Yang 2012) and combined with an
updated systematic literature search of multiple databases (July 1, 2011
to January 17, 2023). Inclusion of publications, data extraction, and risk
of bias assessments were performed in duplicate. (PROSPERO registration
number is: CRD42020158581). Result(s): In total, 5579 citations were
identified in the new systematic search and 22 were included. Six
additional trials were identified from the previous review, resulting in a
total of 28 trials: 23 therapeutic and five prophylactic studies. An
increasing number of studies in the setting of major bleeding such as in
cardiovascular surgery and trauma were identified. Eighty-seven outcomes
were reported with a mean of 11 (min-max. 4-32) per study. There was
substantial variation in outcomes used with a preponderance of surrogate
measures for clinical effect such as laboratory parameters and blood
usage. Conclusion(s): There is an expanding literature on plasma
transfusion to inform guidelines. However, considerable heterogeneity of
reported outcomes constrains comparisons. A core outcome set should be
developed for plasma transfusion studies. Standardization of outcomes will
motivate better study design, facilitate comparison, and improve clinical
relevance for future trials of plasma transfusion. Copyright ©
2024 The Authors. Transfusion published by Wiley Periodicals LLC on behalf
of AABB.

<92>
Accession Number
2029381780
Title
Baroreflex activation therapy in patients with heart failure and a reduced
ejection fraction: Long-term outcomes.
Source
European Journal of Heart Failure. 26(4) (pp 1051-1061), 2024. Date of
Publication: April 2024.
Author
Zile M.R.; Lindenfeld J.; Weaver F.A.; Zannad F.; Galle E.; Rogers T.;
Abraham W.T.
Institution
(Zile) Medical University of South Carolina, Charleston, South Carolina
and the Ralph H. Johnson Department of Veterans Affairs Medical Center,
Charleston, SC, United States
(Lindenfeld) Vanderbilt Heart and Vascular Institute, Nashville, TN,
United States
(Weaver) Division of Vascular Surgery and Endovascular Therapy, Keck
School of Medicine, University of Southern California, Los Angeles, CA,
United States
(Zannad) Universite de Lorraine, Inserm Centre d'Investigation, CHU de
Nancy, Institute Lorrain du Coeur et des Vaisseaux, Nancy, France
(Galle) CVRx, Inc., Minneapolis, MN, United States
(Rogers) NAMSA, Inc., Minneapolis, MN, United States
(Abraham) Division of Cardiovascular Medicine, The Ohio State University,
Columbus, OH, United States
Publisher
John Wiley and Sons Ltd
Abstract
Aims: Carotid baroreflex activation therapy (BAT) restores baroreflex
sensitivity and modulates the imbalance in cardiac autonomic function in
patients with heart failure with reduced ejection fraction (HFrEF). We
tested the hypothesis that treatment with BAT significantly reduces
cardiovascular mortality and heart failure morbidity and provides
long-term safety and sustainable symptomatic improvement. Methods and
Results: BeAT-HF was a prospective, multicentre, randomized, two-arm,
parallel-group, open-label, non-implanted control trial. New York Heart
Association (NYHA) class III subjects, ejection fraction <=35%, previous
heart failure hospitalization or N-terminal pro-B-type natriuretic peptide
(NT-proBNP) >400 pg/ml, no class I indication for cardiac
resynchronization therapy and NT-proBNP <1600 pg/ml were randomized to BAT
plus optimal medical management (BAT group) or optimal medical management
alone (control). The primary endpoint was cardiovascular mortality and HF
morbidity; additional pre-specified endpoints included durability of
safety, quality of life (QOL), exercise capacity (6-min hall walk distance
[6MHWD]), functional status (NYHA class), hierarchical composite win
ratio, freedom from all-cause death, left ventricular assists device
(LVAD) implantation, heart transplant. Overall, 323 patients had 332
primary events, median follow-up was 3.6 years/patient. Both primary
endpoint (rate ratio 0.94, 95% confidence interval [CI] 0.57-1.57; p =
0.82) and components of the primary endpoints were not significantly
different between BAT and control. The system- and procedure-related major
adverse neurological and cardiovascular event-free rate remained 97%
throughout the trial. Symptom improvement (QOL, 6MHWD, NYHA class, all
nominal p < 0.001) in the BAT group was durable in time, sustainable in
extent. Win ratio (1.26, 95% CI 1.02-1.58) and freedom from all-cause
death, LVAD implantation, heart transplant (hazard ratio 0.66, 95% CI
0.43-1.01) favoured the BAT group but did not reach statistical
significance. Conclusion(s): The BeAT-HF primary endpoint was
neutral; however, BAT provided safe, effective, and sustainable
improvements in HFrEF patient's functional status, 6MHWD and
QOL. Copyright © 2024 CVRx and The Authors. European Journal of
Heart Failure published by John Wiley & Sons Ltd on behalf of European
Society of Cardiology.

<93>
Accession Number
2029258659
Title
Sodium-glucose cotransporter 2 inhibitors and skeletal muscle.
Source
European Journal of Heart Failure. 26(4) (pp 936-937), 2024. Date of
Publication: April 2024.
Author
Coats A.J.S.
Institution
(Coats) Heart Research Institute, Sydney, NSW, Australia
Publisher
John Wiley and Sons Ltd

<94>
Accession Number
2032559798
Title
Prognostic Value of Cardiac Magnetic Resonance Imaging in Chronic Aortic
Regurgitation: A Systematic Review and Meta-Analysis.
Source
Reviews in Cardiovascular Medicine. 24(12) (no pagination), 2023. Article
Number: 359. Date of Publication: December 2023.
Author
Ni J.-R.; Xin W.-L.; Hu Y.; Liu S.-D.; Li J.-K.; Wan Z.-H.; Lei J.-Q.
Institution
(Ni, Lei) The First Hospital (First Clinical Medical School), Lanzhou
University, Gansu, Lanzhou 730000, China
(Ni, Hu, Liu, Wan) Department of Cardiovascular Surgery, The First
Hospital of Lanzhou University, Gansu, Lanzhou 730000, China
(Ni, Xin, Li, Lei) Intelligent Imaging Medical Engineering Research Center
of Gansu Province, Gansu, Lanzhou 730000, China
(Ni, Xin, Li, Lei) Accurate Image and Collab. Innov. Intl. Sci. and
Technological Cooperation Base of Gansu Province, Gansu, Lanzhou 730000,
China
(Ni, Xin, Li, Lei) Gansu Province Clinical Research Center for Radiology
Imaging, Gansu, Lanzhou 730000, China
(Xin, Li, Lei) Department of Radiology, The First Hospital of Lanzhou
University, Gansu, Lanzhou 730000, China
Publisher
IMR Press Limited
Abstract
Background: Chronic aortic regurgitation (AR) is a common valvular disease
characterized by an overload of left ventricular volume and pressure.
Accurate assessment of the heart from all angles is crucial for effective
clinical management and prognostic evaluation of AR patients. As an
advanced imaging technique, cardiac magnetic resonance (CMR) has become
the gold standard for assessing cardiac volume and function. Accordingly,
this study aimed to evaluate the prognostic value of CMR in chronic AR.
 Method(s): EMBASE, Cochrane Library, PubMed, and Web of Science were
searched for clinical studies published between inception and July 19,
2022. Only studies that used CMR to assess patients with chronic isolated
AR and provided prognostic data were included. Result(s): For our
analysis, 11 studies, which involved 1702 subjects and follow-up periods
of 0.6-9.7 years, were eligible. We identified 13 CMR-related parameters
associated with AR prognosis. With aortic valve surgery as the outcome, we
estimated the pooled hazard ratios (HRs) for four of these parameters:
aortic regurgitation fraction (ARF), aortic regurgitation volume (ARV),
left ventricle end-diastolic volume (LVEDV), and LV end-systolic volume
(LVESV). The pooled HR for ARF was found to be 4.31 (95% confidence
interval [CI]: 1.12-16.59, p = 0.034), while that for ARV was 3.88 (95%
CI: 0.71-21.04, p = 0.116). Additionally, the combined HRs of LVEDV and
LVESV were estimated to be 2.20 (95% CI: 1.04-4.67, p = 0.039) and 3.14
(95% CI: 1.22-8.07, p = 0.018), respectively. Conclusion(s): The
assessment of ARF, LVEDV, and LVESV via CMR has significant prognostic
value in predicting the prognosis of AR patients with aortic valve surgery
as an endpoint. It is recommended to consider using multi-parameter CMR in
the clinical management of AR patients for timely interventions and
effective prognostic evaluation. Copyright © 2023 The Author(s).

<95>
Accession Number
644382786
Title
Systematic review and meta-analysis of the impact of sex on outcomes after
aortic valve replacement.
Source
Journal of cardiovascular medicine (Hagerstown, Md.). 25(7) (pp 539-550),
2024. Date of Publication: 01 Jul 2024.
Author
El-Andari R.; Bozso S.J.; Fialka N.M.; Alaklabi A.M.; Kang J.J.H.;
Nagendran J.
Institution
(El-Andari, Bozso, Fialka, Kang, Nagendran) Division of Cardiac Surgery,
Department of Surgery, University of Alberta, Edmonton, AB, Canada
(Alaklabi) College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
Abstract
AIMS: In recent years, extensive literature has been produced
demonstrating inferior outcomes for women when compared with men
undergoing heart valve interventions. Herein, we seek to analyze the
literature comparing outcomes between men and women undergoing surgical
aortic valve replacement (SAVR). METHOD(S): A systematic literature
search of PubMed, MEDLINE, and Embase was conducted for articles comparing
differences in outcomes between adult men and women undergoing SAVR. One
thousand nine hundred and ninety titles were screened, of which 75 full
texts were reviewed, and a total of 19 manuscripts met the inclusion
criteria and were included in this review. RESULT(S): Pooled
estimates of mortality demonstrated that women tended to have lower rates
of survival within the first 30 days post-SAVR, although mid-term and
long-term mortality did not differ significantly up to 10 years
postoperatively. Pooled estimates of postoperative data indicated no
difference in the rates of stroke and postoperative bleeding. Rates of
aortic valve reoperation and acute kidney injury favored women.
 CONCLUSION(S): Despite the inferior outcomes for women post-SAVR that
have been reported in recent years, the results of this meta-analysis
demonstrate comparable results between the sexes with comparable mid- to
long-term mortality in data pooled from the literature. Although mortality
favored men in the short term, rates of aortic valve reoperation and acute
kidney injury favored women. Future investigation into this field should
focus on identifying discrepancies in diagnosis and initial surgical
management in order to address any potential factors contributing to
discrepant short-term outcomes. GRAPHICAL ABSTRACT:
http://links.lww.com/JCM/A651. Copyright © 2024 Italian
Federation of Cardiology - I.F.C. All rights reserved.

<96>
Accession Number
2030057439
Title
Correction to: Letermovir prophylaxis for cytomegalovirus in
lung-transplant recipients: a comprehensive study with literature review
of off-label use and real-world experiences (Clinical and Experimental
Medicine, (2024), 24, 1, (68), 10.1007/s10238-024-01330-2).
Source
Clinical and Experimental Medicine. 24(1) (no pagination), 2024. Article
Number: 116. Date of Publication: December 2024.
Author
Hirama T.; Shundo Y.; Ohsumi A.; Watanabe T.; Okada Y.
Institution
(Hirama, Watanabe, Watanabe, Okada) Department of Thoracic Surgery,
Institute of Development, Aging and Cancer, Tohoku University, Miyagi,
Sendai, Japan
(Hirama, Okada) Division of Organ Transplantation, Tohoku University
Hospital, Miyagi, Sendai, Japan
(Shundo) Department of Respiratory Medicine, Faculty of Medicine, Fukuoka
University, Fukuoka, Fukuoka, Japan
(Ohsumi) Department of Thoracic Surgery, Kyoto University Hospital, Kyoto,
Kyoto, Japan
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Correction to: Clinical and Experimental Medicine (2024) 24:68
https://doi.org/10.1007/s10238-024-01330-2 In the original version of this
article, the affiliations of the second-last author, "Tatsuaki Watanabe,"
were incorrectly listed as affiliation 1, 2, 3, 4, but his correct
affiliation should be only 1 "Department of Thoracic Surgery, Institute of
Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan".
And the order of references in the article was incorrect. The current
order of references in the article: 1. Limaye AP, Budde K, Humar A, et al.
Letermovir versus valganciclovir for prophylaxis of cytomegalovirus in
high-risk kidney transplant recipients: a randomized clinical trial. JAMA.
2023;330(1):33-42. https://doi.org/10.1001/jama.2023.9106. 2. Linder KA,
Kovacs C, Mullane KM, et al. Letermovir treatment of cytomegalovirus
infection or disease in solid organ and hematopoietic cell transplant
recipients. Transpl Infect Dis. 2021;23(4):e13687.
https://doi.org/10.1111/tid.13687. 3. Razonable RR, Humar A.
Cytomegalovirus in solid organ transplant recipients-guidelines of the
american society of transplantation infectious diseases community of
practice. Clin Transplant. 2019;33(9):1-23.
https://doi.org/10.1111/ctr.13512. 4. Nikkuni E, Hirama T, Hayasaka K, et
al. Recovery of physical function in lung transplant recipients with
sarcopenia. BMC Pulm Med. 2021;21(1):124.
https://doi.org/10.1186/s12890-021-01442-5. 5. Kumata S, Hirama T,
Watanabe Y, et al. The fraction of sensitization among lung transplant
recipients in a transplant center in Japan. BMC Pulm Med. 2020;20(1):256.
https://doi.org/10.1186/s12890-020-01299-0. 6. Hirama T, Tomiyama F,
Notsuda H, et al. Outcome and prognostic factors after lung
transplantation for bronchiectasis other than cystic fibrosis. BMC Pulm
Med. 2021;21(1):261. https://doi.org/10.1186/s12890-021-01634-z. 7. Hirama
T, Akiba M, Shundo Y, et al. Efficacy and safety of mRNA SARS-CoV-2
vaccines in lung transplant recipients. J Infect Chemother.
2022;28(8):1153-8. https://doi.org/10.1016/j.jiac.2022.04.019. 8. Ui M,
Hirama T, Akiba M, Honda M, Kikuchi T, Okada Y. Cellular and humoral
immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung
transplant recipients in Japan. Vaccine. 2023;41(31):4534-40.
https://doi.org/10.1016/j.vaccine.2023.06.011. 9. Hirama T, Okada Y. Roles
of respirologists in lung transplantation in Japan: narrative review. J
Thorac Dis. 2023;15(9):5174-81. https://doi.org/10.21037/jtd-22-1716. 10.
Katahira M, Hirama T, Eba S, et al. Impact of postoperative continuous
renal replacement therapy in lung transplant recipients. Transplant
Direct. 2020;6(6): e562. https://doi.org/10.1097/TXD.0000000000001013. 11.
Katada Y, Nakagawa S, Nagao M, et al. Risk factors of breakthrough
aspergillosis in lung transplant recipients receiving itraconazole
prophylaxis. J Infect Chemother. 2022;28(1):54-60.
https://doi.org/10.1016/j.jiac.2021.09.020. 12. Saullo JL, Baker AW,
Snyder LD, et al. Cytomegalovirus prevention in thoracic organ
transplantation: A single-center evaluation of letermovir prophylaxis. J
Heart Lung Transplant. 2022;41(4):508-15.
https://doi.org/10.1016/j.healun.2021.12.005. 13. Singha A, Burcham PK,
Logan A, et al. Letermovir for cytomegalovirus prophylaxis in lung
transplant patients with valganciclovir-induced leukopenia.
Transplantology. 2021;2(2):129-39.
https://doi.org/10.3390/transplantology2020013. 14. Aryal S, Katugaha SB,
Cochrane A, et al. Single-center experience with use of letermovir for CMV
prophylaxis or treatment in thoracic organ transplant recipients. Transpl
Infect Dis. 2019;21(6): e13166. https://doi.org/10.1111/tid.13166. 15.
Veit T, Munker D, Barton J, et al. Letermovir in lung transplant
recipients with cytomegalovirus infection: a retrospective observational
study. Am J Transplant. 2021;21(10):3449-55.
https://doi.org/10.1111/ajt.16718. 16. Paraskeva M, Bailey M, Levvey BJ,
et al. Cytomegalovirus replication within the lung allograft is associated
with bronchiolitis obliterans syndrome. Am J Transplant.
2011;11(10):2190-6. https://doi.org/10.1111/j.1600-6143.2011.03663.x. 17.
Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J
Med. 1998;338(24):1741-51. https://doi.org/10.1056/NEJM199806113382407.
18. Rubin RH. The indirect effects of cytomegalovirus infection on the
outcome of organ transplantation. JAMA. 1989;261(24):3607-9. 19. Johansson
I, Martensson G, Nystrom U, Nasic S, Andersson R. Lower incidence of CMV
infection and acute rejections with valganciclovir prophylaxis in lung
transplant recipients. BMC Infect Dis. 2013;13:582.
https://doi.org/10.1186/1471-2334-13-582. 20. Hammond SP, Martin ST,
Roberts K, et al. Cytomegalovirus disease in lung transplantation: impact
of recipient seropositivity and duration of antiviral prophylaxis. Transpl
Infect Dis. 2013;15(2):163-70. https://doi.org/10.1111/tid.12036. 21.
Finlen Copeland CA, Davis WA, Snyder LD, et al. Long-term efficacy and
safety of 12 months of valganciclovir prophylaxis compared with 3 months
after lung transplantation: a single-center, long-term follow-up analysis
from a randomized, controlled cytomegalovirus prevention trial. J Heart
Lung Transplant. 2011;30(9):990-6.
https://doi.org/10.1016/j.healun.2011.02.017. 22. Palmer SM, Limaye AP,
Banks M, et al. Extended valganciclovir prophylaxis to prevent
cytomegalovirus after lung transplantation: a randomized, controlled
trial. Ann Intern Med. 2010;152(12):761-9.
https://doi.org/10.7326/0003-4819-152-12-201006150-00003. 23. Cherrier L,
Nasar A, Goodlet KJ, Nailor MD, Tokman S, Chou S. Emergence of letermovir
resistance in a lung transplant recipient with ganciclovir-resistant
cytomegalovirus infection. Am J Transplant. 2018;18(12):3060-4.
https://doi.org/10.1111/ajt.15135. 24. McCrea JB, Macha S, Adedoyin A, et
al. Pharmacokinetic drug-drug interactions between letermovir and the
immunosuppressants cyclosporine, tacrolimus, sirolimus, and mycophenolate
mofetil. J Clin Pharmacol. 2019;59(10):1331-9.
https://doi.org/10.1002/jcph.1423. 25. Marshall WL, McCrea JB, Macha S, et
al. Pharmacokinetics and tolerability of letermovir coadministered with
azole antifungals (posaconazole or voriconazole) in healthy subjects. J
Clin Pharmacol. 2018;58(7):897-904. https://doi.org/10.1002/jcph.1094. 26.
Nakashima T, Inamoto Y, Fukushi Y, et al. Drug interaction between
letermovir and voriconazole after allogeneic hematopoietic cell
transplantation. Int J Hematol. 2021;113(6):872-6.
https://doi.org/10.1007/s12185-021-03105-x. 27. Hikasa S, Shimabukuro S,
Osugi Y, et al. Tacrolimus Concentration after Letermovir Initiation in
Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole:
A Retrospective. Observational Study Int J Med Sci. 2020;17(7):859-64.
https://doi.org/10.7150/ijms.42011. 28. Kotton CN, Kumar D, Caliendo AM,
et al. The third international consensus guidelines on the management of
cytomegalovirus in solid organ transplantation. Transplant Publ online.
2018. https://doi.org/10.1097/TP.0000000000002191. The order of references
should have been. 1. Limaye AP, Budde K, Humar A, et al. Letermovir vs
Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney
Transplant Recipients: A Randomized Clinical Trial. JAMA.
2023;330(1):33-42. https://doi.org/10.1001/jama.2023.9106. 2. Razonable
RR, Humar A. Cytomegalovirus in solid organ transplant
recipients-Guidelines of the American Society of Transplantation
Infectious Diseases Community of Practice. Clin Transplant.
2019;33(9):1-23. https://doi.org/10.1111/ctr.13512. 3. Kotton CN, Kumar D,
Caliendo AM, et al. The Third International Consensus Guidelines on the
Management of Cytomegalovirus in Solid Organ Transplantation.
Transplantation. Published online 2018.
https://doi.org/10.1097/TP.0000000000002191. 4. Nikkuni E, Hirama T,
Hayasaka K, et al. Recovery of physical function in lung transplant
recipients with sarcopenia. BMC Pulm Med. 2021;21(1):124.
https://doi.org/10.1186/s12890-021-01442-5. 5. Kumata S, Hirama T,
Watanabe Y, et al. The fraction of sensitization among lung transplant
recipients in a transplant center in Japan. BMC Pulm Med. 2020;20(1):256.
https://doi.org/10.1186/s12890-020-01299-0. 6. Hirama T, Tomiyama F,
Notsuda H, et al. Outcome and prognostic factors after lung
transplantation for bronchiectasis other than cystic fibrosis. BMC Pulm
Med. 2021;21(1):261. https://doi.org/10.1186/s12890-021-01634-z. 7. Hirama
T, Akiba M, Shundo Y, et al. Efficacy and safety of mRNA SARS-CoV-2
vaccines in lung transplant recipients. J Infect Chemother.
2022;28(8):1153-1158. https://doi.org/10.1016/j.jiac.2022.04.019. 8. Ui M,
Hirama T, Akiba M, Honda M, Kikuchi T, Okada Y. Cellular and humoral
immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung
transplant recipients in Japan. Vaccine. 2023;41(31):4534-4540.
https://doi.org/10.1016/j.vaccine.2023.06.011. 9. Hirama T, Okada Y. Roles
of respirologists in lung transplantation in Japan: narrative review. J
Thorac Dis. 2023;15(9):5174-5181. https://doi.org/10.21037/jtd-22-1716.
10. Katahira M, Hirama T, Eba S, et al. Impact of Postoperative Continuous
Renal Replacement Therapy in Lung Transplant Recipients. Transplant
Direct. 2020;6(6):e562. https://doi.org/10.1097/TXD.0000000000001013. 11.
Katada Y, Nakagawa S, Nagao M, et al. Risk factors of breakthrough
aspergillosis in lung transplant recipients receiving itraconazole
prophylaxis. J Infect Chemother. 2022;28(1):54-60.
https://doi.org/10.1016/j.jiac.2021.09.020. 12. Saullo JL, Baker AW,
Snyder LD, et al. Cytomegalovirus prevention in thoracic organ
transplantation: A single-center evaluation of letermovir prophylaxis. J
Heart Lung Transplant. 2022;41(4):508-515.
https://doi.org/10.1016/j.healun.2021.12.005. 13. Singha A, Burcham PK,
Logan A, et al. Letermovir for Cytomegalovirus Prophylaxis in Lung
Transplant Patients with Valganciclovir-Induced Leukopenia.
Transplantology. 2021;2(2):129-139.
https://doi.org/10.3390/transplantology2020013. 14. Aryal S, Katugaha SB,
Cochrane A, et al. Single-center experience with use of letermovir for CMV
prophylaxis or treatment in thoracic organ transplant recipients. Transpl
Infect Dis. 2019;21(6):e13166. https://doi.org/10.1111/tid.13166. 15. Veit
T, Munker D, Barton J, et al. Letermovir in lung transplant recipients
with cytomegalovirus infection: A retrospective observational study. Am J
Transplant. 2021;21(10):3449-3455. https://doi.org/10.1111/ajt.16718. 16.
Paraskeva M, Bailey M, Levvey BJ, et al. Cytomegalovirus replication
within the lung allograft is associated with bronchiolitis obliterans
syndrome. Am J Transplant. 2011;11(10):2190-2196.
https://doi.org/10.1111/j.1600-6143.2011.03663.x 17. Fishman JA, Rubin RH.
Infection in organ-transplant recipients. N Engl J Med.
1998;338(24):1741-1751. https://doi.org/10.1056/NEJM199806113382407. 18.
Rubin RH. The indirect effects of cytomegalovirus infection on the outcome
of organ transplantation. JAMA. 261(24):3607-3609. 19. Johansson I,
Martensson G, Nystrom U, Nasic S, Andersson R. Lower incidence of CMV
infection and acute rejections with valganciclovir prophylaxis in lung
transplant recipients. BMC Infect Dis. 2013;13:582.
https://doi.org/10.1186/1471-2334-13-582. 20. Hammond SP, Martin ST,
Roberts K, et al. Cytomegalovirus disease in lung transplantation: impact
of recipient seropositivity and duration of antiviral prophylaxis. Transpl
Infect Dis. 2013;15(2):163-170. https://doi.org/10.1111/tid.12036. 21.
Finlen Copeland CA, Davis WA, Snyder LD, et al. Long-term efficacy and
safety of 12 months of valganciclovir prophylaxis compared with 3 months
after lung transplantation: a single-center, long-term follow-up analysis
from a randomized, controlled cytomegalovirus prevention trial. J Heart
Lung Transplant. 2011;30(9):990-996.
https://doi.org/10.1016/j.healun.2011.02.017. 22. Palmer SM, Limaye AP,
Banks M, et al. Extended valganciclovir prophylaxis to prevent
cytomegalovirus after lung transplantation: a randomized, controlled
trial. Ann Intern Med. 2010;152(12):761-769.
https://doi.org/10.7326/0003-4819-152-12-201006150-00003. 23. Linder KA,
Kovacs C, Mullane KM, et al. Letermovir treatment of cytomegalovirus
infection or disease in solid organ and hematopoietic cell transplant
recipients. Transpl Infect Dis. 2021;23(4):e13687.
https://doi.org/10.1111/tid.13687. 24. Cherrier L, Nasar A, Goodlet KJ,
Nailor MD, Tokman S, Chou S. Emergence of letermovir resistance in a lung
transplant recipient with ganciclovir-resistant cytomegalovirus infection.
Am J Transplant. 2018;18(12):3060-3064. https://doi.org/10.1111/ajt.15135.
25. McCrea JB, Macha S, Adedoyin A, et al. Pharmacokinetic Drug-Drug
Interactions Between Letermovir and the Immunosuppressants Cyclosporine,
Tacrolimus, Sirolimus, and Mycophenolate Mofetil. J Clin Pharmacol.
2019;59(10):1331-1339. https://doi.org/10.1002/jcph.1423. 26. Marshall WL,
McCrea JB, Macha S, et al. Pharmacokinetics and Tolerability of Letermovir
Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in
Healthy Subjects. J Clin Pharmacol. 2018;58(7):897-904.
https://doi.org/10.1002/jcph.1094. 27. Nakashima T, Inamoto Y, Fukushi Y,
et al. Drug interaction between letermovir and voriconazole after
allogeneic hematopoietic cell transplantation. Int J Hematol.
2021;113(6):872-876. https://doi.org/10.1007/s12185-021-03105-x. 28.
Hikasa S, Shimabukuro S, Osugi Y, et al. Tacrolimus Concentration after
Letermovir Initiation in Hematopoietic Stem Cell Transplantation
Recipients Receiving Voriconazole: A Retrospective, Observational Study.
Int J Med Sci. 2020;17(7):859-864. https://doi.org/10.7150/ijms.42011. The
original article has been corrected. Copyright © The Author(s),
under exclusive licence to Springer Nature Switzerland AG 2024.

<97>
Accession Number
619236053
Title
The Comparison of the Effects of Nebivolol and Metoprolol on Erectile
Dysfunction in the Cases with Coronary Artery Bypass Surgery.
Source
Annals of thoracic and cardiovascular surgery : official journal of the
Association of Thoracic and Cardiovascular Surgeons of Asia. 23(2) (pp
91-95), 2017. Date of Publication: 20 Apr 2017.
Author
Gur O.; Gurkan S.; Yumun G.; Turker P.
Institution
(Gur, Gurkan, Yumun) Department of Cardiovascular Surgery, Namik Kemal
University, Tekirdag, Turkey
(Turker) Department of Urology, Namik Kemal University, Tekirdag, Turkey
Abstract
PURPOSE: Beta-blocker use is common in the cases with coronary artery
bypass surgery. According to the literature, beta-blockers have positive
effects but may cause erectile dysfunction (ED). The most commonly used
beta-blockers in ischemic cardiac disease are nebivolol and metoprolol. In
our clinic, we aimed to compare the effects of nebivolol and metoprolol
succinate on ED in the sexually active cases with coronary artery bypass
surgery. METHOD(S): In our clinic, a total of 119 patients with
coronary artery bypass surgery were included in the study. International
Index of Erectile Function (IIEF-5) Test was used to evaluate whether the
patients had ED and to grade the cases. RESULT(S): No significant
difference was found in terms of anti-ischemic efficacy between metoprolol
succinate and nebivolol in the postoperative period; however, the
incidence of any grade ED was %85.96 in Group 1, %83.87 in Group 2. This
difference was considered as statistically significant (p = 0.036).
 CONCLUSION(S): Beta-blocker use increases the risk of ED in cases
with ischemic cardiac disease. We suggest that the complaints of ED could
be less frequent with nebivolol use in sexually active cases with ischemic
cardiac disease.

<98>
Accession Number
2032627329
Title
A screening pathway for enrolling distressed patients with coronary heart
disease and baseline data from the randomised controlled TEACH trial.
Source
Journal of Psychosomatic Research. Conference: 11th Annual Scientific
Conference of the European Association of Psychosomatic Medicine (EAPM).
Lausanne Switzerland. 181 (no pagination), 2024. Article Number: 111735.
Date of Publication: June 2024.
Author
Herrmann L.C.; Albus C.; Bersch K.; Geiser F.; Hellmich M.; Belnap B.H.;
Kindermann I.; Michal M.; Nohre M.; Sadlonova M.; Wachter R.
Institution
(Herrmann, Bersch, Belnap, Sadlonova) University of Gottingen Medical
Centre (DE), Germany
(Albus, Hellmich) University Hospital of Cologne, Germany
(Geiser) University Hospital of Bonn, Germany
(Kindermann) University Hospital of Homburg, Germany
(Michal) University of Mainz Medical Centre, Germany
(Nohre) Hannover Medical School, Germany
(Wachter) University Hospital of Leipzig, Germany
Publisher
Elsevier Inc.
Abstract
Background/significance: The long-term trajectory of coronary heart
disease (CHD) is substantially influenced by psychological adjustment and
patient behaviours. (Blended) collaborative care (BCC) has been shown to
improve mental health and cardiovascular risk factors in the U.S.A. but
has so far not been tested for this purpose in European health care
systems. In the multicentre randomised controlled trial "Efficacy of
team-based care for distressed patients in secondary prevention of chronic
coronary heart disease" (TEACH) we examine the effects of a 12 month BCC
intervention vs. usual care on quality of life, psychological adjustment,
health behaviours, somatic risk factors, and medical outcomes in
distressed CHD patients recruited at seven university hospitals across
Germany. Method(s): To identify patients with persistent distress we
applied a stepwise consent and screening procedure with two assessments.
We first screened patients hospitalized on a cardiology or cardiac surgery
ward for distress, using the Hospital Anxiety and Depression Scale (HADS)
and Perceived Stress Scale (PSS-4). Patients with elevated distress (HADS
total > 12) and/or PSS-4 > 5) and without obvious exclusion criteria were
eligible for a second phone-based screening approximately three months
later. Those who again reported elevated distress and had at least one
insufficiently controlled somatic risk factor (hypertension, elevated LDL
cholesterol, diabetes, smoking, or physical inactivity) were invited to
participate in the RCT if they had no exclusion criteria. Result(s):
Of 2147 patients with initial elevated distress screening, we rescreened
1468 (68%) three months later. Of these, 1031 (70.2%) were still
distressed and 854 patients (82.8% of still distressed patients) showed at
least one insufficiently controlled medical / behavioural risk factor.
After applying predefined exclusion criteria, 842 patients were eligible
to participate in the RCT, 459 (54.5%) gave their written informed consent
and 457 could actually be randomised. The RCT patients had a mean age of
63 +/- 9.5 years and 77% were male. Medical records identified 280
patients (61%) with a history of myocardial infarction, while 336 patients
(74%) had undergone coronary interventions, 160 patients (35%) had
received coronary bypass surgery, and 180 (39%), had documented heart
failure. The most frequent somatic risk factors were hypertension and
dyslipidemia (84% each). Depression had been diagnosed in 184 patients
(40%) and anxiety disorders in 86 patients (19%). Any mental disorder was
documented in 247 patients (54%) and 192 patients (42%) reported previous
mental health treatments. At baseline 44% of patients were mostly or
completely satisfied with their treatment in general. However, while 69%
were satisfied with their heart disease treatment, only 38% were satisfied
with their treatment for psychological problems. Discussion/conclusion:
Our results suggest that a substantial portion of hospitalised CHD
patients with psychological distress continue to report elevated distress
three months later. Furthermore, at three-month after discharge >80% of
distressed patients have at least one insufficiently controlled somatic
risk factor. These patients show a high burden of both cardiac and mental
morbidity and often feel dissatisfied with their mental health care. In
the fall we will report about the efficacy of our BCC
intervention. Copyright © 2024

<99>
Accession Number
2032626976
Title
Electronic patient reported outcome measures (ePROMs) and managing
emotional symptoms experienced by heart transplant recipients.
Source
Journal of Psychosomatic Research. Conference: 11th Annual Scientific
Conference of the European Association of Psychosomatic Medicine (EAPM).
Lausanne Switzerland. 181 (no pagination), 2024. Article Number: 111789.
Date of Publication: June 2024.
Author
Wasim A.; Lodge D.; Thobani T.; Groe K.; Syeda N.F.; Zhao X.; Starkman R.;
Mucsi I.
Institution
(Wasim, Lodge, Thobani, Groe, Syeda, Zhao, Starkman, Mucsi) Ajmera
Transplant Centre, University Health Network, Toronto, Canada
Publisher
Elsevier Inc.
Abstract
Background: Many heart transplant recipients (HTR) experience significant
emotional symptoms which frequently remain undermanaged and impair quality
of life. This study aimed to qualitatively characterize experiences and
management needs surrounding emotional symptoms for HTRs and explore the
potential role of electronic patient-reported outcomes measures (ePROMs)
in this context. Method(s): Adult (>=18 years) HTRs, caregivers, and
healthcare professionals (HCPs) were recruited using purposive sampling
and snowball recruitment. A qualitative description framework was used to
explore post-transplant symptom experiences of HTRs. Semi-structured
interviews were conducted exploring symptoms experienced and attitudes to
ePROMs. Interviews were audio-recorded and transcribed verbatim. Thematic
analysis using deductive and inductive coding strategies generated key
themes. (Ethics approval: UHN REB 19-5770). Result(s): Five HTRs
(age: 39-81 years, 12-24 years post-transplant, 4/5 female), one caregiver
(age: 53 years, female), and five HCPs (age: 45-55 years, 4/5 female)
reported that HTRs faced significant emotional challenges post-transplant.
Four themes were identified. Theme 1, "Transplant trauma": emotional
trauma after transplant, including elevated levels of anxiety, depressive
symptoms, survival guilt, fear of organ rejection, and fixation on the
donor and their family. The trauma is reported as stemming in part from
near-death experiences pre- and peri-transplant, and from concerns
regarding the longevity of their transplanted organ. Theme 2, "Social
anxiety": heightened anxiety surrounding social life due to anticipated
and perceived social difficulties related to transplant (e.g., maintaining
stable relationships, inability to resume employment or education, and
financial constraints). Theme 3, "Missing mental health": lack of
recognition of mental health needs in post-transplant care. Theme 4, "Pros
and cons to ePROMS": mixed attitudes towards ePROMs. Most participants
appreciated that monitoring of emotional symptoms would be facilitated by
ePROMS. Concerns included lack of feedback and action after questionnaire
completion. Discussion(s): Emotional symptoms and concerns
experienced by HTRs are not adequately addressed in post-transplant care.
ePROMs were recognized as a potentially effective tool to monitor and
support symptom management. Our results confirm previous
findings1 that heart transplant is an emotionally challenging
journey. Our results also brought to light new topics, including the
importance of near-death experiences and restricted social activities. Our
analysis suggests that HTR, caregiver and HCP stakeholders perceive
current emotional monitoring as deficient, reinforcing the need for more
whole-person centered post-transplant care. Finally, our findings align
with previous research suggesting that ePROMs may improve symptom
management in chronic conditions2. Conclusion(s): This
analysis improves our understanding of emotional symptom experiences of
HTRs and the potential role of ePROMs in post-transplant care to improve
the management of emotional symptoms for HTRs. References: 1. Conway A,
Schadewaldt V, Clark R, Ski C, Thompson DR, Doering L. The psychological
experiences of adult heart transplant recipients: a systematic review and
meta-summary of qualitative findings. Heart Lung. 2013;42(6):449-455. 2.
Aiyegbusi OL, Nair D, Peipert JD, Schick-Makaroff K, Mucsi I. A narrative
review of current evidence supporting the implementation of electronic
patient-reported outcome measures in the management of chronic diseases.
Ther Adv Chronic Dis. 2021;12:20406223211015958. Copyright © 2024

<100>
[Use Link to view the full text]
Accession Number
644410803
Title
Prevalence of Genetic Dilated Cardiomyopathy: A Systematic Literature
Review.
Source
Circulation. Conference: American Heart Association's Epidemiology and
Prevention/Lifestyle and Cardiometabolic Health 2024 Scientific Sessions.
Chicago, IL United States. 149(Supplement 1) (no pagination), 2024. Date
of Publication: March 2024.
Author
Fazeli M.S.; Myers M.; Zhong Y.; Maruyama S.; Bueno C.; Bastien A.;
Breznen B.; Golchin N.
Publisher
Lippincott Williams and Wilkins
Abstract
Background: Dilated cardiomyopathy (DCM) is a leading cause of heart
failure and cardiac transplantation worldwide. Many cases of DCM are due
to genetic or idiopathic etiology. Two prominent contributors to genetic
DCM (gDCM) are the TTN and MYH7 genes, which encode proteins associated
with DCM etiology. Purpose(s): This study aimed to synthesize the
published literature on the global prevalence of adult and pediatric gDCM
within the clinical DCM population and the general population.
 Method(s): A systematic review was conducted by searching MEDLINE and
Embase from database inception to 09/19/2022. We included observational
studies reporting the prevalence of gDCM within any population; prevalence
of TTN and MYH7 mutations were also extracted. Excluded were studies using
family history as a proxy for gDCM. Median with interquartile range (IQR)
or mean with standard deviation (SD) weighted by sample size (in cases of
calculations with <10 studies) were used to summarize the data.
 Result(s): Of 2,720 identified abstracts, 57 studies were included in
the review. Among the adult or mixed (adults and children) DCM population
in any country, median prevalence was 21.0% for overall DCM- related
genetic mutations, 11.4% for TTN mutations, and 3.2% for MYH7 mutations
(Table). The prevalence of pediatric gDCM within the DCM population was
similar (weighted mean: 21.3%). Data on prevalence of gDCM within the
general population were scarce. Conclusion(s): This study highlights
the variable prevalence of gDCM reported across different populations and
settings. The current evidence may underestimate the genetic causes due to
technical limitations in genetic testing and limited screening. Accurately
determining the prevalence of gDCM is critical for identifying high-risk
populations, developing targeted prevention strategies for disease
complications, and improving outcomes; epidemiological studies using
long-read sequencing techniques and large cohort datasets with
genotype-phenotype correlation analyses are needed. (Figure Presented).

<101>
Accession Number
2032488750
Title
Infective Endocarditis and Antithrombotic Therapy.
Source
Cardiology (Switzerland). (no pagination), 2024. Date of Publication:
2024.
Author
Morelli C.; Rocca B.; Gigante B.
Institution
(Morelli, Rocca) NeuroFarBa Department, University of Florence, Florence,
Italy
(Rocca) Department of Safety and Bioethics, Catholic University, School of
Medicine, Rome, Italy
(Gigante) Division of Cardiovascular Medicine, Department of Medicine,
Karolinska Institutet, Stockholm, Sweden
Publisher
S. Karger AG
Abstract
Background: Incidence of infective endocarditis (IE) is progressively
raising because of the increasing number of cardiovascular invasive
procedures, support treatment and devices, awareness in the medical
community, and improved diagnostic modalities. IE pathophysiology is a
unique model of immunothrombosis, and the clinical course is often
complicated by either embolic or hemorrhagic events. Managing
antithrombotic treatment is challenging and the level of supporting
evidence scant. The aim of this review was to discuss and present the
embolic and bleeding complication associated with IE and review the
available evidence on antithrombotic treatment in patients with IE with
and without a previous indication to antithrombotic drugs. Summary:
Embolic events occur in 20 40% of patients with IE and are associated with
high morbidity and mortality. Acute ischemic stroke is the most common
neurological complication. A beneficial effect of antithrombotic therapy
in preventing ischemic stroke for patients with IE has never been formally
tested in adequately powered randomized clinical trials. Atrial
fibrillation is a common complication associated with severe infections,
requiring anticoagulation. Furthermore, patients with IE have a high risk
of unprovoked and anticoagulation treatment-related bleeding. In
particular, intracerebral bleeding is the most severe complication in
about 5% of patients with IE. Single antiplatelet therapy with low-dose
aspirin after hospitalization for IE has been shown to reduce causes
mortality within 90 days without an increase of hemorrhagic strokes. In
the absence of bleeding complications, recent guidelines recommend to
maintain low-dose aspirin. No data are available on the management of
patients with IE while on dual antiplatelet therapy. Key Messages: Several
gaps in knowledge remain about antithrombotic management in patients with
IE and most of the evidence relies on observational studies.
Individualized strategies based on clinical evaluation, comorbidities,
patient engagement, and shared decisions strategies are
encouraged. Copyright © 2024 S. Karger AG. All rights reserved.

<102>
Accession Number
2030090261
Title
The efficacy of wound catheter infusion with local anesthetics for the
treatment of postoperative pain in children: A systematic review.
Source
Paediatric and Neonatal Pain. (no pagination), 2024. Date of Publication:
2024.
Author
Swenker D.J.; Dirckx M.; Staals L.M.
Institution
(Swenker) Department of Anesthesiology, Erasmus MC, University Medical
Center Rotterdam, Rotterdam, Netherlands
(Dirckx, Staals) Department of Anesthesiology, Erasmus MC Sophia
Children's Hospital, University Medical Center Rotterdam, Rotterdam,
Netherlands
Publisher
John Wiley and Sons Inc
Abstract
Wound catheter infusion (WCI) with local anesthetics (LA) is a regional
anesthesia technique, which has shown to produce effective postoperative
analgesia in adults, without any adverse effects on wound healing. To
investigate the efficacy and safety of WCI with LA for the treatment of
postoperative pain in children, we conducted a systematic review of
literature published until 2020. The literature search included articles
concerning subcutaneous WCI with LA, in the surgical wound, as treatment
of postoperative pain, in children <18 years of age. Exclusion criteria
were studies describing peripheral nerve blocks, intercostal, abdominal or
thoracic wall blocks and single local anesthetic infiltration of the
surgical wound. The articles were appraised for quality and only
randomized controlled trials with a Jadad score >=3 were included for
evaluation of results concerning postoperative pain scores and opioid use.
All relevant original studies, including observational studies and case
reports, were assessed for adverse events and measurements of LA plasma
concentrations during WCI. A total of 1907 articles were found, leading to
92 relevant abstracts selected for further review. After exclusion of
articles of which full texts could not be retrieved or because of
exclusion criteria, 28 articles remained. Thirteen articles described
randomized controlled trials, of which 10 were assessed as good or
excellent in quality. Due to the small number and heterogeneity of the
studies, the data could not be pooled. Instead, results were described per
type of procedure: abdominal surgery, extremity surgery, thoracic surgery
and iliac crest bone harvesting. Reduced pain scores and opioid needs were
demonstrated after abdominal and extremity surgery. In five studies,
plasma levels of LA were measured, which all remained below toxic
thresholds. In all relevant studies, no serious adverse events concerning
the use of WCI were reported. Copyright © 2024 The Author(s).
Paediatric and Neonatal Pain published by John Wiley & Sons Ltd.

<103>
Accession Number
644417996
Title
Hospital policy of tranexamic acid to reduce transfusion in major
non-cardiac surgery (TRACTION): protocol for a phase IV randomised
controlled trial.
Source
BMJ open. 14(6) (pp e084847), 2024. Date of Publication: 03 Jun 2024.
Author
Houston B.L.; McIsaac D.I.; Breau R.H.; Andrews M.; Avramescu S.; Bagry
H.; Balshaw R.F.; Daya J.; Duncan K.; Harle C.; Jacobsohn E.; Kerelska T.;
McIsaac S.; Ramsay T.; Saha T.; Perelman I.; Recio A.; Solvason D.; Szoke
D.; Tenenbein M.; Fergusson D.A.; Zarychanski R.
Institution
(Houston, Zarychanski) Hematology and Medical Oncology, University of
Manitoba/CancerCare Manitoba, Winnipeg, MB, Canada
(McIsaac, Breau, Andrews) University of Ottawa, Ottawa, ON, Canada
(McIsaac, Breau, Ramsay, Perelman, Fergusson) Ottawa Hospital Research
Institute (OHRI), Ottawa, ON, Canada
(Avramescu, Kerelska) Humber River Regional Hospital, Toronto, ON, Canada
(Bagry, Balshaw, Daya, Jacobsohn, Recio, Solvason, Tenenbein) University
of Manitoba, Winnipeg, MB, Canada
(Duncan, McIsaac) Northern Ontario School of Medicine, Sudbury, ON, Canada
(Harle, Szoke) Western University, London, ON, Canada
(Saha) Queen's University, Kingston, Ontario, Canada
Abstract
INTRODUCTION: Tranexamic acid (TXA) is an inexpensive and widely available
medication that reduces blood loss and red blood cell (RBC) transfusion in
cardiac and orthopaedic surgeries. While the use of TXA in these surgeries
is routine, its efficacy and safety in other surgeries, including
oncologic surgeries, with comparable rates of transfusion are uncertain.
Our primary objective is to evaluate whether a hospital-level policy
implementation of routine TXA use in patients undergoing major non-cardiac
surgery reduces RBC transfusion without increasing thrombotic risk.
METHODS AND ANALYSIS: A pragmatic, registry-based, blinded,
cluster-crossover randomised controlled trial at 10 Canadian sites,
enrolling patients undergoing non-cardiac surgeries at high risk for RBC
transfusion. Sites are randomised in 4-week intervals to a hospital policy
of intraoperative TXA or matching placebo. TXA is administered as 1g at
skin incision, followed by an additional 1 g prior to skin closure.
Coprimary outcomes are (1) effectiveness, evaluated as the proportion of
patients transfused RBCs during hospital admission and (2) safety,
evaluated as the proportion of patients diagnosed with venous
thromboembolism within 90 days. Secondary outcomes include: (1)
transfusion: number of RBC units transfused (both at a hospital and
patient level); (2) safety: in-hospital diagnoses of myocardial
infarction, stroke, deep vein thrombosis or pulmonary embolism; (3)
clinical: hospital length of stay, intensive care unit admission, hospital
survival, 90-day survival and the number of days alive and out of hospital
to day 30; and (4) compliance: the proportion of enrolled patients who
receive a minimum of one dose of the study intervention. ETHICS AND
DISSEMINATION: Institutional research ethics board approval has been
obtained at all sites. At the completion of the trial, a plain language
summary of the results will be posted on the trial website and distributed
in the lay press. Our trial results will be published in a peer-reviewed
scientific journal. TRIAL REGISTRATION NUMBER: NCT04803747. Copyright
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC
BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<104>
Accession Number
644416242
Title
Association between overweight and obesity with coronary artery bypass
graft failure: an individual patient data analysis of clinical trials.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. (no pagination), 2024.
Date of Publication: 03 Jun 2024.
Author
An K.R.; Sandner S.; Redfors B.; Alexander J.H.; Alzghari T.; Caldonazo
T.; Cancelli G.; Dell'Aquila M.; Dimagli A.; Gibson C.M.; Harik L.; Heise
R.; Kulik A.; Lamy A.; Leith J.; Peper J.; Perezgrovas-Olaria R.; Rossi
C.S.; Ruel M.; Soletti G.; Ten Berg J.M.; Willemsen L.M.; Wojdyla D.M.;
Zhao Q.; Zhu Y.; Verma S.; Gaudino M.F.L.
Institution
(An, Alzghari, Caldonazo, Cancelli, Dell'Aquila, Dimagli, Harik, Leith,
Perezgrovas-Olaria, Rossi, Soletti, Gaudino) Department of Cardiothoracic
Surgery, Weill Cornell Medicine, New York, NY, USA
(An, Verma) Division of Cardiac Surgery, St Michael's Hospital, University
of Toronto, Toronto, ON, Canada
(Sandner) Department of Cardiac Surgery, Medical University of Vienna,
Vienna, Austria
(Redfors, Heise) Department of Population Health Sciences, Weill Cornell
Medicine, New York, NY, USA
(Redfors) Department of Cardiology, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Redfors) Department of Molecular and Clinical Medicine, Institute of
Medicine, Gothenburg University, Sweden
(Alexander) Department of Medicine and Duke Clinical Research Institute,
Duke University, Durham, United States
(Gibson) Division of Cardiovascular Medicine, Department of Medicine, Beth
Israel Deaconess Medical Center and Harvard Medical School, Boston, MA,
United States
(Kulik) Division of Cardiac Surgery, Boca Raton Regional Hospital and
Florida Atlantic Hospital, Boca Raton, FL, United States
(Lamy) Department of Surgery, McMaster University, Hamilton, Ontario,
Canada
(Peper, Ten Berg, Willemsen) Department of Cardiology, St Antonius
Hospital, Nieuwegein, Netherlands
(Ruel) Division of Cardiac Surgery, University of Ottawa Heart Institute,
Ottawa, ON, Canada
(Wojdyla) Duke Clinical Research Institute, Duke University, Durham,
United States
(Zhao, Zhu) Ruijin Hospital, Shanghai Jiao Tong University School of
Medicine, Shanghai, China
Abstract
OBJECTIVES: The association between obesity and graft failure after
coronary artery bypass grafting has not been previously investigated.
 METHOD(S): We pooled individual patient data from randomized clinical
trials with systematic post-operative coronary imaging to evaluate the
association between obesity and graft failure at the individual graft and
patient levels. Penalized cubic regression splines and mixed-effects
multivariable logistic regression models were performed. RESULT(S):
Six trials comprising 3,928 patients and 12,048 grafts were included. The
median time to imaging was 1.03 (IQR, 1.00-1.09) years. By body mass index
(BMI) category, 800 (20.4%) patients were normal weight (BMI 18.5-24.9),
1,668 (42.5%) were overweight (BMI 25-29.9), 983 (25.0%) were obesity
class 1 (BMI 30-34.9), 344 (8.8%) were obesity class 2 (BMI 35-39.9), and
116 (2.9%) were obesity class 3 (BMI 40+). As a continuous variable, BMI
was associated with reduced graft failure (adjusted odds ratio [aOR] 0.98
[95% CI, 0.97-0.99]) at the individual graft level. Compared to normal
weight patients, graft failure at the individual graft level was reduced
in overweight (aOR 0.79 [95% CI, 0.64-0.96]), obesity class 1 (aOR 0.81
[95% CI, 0.64-1.01]), and obesity class 2 (aOR 0.61 [95% CI, 0.45-0.83])
patients, but not different compared to obesity class 3 (aOR 0.94 [95% CI,
0.62-1.42]) patients. Findings were similar, but did not reach
significance, at the patient level. CONCLUSION(S): In a pooled
individual patient data analysis of randomized clinical trials, BMI and
obesity appear to be associated with reduced graft failure at one year
after coronary artery bypass grafting. Copyright © The Author(s)
2024. Published by Oxford University Press on behalf of the European
Association for Cardio-Thoracic Surgery. All rights reserved.

<105>
Accession Number
644408866
Title
Revascularization in Left Ventricular Systolic Dysfunction: A
Meta-Analysis of Kaplan-Meier Reconstructed Individual Patient Data.
Source
The Canadian journal of cardiology. (no pagination), 2024. Date of
Publication: 30 May 2024.
Author
Lee G.; Malik A.; Vervoort D.; Tam D.Y.; Marquis-Gravel G.; Redfors B.;
Gaudino M.; Fremes S.E.
Institution
(Lee, Malik) Division of Cardiac Surgery, University of Toronto, Toronto,
ON, Canada
(Vervoort) Institute of Health Policy, Management and Evaluation,
University of Toronto, Toronto, ON, Canada
(Tam) Cedars-Sinai Medical Centre, Los Angeles, CA, United States
(Marquis-Gravel) Montreal Heart Institute and Universite de Montreal,
Montreal, Quebec, Canada
(Redfors) Department of Cardiology, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Gaudino) Department of Cardiothoracic Surgery, Weill Cornell Medicine,
NY, United States
(Fremes) Division of Cardiac Surgery, University of Toronto, Toronto,
Ontario, Canada; Institute of Health Policy, Management and Evaluation,
University of Toronto, Toronto, Ontario, Canada
Abstract
BACKGROUND: Coronary artery disease is a common etiology of ischemic left
ventricular systolic dysfunction (LVSD), for which the optimal
revascularization strategy remains unclear. We aimed to determine whether
percutaneous coronary intervention (PCI) or coronary artery bypass
grafting (CABG) results in greater survival advantage in patients with
LVSD. METHOD(S): A study-level (SLMA) and reconstructed individual
patient data meta-analysis (rIPDMA) from Kaplan-Meier (KM) survival curves
were performed. A systematic search of MEDLINE, EMBASE, and Cochrane was
conducted for observational and randomized studies published after 2010
that compared PCI to CABG in patients with left ventricular ejection
fraction <=40%. The primary outcome was all-cause mortality at longest
follow-up. The secondary outcomes were myocardial infarction (MI), stroke,
repeat revascularization, cardiovascular mortality, and major adverse
cardiovascular and cerebrovascular events (MACCE) at longest follow-up.
 RESULT(S): Fourteen studies (11 observational, three randomized,
13,063 patients) were eligible for SLMA. Seven contained digitizable KM
curves from which individual patient data could be reconstructed.
Study-level analysis found PCI associated with increased all-cause
mortality (Hazard Ratio 1.41 [95% Confidence Interval 1.18-1.69]), MI
(2.10 [1.62-2.72]), repeat revascularization (2.39 [1.37-4.17]) and MACCE
(1.58 [1.23-2.03]), without significant differences in stroke (0.86
[0.39-1.92]) or cardiovascular mortality (1.42 [0.78-2.59]). In the
rIPDMA, PCI resulted in increased all-cause mortality (1.57 [1.34-1.87])
and repeat revascularization (3.63 [3.12-4.21]) but overall lower risk of
stroke (0.62 [0.39-0.99]) due to fewer events during initial follow-up.
 CONCLUSION(S): In patients with ischemic LVSD, PCI was associated
with higher risk of all-cause mortality and repeat revascularization than
CABG but lower risk of short-term stroke. Copyright © 2024.
Published by Elsevier Inc.

<106>
Accession Number
644407376
Title
Rationale and design of the Early valve replacement in severe ASYmptomatic
Aortic Stenosis Trial.
Source
American heart journal. (no pagination), 2024. Date of Publication: 29
May 2024.
Author
Richardson C.; Gilbert T.; Aslam S.; Brookes C.L.; Singh A.; Newby D.E.;
Dweck M.R.; Stewart R.; Myles P.S.; Briffa T.; Selvanayagam J.; Chow C.K.;
Murphy G.J.; Akowuah E.F.; Lord J.; Barber S.; Paola A.S.D.; McCann G.P.;
MBedBiol G.S.H.
Institution
(Richardson, Aslam, Brookes, Singh, Murphy, Barber, Paola, McCann)
University of Leicester, Leicester, United Kingdom
(Gilbert, Briffa) University of Western Australia, Perth, Australia
(Newby, Dweck) University of Edinburgh, Edinburgh, United Kingdom
(Stewart) University of Auckland, Auckland, New Zealand
(Myles) Alfred Health, Melbourne, Australia
(Selvanayagam) Flinders Medical Centre, Adelaide, Australia
(Chow) University of Sydney, Sydney, Australia
(Akowuah) South Tees Hospitals NHS Trust, United Kingdom
(Lord) University of Southampton, Southampton, United Kingdom
(MBedBiol) Royal Perth Hospital, Perth, Australia
Abstract
BACKGROUND: Aortic valve replacement in asymptomatic severe aortic
stenosis is controversial. The Early valve replacement in severe
ASYmptomatic Aortic Stenosis (EASY-AS) trial aims to determine whether
early aortic valve replacement improves clinical outcomes, quality of life
and cost-effectiveness compared to a guideline recommended strategy of
'watchful waiting'. METHOD(S): In a pragmatic international, open
parallel group randomized controlled trial (NCT04204915), 2844 patients
with severe aortic stenosis will be randomized 1:1 to either a strategy of
early (surgical or transcatheter) aortic valve replacement or aortic valve
replacement only if symptoms or impaired left ventricular function
develop. Exclusion criteria include other severe valvular disease, planned
cardiac surgery, ejection fraction <50%, previous aortic valve replacement
or life expectancy <2 years. The primary outcome is a composite of
cardiovascular mortality or heart failure hospitalization. The primary
analysis will be undertaken when 663 primary events have accrued,
providing 90% power to detect a reduction in the primary endpoint from
27.7% to 21.6% (hazard ratio 0.75). Secondary endpoints include
disability-free survival, days alive and out of hospital, major adverse
cardiovascular events and quality of life. RESULT(S): Recruitment
commenced in March 2020 and is open in the UK, Australia, New Zealand and
Serbia. Feasibility requirements were met in July 2022, and the main phase
opened in October 2022, with additional international centers in set-up.
 CONCLUSION(S): The EASY-AS trial will establish whether a strategy of
early aortic valve replacement in asymptomatic patients with severe aortic
stenosis reduces cardiovascular mortality or heart failure hospitalization
and improves other important outcomes. Copyright © 2024.
Published by Elsevier Inc.

<107>
Accession Number
644404326
Title
Machine-Learning Approaches for Risk Prediction in Transcatheter Aortic
Valve Implantation: Systematic Review and Meta-Analysis.
Source
The Journal of thoracic and cardiovascular surgery. (no pagination),
2024. Date of Publication: 28 May 2024.
Author
Jacquemyn X.; Van Onsem E.; Dufendach K.; Brown J.A.; Kliner D.; Toma C.;
Serna-Gallegos D.; Sa M.P.; Sultan I.
Institution
(Jacquemyn, Van Onsem) Department of Cardiovascular Sciences, KU Leuven,
Leuven, Belgium
(Dufendach, Brown, Serna-Gallegos, Sa, Sultan) Department of
Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh,
Pennsylvania; UPMC Heart and Vascular Institute, University of Pittsburgh
Medical Center, Pittsburgh, Pennsylvania
(Kliner, Toma) UPMC Heart and Vascular Institute, University of Pittsburgh
Medical Center, Pittsburgh, Pennsylvania; Department of Interventional
Cardiology, University of Pittsburgh, Pittsburgh, Pennsylvania
Abstract
OBJECTIVES: With the expanding integration of artificial intelligence (AI)
and machine learning (ML) into the structural heart domain, numerous ML
models have emerged for the prediction of adverse outcomes following
transcatheter aortic valve implantation (TAVI). We aim to identify,
describe, and critically appraise ML prediction models for adverse
outcomes after TAVI. Key objectives consisted in summarizing model
performance, evaluating adherence to reporting guidelines, and
transparency. METHOD(S): We searched PubMed, SCOPUS, and Embase
through August 2023. We selected published machine learning models
predicting TAVI outcomes. Two reviewers independently screened articles,
extracted data, and assessed the study quality according to the PRISMA
guidelines (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses). Outcomes included summary C-statistics and model risk of
bias assessed with the Prediction Model Risk of Bias Assessment Tool
(PROBAST). C-statistics were pooled using a random-effects model.
 RESULT(S): Twenty-one studies (118,153 patients) employing various ML
algorithms (76 models) were included in the systematic review. Predictive
ability of models varied: 11.8% inadequate (C-statistic <0.60), 26.3%
adequate (C-statistic 0.60-0.70), 31.6% acceptable (C-statistic
0.70-0.80), and 30.3% demonstrated excellent (C-statistic >0.80)
performance. Meta-analyses revealed excellent predictive performance for
early mortality (C-statistic: 0.81 [95% CI, 0.65-0.91]), acceptable
performance for 1-year mortality (C-statistic: 0.76 [95% CI, 0.67-0.84]),
and acceptable performance for predicting permanent pacemaker implantation
(C-statistic: 0.75 [95% CI, 0.51-0.90]). CONCLUSION(S): ML models for
TAVI outcomes exhibit adequate to excellent performance, suggesting
potential clinical utility. We identified concerns in methodology and
transparency, emphasizing the need for improved scientific reporting
standards. Copyright © 2024. Published by Elsevier Inc.

<108>
Accession Number
644404025
Title
Treatment strategies of the thromboembolic risk in kidney failure patients
with atrial fibrillation.
Source
Nephrology, dialysis, transplantation : official publication of the
European Dialysis and Transplant Association - European Renal Association.
(no pagination), 2024. Date of Publication: 30 May 2024.
Author
Genovesi S.; Camm A.J.; Covic A.; Bulracu A.; Meijers B.; Franssen C.;
Luyckx V.; Liakopoulos V.; Alfano G.; Combe C.; Basile C.
Institution
(Genovesi) School of Medicine and Surgery, University of Milano-Bicocca,
Nephrology Clinic, Monza, Italy
(Genovesi) Istituto Auxologico Italiano, IRCCS, Milan, Italy
(Camm) St. George's University of London, London, United Kingdom
(Covic, Bulracu) Nephrology Clinic, Dialysis and Renal Transplant Center -
'C.I. Parhon' University Hospital, 'Grigore T. Popa' University of
Medicine, Iasi, Romania
(Meijers) Nephrology Unit, University Hospitals Leuven and Department of
Microbiology, Immunology and Organ Transplantation, KU Leuven, Leuven,
Belgium
(Franssen) Department of Nephrology, University Medical Center Groningen,
University of Groningen, Netherlands
(Luyckx) Renal Division, Brigham and Women's Hospital, Harvard Medical
School, Boston, MA, US; Department of Paediatrics and Child Health,
University of Cape Town, South Africa; Department of Public and Global
Health, Epidemiology, Biostatistics and Prevention Institute, University
of Zurich, Zurich, Switzerland
(Liakopoulos) Second Department of Nephrology, AHEPA University Hospital,
Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
(Alfano) Nephrology Dialysis and Transplant Unit, University Hospital of
Modena, Modena, Italy
(Combe) Department of Nephrology, CHU de Bordeaux and INSERM U1026,
University of Bordeaux, Bordeaux, France
(Basile) Associazione Nefrologica Gabriella Sebastio, Martina Franca,
Italy
Abstract
The incidence and prevalence of atrial fibrillation (AF) in patients
affected by kidney failure, i.e. glomerular filtration rate <15
ml/min/1.73 m2, is high and probably underestimated. Numerous
uncertainties remain regarding how to prevent thromboembolic events in
this population because both cardiology and nephrology guidelines do not
provide clear recommendations. The efficacy and safety of oral
anticoagulant therapy (OAC) in preventing thromboembolism in patients with
kidney failure and AF has not been demonstrated for either vitamin K
antagonists (VKA) or direct anticoagulants (DOAC). Moreover, it remains
unclear which is more effective and safer between them, because estimated
creatinine clearance < 25-30 ml/min was an exclusion criterion of the
randomized control trials (RCTs). Three RCTs comparing DOACs and VKAs in
kidney failure failed to reach the primary endpoint because they were
underpowered. The left atrial appendage is the main source of
thromboembolism in the presence of AF. Left atrial appendage closure
(LAAC) has recently been proposed as an alternative to OAC. RCTs comparing
the efficacy and safety of LAAC vs. OAC in kidney failure were terminated
prematurely due to recruitment failure. A recent prospective study showed
a reduction in thromboembolic events in hemodialysis patients with AF and
undergoing LAAC compared to patients taking or not taking OAC. We review
current treatment standards and discuss recent developments in managing
the thromboembolic risk in kidney failure patients with AF. The importance
of shared decision-making with the multidisciplinary team and the patient,
to consider individual risks and benefits of each treatment option is
underlined. Copyright © The Author(s) 2024. Published by Oxford
University Press on behalf of the ERA.

<109>
Accession Number
644403570
Title
Perceived family-centered care and post-traumatic stress in parents of
infants cared for in the paediatric cardiac intensive care unit.
Source
Nursing in critical care. (no pagination), 2024. Date of Publication: 30
May 2024.
Author
Lisanti A.J.; Min J.; Golfenshtein N.; Marino B.S.; Curley M.A.Q.;
Medoff-Cooper B.
Institution
(Lisanti, Curley, Medoff-Cooper) Department of Family and Community
Health, School of Nursing, University of Pennsylvania, Philadelphia, PA,
United States
(Lisanti, Curley, Medoff-Cooper) Research Institute, Children's Hospital
of Philadelphia, Philadelphia, PA, United States
(Min) Department of Biomedical and Health Informatics, Research Institute,
Children's Hospital of Philadelphia, Philadelphia, PA, United States
(Golfenshtein) Department of Nursing, University of Haifa, Haifa, Israel
(Marino) Department of Pediatric Cardiology, Cleveland Clinic Children's,
Cleveland, OH, United States
Abstract
BACKGROUND: Family-centred care (FCC), while a core value of paediatric
hospitals, has not been well-studied in the paediatric cardiac intensive
care unit (PCICU). AIMS: To describe parents' perceptions of FCC provided
by nurses in the PCICU during their infant's recovery from neonatal
cardiac surgery and explore associations of perceptions of FCC on parent
post-traumatic stress (PTS) 4months post-discharge. STUDY DESIGN: Data
obtained from a previously conducted randomized clinical trial (RCT) on
telehealth home monitoring after neonatal cardiac surgery at three
free-standing paediatric hospitals were analysed from a subset of 164
parents who completed the FCC Scale at hospital discharge, which measures
a parent's experience of nursing care that embodies core principles of
FCC. The RCT intervention was provided after hospital discharge, having no
influence on parent's perception of FCC. The intervention also had no
effect on PTS. RESULT(S): Perceived FCC was lowest for items 'nurses
helped me feel welcomed' and 'nurses helped me feel important in my
child's care'. Having 12%-19% points lower perception of FCC at hospital
discharge was associated with parent experience of six or more PTS
symptoms, at least moderate PTS symptom severity, or PTS disorder
diagnosis at 4-month follow-up. Every 10% increase in parental perceptions
of FCC was associated with less PTS symptoms (beta=-0.29, SE=0.12; p=.02)
and lower PTS symptom cluster scores of arousal (beta=-0.18, SE=0.08;
p=.02). CONCLUSION(S): Parents who perceived lower FCC during their
infants' hospitalization were at increased risk for the development of PTS
symptoms, more PTS symptom severity and PTS disorder diagnosis 4-months
post-discharge. RELEVANCE TO CLINICAL PRACTICE: Nurses have a prominent
role to support the implementation of FCC for infants with cardiac defects
and their parents. FCC may positively influence overall parent mental
health and well-being, reducing the trauma and distress of the PCICU
experience. Copyright © 2024 The Author(s). Nursing in Critical
Care published by John Wiley & Sons Ltd on behalf of British Association
of Critical Care Nurses.

EPICORE Embase Updates

Sunday, June 16, 2024

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

No comments:

Post a Comment

Followers

Blog Archive

About Me